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Abstract 
Ulcerative colitis (UC) is a chronic inflammation of colonic mucosa and submucosa, 
characterised by abdominal pain, rectal bleeding and diarrhoea. Although the aetiology of 
UC remains elusive, the mucosal immune response, microbial features and intestinal 
epithelial barrier defects are all implicated in the pathogenesis of UC. Current drug therapies 
are not completely effective for the management of UC and many patients eventually require 
surgical interventions. Therefore there is a need for effective and safe therapies in UC.  
 Both heparins (unfractionated heparin, UFH and low molecular weight heparins, 
LMWHs) and heparin-like molecules such as fucoidans are complex mixture of 
polysaccharides. Heparins are widely used anticoagulants whereas fucoidan extracts are 
available as health supplements. Heparins and fucoidans have been reported to possess a 
wide range of biological activities including anti-inflammatory activity. At present, the use 
of heparins for the treatment of UC remains uncertain and requires further investigation. 
Moreover, the use of heparins is largely limited by the risk of bleeding in conditions where 
anticoagulation is not required. Therefore we aimed to investigate the therapeutic potential 
of sulphated polysaccharides (enoxaparin and fucoidans) in a model of colitis with a goal of 
identifying specific oligosaccharides that are responsible for their anti-inflammatory 
activity. 
 We first examined whether UFH, LMWHs (dalteparin and enoxaparin) and 
individual oligosaccharides of enoxaparin can affect cell growth in vitro. In UC, cell 
proliferation is required for mucosal healing. Enoxaparin was separated into different 
oligosaccharides by ion-exchange chromatography (IC). The proliferation and viability of 
human colonic epithelial cancer cells (HT-29, DLD-1 and HCT-116) were investigated in 
the presence and absence of different concentrations of UFH, dalteparin, enoxaparin and its 
xvii 
 
oligosaccharides. Protein quantification, the numbers of cell colonies and proportion of cells 
in different phases of the cell cycle were measured. Cell viability was assessed by a 
colorimetric method, trypan blue exclusion and by measuring apoptosis. Subsequently, 
investigation of the potential of fucoidan extracts, enoxaparin and its oligosaccharides in 
colitis was evaluated in vivo. Colitis was induced in male C57BL/6 mice by the 
administration of dextran sulphate sodium (DSS) through the drinking water. Mice received 
different treatment once daily either intraperitoneally or orally. Animals were monitored 
daily for their body weight, stool consistency and rectal bleeding. The experiment was 
terminated on day 8 and the colons of mice were weighed and processed for histology and 
to measure cytokine levels. 
 UFH, dalteparin and enoxaparin inhibited cell proliferation in a dose-dependent 
manner. This inhibitory effect was well-correlated with the induction of cell cycle arrest in 
the G1 phase and was not associated with any significant changes in cell viability. The 
isolated oligosaccharides of intact enoxaparin have different degrees of polymerisation 
ranging from 2 saccharides (dp2; ~ 600 Da) to 24 saccharides (dp24; ~ 8000 Da). Each IC-
derived oligosaccharide of enoxaparin had either no, anti- or pro- proliferative effects, 
depending on its composition. Disaccharides devoid of anticoagulant activity had the 
strongest anti-proliferative effect, whereas the hexasaccharides promoted cell growth. In 
vivo results showed that orally administered but not intraperitoneal injected enoxaparin was 
effective in suppressing the pathology of colitis. The observed effect of oral enoxaparin 
corresponded well to the reduction of macrophage-associated responses as well as the 
suppression of inflammatory cytokine levels. Like enoxaparin, fucoidan extracts also 
ameliorated colitis by reducing the levels of a number of pro-inflammatory cytokines. 
Intriguingly, among oligosaccharides of enoxaparin tested, oligosaccharides shorter than dp8 
were identified to be responsible for the anti-inflammatory activity of enoxaparin. 
xviii 
 
Tetrasaccharides and hexasacchrides were the two main active components that relieved 
colitis-associated body weight loss and prevented macroscopic changes to the colon tissue.  
 In conclusion, enoxaparin and fucoidan extracts possess anti-inflammatory activity 
and are effective in an acute colitis model. The in vitro and in vivo results highlighted that 
depending on their composition, different oligosaccharides can have distinctive effects. It is 
important to isolate and test different oligosaccharides from the mixture. This approach 
potentially leads to the identification of specific oligosaccharides that are responsible for 
anti-inflammatory effects of the parent molecules and could reduce the unwanted side effect 
associated with the administration of a mixture of polysaccharides. For example, the 
tetrasaccharide of enoxaparin, shorter than antithrombin-binding pentasaccharide, does not 
bind to antithrombin, thus its use is unlikely to be associated with a risk of bleeding even 
when administered at high doses. The identified non-anticoagulant enoxaparin 
oligosaccharides that have colitis-suppressing properties could therefore represent a novel 
therapeutic option for the management of UC. 
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Chapter 1 Literature Review 
1.1 Ulcerative colitis 
Ulcerative colitis (UC) and Crohn’s disease (CD) are the two main forms of inflammatory 
bowel diseases (IBD). Both are chronic, progressive inflammatory disorders of the 
gastrointestinal tract (GIT) [1]. UC is restricted to the submucosa or mucosa of the large 
intestine [2]. In UC, inflammation involves the rectum (proctitis), and may extend 
contiguously to the sigmoid colon (proctosigmoiditis), distal colon (left-sided colitis), 
transverse colon (extensive colitis) or the entire colon (pancolitis) [2]. Unlike in UC, patients 
with CD typically display a deeper transmucosal inflammation of any part of the GIT. 
However, CD is usually confined to the terminal portion of the small intestine, the ileum and 
colon [3]. Both types of IBD involve alterations of mucosal immunity and physiological 
responses. Even though UC and CD share several similar chronic and relapsing 
inflammatory characteristics, they differ in their pathological and clinical features, as well 
as in their responsiveness to certain therapeutic drugs [4]. 
 Previously, northern Europe and North America were known as high-incidence and 
prevalence areas of UC. In 2004, more than 1 million people in Europe and 0.7 million 
people in the United States suffered from UC [5]. Recently, the number of UC cases has 
increased in countries where it was previously uncommon; this includes southern Europe, 
Australia, Africa, Latin America and Asia [5-7]. The rising incidence of this debilitating 
chronic inflammatory disease reinforces the need for a better understanding of the 
underlying pathogenesis, a prerequisite for the development of novel therapeutic approaches. 
A better insight into the medical management of UC ultimately improves patients’ quality 
of life and reduces the risk of further complications.  
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1.1.1 Pathophysiology of UC  
Although the full aetiology of UC remains unknown, it is clearly a multifactorial intestinal 
disease [1]. The intestinal barrier is constituted of epithelial cells that are tightly arranged 
and organised to control the permeability of luminal antigens. However, in UC, the integrity 
and function of the intestinal barrier is compromised due to a dysfunctional mucus layer, 
alterations of tight junction proteins and the presence of extracellular degrading enzymes 
[8,9]. As a result, luminal antigens have access into the mucosa across the disrupted 
epithelial barrier [9]. Excessive recognition and processing of microbial antigens and the 
release of pro-inflammatory mediators by antigen presenting cells, further enhances the 
migration and accumulation of inflammatory cells from the vasculature into the gut mucosa 
[10]. These activated innate immune and effector cells then release pro-inflammatory 
cytokines, perpetuating the cycle of chronic inflammation [2]. 
1.1.1.1 Epithelial barrier dysfunction 
The intestinal epithelium serves as an important part of the host’s immune defence by acting 
as a barrier to prevent bacterial entry into the lamina propria but selectively allows the 
passage of essential dietary nutrients, electrolytes and water into the systemic circulation 
[11]. A mucus layer, produced by goblet cells, permits the diffusion of required 
macromolecular components across the intestinal epithelium but prevents the entry of 
microbes from the gut to the lamina propria [12]. The mucus barrier contains secreted 
mucins, trefoil peptides, antimicrobial peptides and immunoglobulin A that contribute 
towards maintaining a balanced microbiota homeostasis and immune defence [12]. In UC, 
epithelial barrier dysfunction occurs as a result of diminished mucus secretion and defects 
at the level of epithelial tight junctions (Fig. 1.1) [8]. As the thickness and continuity of the 
mucus barrier is reduced and becomes less effective, bacteria are in direct contact with 
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epithelial cells [8]. With defective tight junction between the intestinal epithelial cells, 
increased permeability allows microbes or microbial antigens to translocate from the gut 
lumen to the lamina propia (Fig. 1.1) [13]. These bacterial antigens are subsequently 
recognised by antigen presenting cells, mainly macrophages and dendritic cells [10]. 
 
Figure 1.1 Immunopathogenic mechanisms of UC.  
In UC, luminal antigens gain access to the intestinal lamina propria through disrupted epithelial 
barrier. The presence of pathogenic bacteria are detected by macrophages and dendritic cells through 
Toll-like receptors. Upon antigen recognition, activated macrophages and dendritic cells produce 
pro-inflammatory cytokines. Pro-inflammatory cytokines promote differentiation of naive T cells to 
effector T cells and further amplify the inflammatory immune response. Secreted pro-inflammatory 
mediators perpetuate the cycle of chronic inflammation by recruiting a large number of leukocytes 
including neutrophils and macrophages, from the circulation into the intestinal lamina propria. 
Interleukin, IL; inducible nitric oxide synthase, iNOS; intercellular adhesion molecule-1, ICAM-1; 
major histocompatibility complex, MHC; natural killer T cell, NK T; nitric oxide, NO; P-selectin 
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glycoprotein ligand-1, PSGL-1; T cell receptor, TCR; T helper cell, Th; Toll-like receptor, TLR; T 
regulatory cell, Treg; transforming growth factor-β, TGF-β; tumour necrosis factor-α, TNF-α. 
1.1.1.2 Antigen recognition 
Luminal antigens are recognised by macrophages via Toll-like receptors (TLRs) during 
phagocytosis. Luminal antigens may also be sampled by activated dendritic cells, whose 
dendrites penetrate into the gut lumen via the paracellular space between epithelial cells (Fig. 
1.1) [2]. In UC, dendritic cells accumulate at the site of inflammation and have exaggerated 
responses to antigenic stimuli [2]. Apart from macrophages and dendritic cells, intestinal 
epithelial cells also serve as antigen-presenting cells and play a key role in intestinal 
inflammation [14]. Under physiological conditions, intestinal epithelial cells express various 
types of pattern-recognition receptors such as TLRs and nucleotide oligomerization domain 
(NOD)-like receptors that recognise microbial antigens and are important in maintaining 
mucosal homeostasis [14]. However, in UC, increased expression of enterocyte TLRs is 
likely to trigger excessive immune responses against pathogens that invade the epithelial 
barrier. Activation of TLRs on epithelial cells by pathogen-associated molecular patterns 
induces a signalling cascade that results in the activation of nuclear-factor kappa B (NF-қB) 
which stimulates the transcription of pro-inflammatory cytokines such as tumor necrosis 
factor (TNF)-α, interleukin (IL)-6, interferon (IFN)-γ and IL-1β [4]. These pro-inflammatory 
mediators subsequently activate more target cells to mediate additional immune responses 
[15] as well as modify the function of tight junctions, which further increase epithelial 
permeability [13]. 
1.1.1.3 Dysregulation of mucosal immune response 
Increased bacterial translocation and uptake clearly disturb intestinal homeostasis [10].  
Neutrophils, macrophages and dendritic cells are important innate immune cells in the 
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maintenance of intestinal immune system homeostasis. However, excessive antigen 
recognition and aberrant immune responses lead to a massive recruitment and accumulation 
of these immune cells in the inflamed mucosa of patients with UC [1]. Activated neutrophils 
release pro-inflammatory cytokines and chemokines to attract monocytes and dendritic cells. 
At the same time, they also produce large amounts of reactive oxygen species that are 
intended to fight pathogens but which also damage the surounding tissues [16]. Recruited 
macrophages produce significant amounts of TNF-α, which expands the inflammatory 
response [4]. When the excessive pathogenic challenge exceeds the killing capacity of 
macrophages and neutrophils, an adaptive immune response, which is initiated by dendritic 
cells, is predominantly involved. 
 Dendritic cells present antigens through the major histocompatibility complex class 
II (MHC-II) on the cell surface to naive T cells [4]. Activated naive T cells differentiate into 
different effector T cells and regulatory T cells (Treg) (Fig. 1.1) [10]. Helper T cells (Th1, 
Th2 and Th17) are critical for a protective immune response against pathogens. However, 
their exaggerated activation can generate and sustain the chronic inflammation observed in 
UC (Fig. 1.1) [10]. Th2 are the dominant T helper subset in UC, that produce IL-4, IL-5 and 
IL-13 [2,17]. Data from genome-wide association studies suggest that Th17 cells are also 
associated with UC [18]. These cells are activated by the transforming growth factor beta 
(TGF-β) + IL-6/ IL-23 pathway and secrete a number of pro-inflammatory cytokines 
including IL-17A, IL-21, IL-22 and IFN-γ. In particular IL-17A, which is upregulated in 
intestinal biopsies of UC patients, promotes neutrophil recruitment from blood vessels to the 
mucosa and induces IL-8 to be released from epithelial cells [18]. In patients with UC, the 
numbers of both peripheral blood and colonic Treg cells, which under normal conditions 
balance mucosal homeostasis, are decreased [19]. It is thought that this reduced number of 
Treg cells in UC is responsible for directing the active immune responses towards 
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inflammation [4]. Moreover, a high number of non-classical natural killer T (NK T) cells are 
detected in the lamina propria of the inflamed colon [20]. NK T cells are a major source of 
IL-13 and are associated with the lesions in UC [20]. IL-13 induces epithelial cell death, 
which further interrupts the integrity of the epithelial barrier and hence facilitates the 
infiltration of even more pathogens [20,21]. Additionally, IL-13-mediated epithelial cell 
damage induces the production of auto-antibodies against goblet cell glycoproteins, 
epithelial cells and other tissues that carry the same epitopes. Binding of auto-antibodies to 
endogenous glycoproteins may lead to further damage of the intestinal epithelium and 
manifestation of extra-intestinal inflammation observed in UC [22]. 
1.1.1.4 Leukocyte recruitment  
Infiltration of leukocytes into the affected mucosa is a critical event during colitis. Adhesion 
molecules that include E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular 
cell adhesion molecule-1 (VCAM-1) are required for leukocyte adhesion on the vascular 
endothelial cells before leukocytes can migrate into the gut mucosa. Upregulation of cell 
adhesion molecules enhances the recruitment of leukocytes [23]. Bacterial antigens and pro-
inflammatory cytokines such as TNF-α, IL-1β or lipopolysaccharide (LPS) have been shown 
to cause a pronounced upregulation of adhesion molecule expression on the surface of 
endothelial cells that increase leukocyte recruitment [24,25]. Imperatively, human intestinal 
microvascular endothelial cells from chronically inflamed tissue in patients with UC exhibit 
higher cytokine-mediated leukocyte-binding capacity when compared with endothelial cells 
derived from normal mucosa of uninvolved intestinal segments from the same patients [26]. 
Overall, this enhanced binding of leukocytes onto the endothelium facilitates the 
transmigration of immune cells from the vasculature into the intestinal lamina propria, which 
also contributes to chronic intestinal inflammation (Fig. 1.1) [23,24,27].  
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1.1.1.5 Heparanase as extracellular degrading enzyme 
Heparanase is an endo-β-D-glucuronidase capable of degrading heparan sulphate (HS) 
chains [9]. HS chains are attached to the surface of many types of cells and extracellular 
matrix (ECM) proteins to form HS proteoglycans that play important functional and 
structural roles [9]. Specifically, in the gut, HS chains are found on epithelial cell surface, in 
the basal lamina of the intestinal mucosa as well as basement membrane surrounding the 
endothelium in the intestinal lamina propria [28]. Therefore they are involved in maintaining 
a healthy and functional gut barrier, regulating vascular permeability and facilitating cell-
cell interactions [9,29]. Heparanase expression is reported to be higher in the inflamed 
mucosa of patients with chronic UC compared with people without UC [30,31]. It has been 
proposed that the presence of heparanase disintegrates HS within the basement membrane 
surrounding the endothelium in the intestinal lamina propria, which facilitates the migration 
of inflammatory cells from the circulation to the inflamed mucosa (Fig. 1.1). Heparanase 
also may cause substantial degradation of HS in the sub-epithelial basal lamina of the colon, 
contributing the loss of epithelial barrier integrity and fluid leakage into the interstitium and 
adjacent tissues [32,33]. Since HS proteoglycans are required for cell growth [34], 
degradation of HS chains may also hinder mucosal healing following active inflammation 
[9]. Heparanase is also believed to exert a direct pro-inflammatory effect on macrophages, 
prompting them to release TNF-α and IFN-γ [30]. Inversely, secreted TNF-α, IFN-γ and IL-
1β stimulate the secretion of heparanase by colonic epithelial cells and the underlying 
microvascular endothelial cells [30,35]. 
1.1.2 Current management strategies  
Pharmacological and surgical interventions are currently the two main approaches for 
managing UC [2]. Surgery is usually indicated when patients are unresponsive to medication 
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and present intractable symptoms or life-threatening complications such as perforation, 
refractory rectal bleeding, toxic megacolon, fulminant colitis, multifocal dysplasia or cancer 
[17]. Drugs such as corticosteroids, aminosalicylates and immunosuppressants aim to 
decrease the level of inflammation [2]. These agents are not always effective in ensuring 
long term remission and are associated with significant side effects [2,36]. Currently, TNF-
α inhibitors (infliximab, adalimumab and golimumab) have been approved by the US Food 
and Drug Administration for the treatment of steroid-resistant UC or cases where 
immunomodulatory therapy is ineffective [37]. However, TNF inhibitors are relatively 
expensive. For example, the cost for infliximab is about US $1900 for 100 mg. This means 
that an average adult patient with UC would need to pay US $6650 for a single dose of 
infliximab (body weight = 70 kg, 5 mg/kg per dose) [38]. In addition, prolonged use of 
infliximab is associated with a mildly increased risk of infections and lymphoma [39]. 
Importantly, approximately 30 to 40% of patients do not respond to infliximab treatment and 
in up to 40% of patients the initial therapeutic response of infliximab is lost after one to two 
years [36,39]. Apart from this, approximately 17% of patients treated with infliximab will 
eventually require a surgical intervention [39].  
 Influencing migration of lymphocytes using anti-adhesion molecules is an appealing 
new treatment option for UC [40]. Vedolizumab is a monoclonal antibody that inhibits 
lymphocyte migration by disabling the function of a transmembrane protein involved in cell 
adhesion called integrin α4β7. Randomised controlled trials have demonstrated the 
effectiveness of vedolizumab in both the induction and maintenance of clinical response and 
remission in active UC without increasing the risk of infections [41]. On the other hand, 
monoclonal antibodies that target other lymphocyte surface molecules such as CD3 or CD25 
have generated only mixed results in patients with UC [36] and evidence of the long-term 
therapeutic efficacy and clinical safety of these new therapeutic approaches is still lacking.  
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 Overall, there is a need to develop novel treatment strategies for the management of 
UC which are effective, safe and less expensive than the available therapeutic options. 
Current treatments are limited in their ability to sustain a remission of symptoms and to 
prevent recurrent inflammation. The main therapy focus in UC has shifted towards 
preserving gut function with a reduced risk of hospitalisation, colorectal dysplasia and 
colectomy [42]. Among the increasing numbers of investigational therapeutic targets, 
polysaccharides obtained from natural sources are being explored for UC. Initially, the 
serendipitous observation of improved symptoms in patients with UC treated with 
unfractionated heparin (UFH) for thrombosis opened up a potential new therapeutic avenue 
for the treatment of UC [43]. Also, other heparin-like molecules such as fucoidans with 
notable immune-modulatory and anti-inflammatory activities, have gained considerable 
interest as alternative therapeutic approach for UC. 
1.2 Heparins 
UFH has been clinically used as a potent anticoagulant agent for more than 70 years [44]. It 
belongs to the family of glycosaminoglycans (GAGs), which are a large group of long 
unbranched carbohydrate polymers [45]. Endogenous heparin is found in the secretory 
granules of mast cells. It is believed that the heparin regulates the storage and release of mast 
cell components during tissue injury as a defence mechanism against invading pathogens, 
rather than for anticoagulation purposes [46]. Commercially available UFH is extracted and 
purified mainly from porcine intestinal mucosa [47]. Due to the nature, origin and 
preparation process, UFH is a heterogeneous mixture of unidentified anionic 
oligosaccharides ranging from a molecular weight (MW) of 3 - 30 kDa, with an average 
weight of 15 kDa [48]. UFH consists of repeating disaccharide units, N-acetyl glucosamine 
with either iduronic (90%) or glucuronic acid (10%), and different degrees and patterns of 
10 
 
sulphation (Fig. 1.2A) [45]. Despite its widespread clinical use, UFH is associated with a 
number of adverse effects such as bleeding and thrombocytopenia. Furthermore, UFH has a 
low bioavailability when administered other than intravenously and shows an unpredictable 
dose response [48]. These limitations led to the development of LMWHs, which are prepared 
by controlled chemical or enzymatic depolymerisation of UFH [49]. 
 Depending on the depolymerisation process, LMWHs are composed of UFH-derived 
chains with distinct lengths and a MW between 3600 Da and 6500 Da [50]. Therefore, it is 
important to point out that each of the currently available LMWHs has to be regarded as an 
individual chemical entity [49]. Due to structural heterogeneity and polydispersity, complete 
structural characterisation and sequencing of LMWHs or their parent compound, UFH, is 
extremely complex [49]. Consequently, UFH and LMWHs are generally characterized and 
labelled in terms of their anticoagulant effect (a measurement of the binding affinity of the 
components of these agents to the enzymes in coagulation cascade, as anti-thrombin or anti-
factor Xa activity) rather than by their MW [51].  
 Heparin exerts its anticoagulant activity by activating antithrombin [52]. A unique 
pentasaccharide sequence (Fig. 1.2B) induces conformational change within the 
antithrombin structure that accelerates its interaction with thrombin and factor Xa by 1000-
fold [52]. The major difference between LMWHs and UFH is their relative inhibitory effect 
on factor Xa and thrombin. Both LMWHs and UFH can inhibit factor Xa, by binding to 
antithrombin. To inactivate thrombin, UFH must bind to antithrombin and the enzyme, 
thereby forming a ternary (heparin-antithrombin-thrombin) complex [48]. UFH chains are 
composed of more than 18 saccharide units so they can easily form the ternary complex. 
Unlike UFH, LMWH chains are composed of fewer than 18 saccharide units so they can not 
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bind simultaneously to both thrombin and antithrombin, and hence only inhibit factor Xa but 
not thrombin [48].  
 
Figure 1.2 Structure of heparins.  
(A) The repeating disaccharide unit of heparins: alternating uronic acid (epimerises from glucuronic 
acid to iduronic acid) and glucosamine, with possible sulphation at R and R’ positions. (B) 
Pentasaccharide anti-thrombin binding sequence of heparins. 
1.2.1 Potential mechanism of actions of heparins in UC  
The effect of heparins in UC is thought to be based on their anti-inflammatory and mucosal 
healing activities [53]. Mechanisms by which heparins are postulated to exert their beneficial 
effects in UC are discussed (Fig. 1.3). 
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Figure 1.3 Potential heparin-mediated mechanisms in UC.  
(A) Syndecan-1 is an important HS proteoglycans present on intestinal epithelial cell surfaces. 
Syndecan-1 acts as a co-receptor for basic fibroblast growth factor and facilitates the binding of 
bFGF to its receptor, which stimulate cell growth. In UC, there is shedding of HS chains present on 
syndecan-1. It is thought that the structural similarity between heparins and HS enables heparins to 
substitute for lost HS chains, restoring bFGF-FGF receptor binding and assisting mucosal healing in 
UC. (B) Heparanase, an endo-β-D-glucuronidase capable of cleaving HS chains, is expressed by 
activated immune cells, epithelial cells and endothelial cells at the site of inflammation. Cleavage of 
HS chains promotes the release of extracellular matrix-bound growth factors as well as recruitment 
of immune cells. Since heparins are structurally similar to HS, heparins act as alternative substrates 
and minimize the degradation of HS chains. (C) Pro-inflammatory cytokines induce nitric oxide 
production by up-regulating inducible nitric oxide synthase. In UC, NO is released locally by the 
colonic epithelium, infiltrating neutrophils and macrophages. Heparins reduce the production of NO 
and protect against inflammation by down-regulating iNOS. (D) During inflammation, leukocytes 
are recruited from the circulation to the sites of inflammation. Heparins interfere with leukocyte 
recruitment by interacting with adhesion molecules, as well as inhibiting the release of cytokines and 
chemokines, thus blocking leukocyte migration into the gut mucosa. Subsequently the influx of 
leukocytes to sites of inflammation is reduced. Heparins increase the synthesis and release of TFPI. 
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By blocking the activity of tissue factor, heparins are thought to prevent coagulation as well as 
inflammation. Basic fibroblast growth factor, bFGF; heparan sulphate, HS; inducible nitric oxide 
synthase, iNOS; intercellular adhesion molecule-1, ICAM-1; nitric oxide, NO; P-selectin 
glycoprotein ligand-1, PSGL-1; tissue factor pathway inhibitor, TFPI; vascular cell adhesion 
molecule-1, VCAM-1. 
1.2.1.1 Mucosal healing and barrier function 
Mucosal healing has been identified as one of the ultimate therapeutic goals in UC as the 
inflammation is restricted to mucosa and submucosa [42]. Mucosal healing is essential for 
the resolution of chronic inflammation in the colon or rectum and thus for the remission of 
the disease [54]. Mucosal epithelial repair is a complex process involving remodelling of the 
ECM, angiogenesis, epithelial cell proliferation and differentiation of the colonic mucosa 
[55]. These processes are initiated by regulatory factors such as cytokines, chemokines and 
growth factors that interact with HS proteoglycans or HS-rich ECM to restore mucosal 
integrity and promote epithelial repair [55].  
 HS proteoglycans play an essential role in sustaining epithelial barrier function and 
support the basement membrane below [33,56]. Loss of HS proteoglycans from the 
basolateral surface of intestinal epithelial cells was reported to decrease the integrity of the 
epithelial barrier, which was associated with the leakage of plasma proteins into the intestinal 
lumen [33]. However, such leakage was inhibited upon restoring the integrity of HS 
proteoglycans [33]. As HS proteoglycans expression is significantly altered in UC [57], the 
integrity of the epithelial barrier is also likely to be compromised. The observed loss of 
epithelial syndecan-1 during colitis [28,33] is mostly caused by the presence of heparanase 
and increased levels of pro-inflammatory cytokines, such as TNF-α and IL-1β [58]. 
Importantly, reduced levels of HS proteoglycans potentiate the effects of pro-inflammatory 
cytokines, resulting in a vicious cycle of loss and down-regulation of HS proteoglycans [28].  
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 Among various types of HS proteoglycans, syndecans have a crucial role in wound 
healing and inflammation [29]. Syndecans consist of a core protein and three covalently 
linked HS chains. Among syndecans, syndecan-1 is highly expressed on the basolateral 
surface of epithelial cells and is identified as a co-receptor of basic fibroblast growth factor 
(bFGF) [59]. This growth factor is a potent stimulator of epithelial cell growth [60,61]. HS 
chains of syndecan-1 mediate and stabilise the interaction between bFGF and epithelial cell 
surface receptor for signal transduction of cell growth, as shown in Figure 1.3 [62,63]. 
However, during active UC, syndecan-1 in the inflamed epithelium is down-regulated 
predominantly in the reparative epithelium adjacent to ulcer margins [57]. This down-
regulation of syndecan-1 reduces the interaction between bFGF and cell surface receptor, 
resulting in decreased stimulation of cell growth [64].  
Interestingly, studies have reported that heparins can substitute for the functions of HS 
present on syndecan-1 [33,65]. In syndecan-1 knock-out mice with colitis, enoxaparin, a 
LMWH, improved intestinal wound healing as well as reduced the rate of mortality [65]. 
Because of the structural similarity, LMWHs are thought to act as functional analogues of 
HS chains of syndecan-1 [65]. UFH substituted for the lost HS chains that are required for 
syndecan-1 functions, restoring bFGF-receptor interaction for cell growth in vitro [57]. 
Likewise, subcutaneous enoxaparin significantly decreased the severity of colitis by 
reducing the colitis-associated shedding of syndecan-1 [66]. These results suggested that 
heparins could potentially substitute for endogenous HS chains and therefore potentially 
restore bFGF receptor binding and stimulate epithelial repair in colitis (Fig. 1.3). 
1.2.1.2 Inhibition of heparanase activity 
It is well-recognised that heparanase activity strongly influences inflammation [67]. 
Heparanase is responsible for the degradation of HS which is thought to be essential for this 
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activity [67]. Degradation of HS by heparanase occurs under physiological as well as 
pathological conditions such as in tissue development and tissue remodelling, wound repair, 
inflammation and angiogenesis [9]. Normally, heparanase expression is restricted to certain 
tissues such as activated immune cells and platelets [9]. However, in UC, heparanase is 
expressed locally at the site of inflammation [31] and also in mice with induced colitis [30]. 
Overexpression of heparanase in the colon during inflammation degrades ECM, as well as 
the basement membrane, resulting in barrier damage with ulceration [9]. This temporary 
disruption of the basement membrane facilitates the migration of leukocytes through the 
vascular endothelium [29]. Since heparins are structurally similar to HS, they are believed 
to compete with HS for the binding site of heparanase (Fig. 1.3) [68]. Because of this 
competition, heparins act as alternative substrate and minimize the degradation of HS 
[69,70]. Consistent with this model, heparins decrease the degradation of ECM as well as 
the migration of immune cells to the site of inflammation [68,69]. 
1.2.1.3 Inhibition of inducible nitric oxide synthase activity 
Pro-inflammatory cytokines induces nitric oxide (NO) production by up-regulating 
inducible nitric oxide synthase (iNOS) [71]. It is reported that iNOS is expressed locally in 
the colonic mucosa of patients with active UC [72]. Initially iNOS leads to production of 
NO as a part of the cellular defence against invading antigens [71]. However, under 
conditions of chronic inflammation, excess levels of NO at the sites of inflammation can 
cause direct cytotoxic effects. Furthermore, NO reacts with oxygen radicals to form the 
oxidising agent peroxynitrate which can have damaging effects in large quantities [71]. In 
this context, heparin-dependent down-regulation of iNOS during inflammation [73,74] was 
shown to reduce the cellular production of NO and to protect against inflammation (Fig. 1.3) 
[75,76].  
16 
 
1.2.1.4 Potentiation of tissue factor pathway inhibitor 
The link between coagulation and inflammation in UC is still unclear. It has been postulated 
that chronic inflammation causes imbalance of the coagulation process [77]. Activation of 
leukocytes during chronic intestinal inflammation leads to propagation and generation of 
tissue factor [77]. Tissue factor, a transmembrane glycoprotein and cofactor for clotting 
factor VII/ VIIa, initiates and amplifies blood coagulation, eventually leading to a 
hypercoagulant state. Beyond its role in coagulation, tissue factor increases the secretion of 
pro-inflammatory cytokines. These cytokines play an important role in different 
inflammatory conditions including in colitis [78]. In contrast, tissue factor pathway inhibitor 
(TFPI), synthesised by endothelial cells, prevents coagulation as well as inflammation. UFH 
and LMWHs have been shown to increase the synthesis and release of TFPI from endothelial 
cells (Fig. 1.3) [79]. Therefore, in addition to their anticoagulant role, the release of TFPI 
could potentially contribute to the observed clinical benefits of heparins against 
inflammation. 
1.2.1.5 Interference with the inflammation cascade: transmigration of leukocytes 
The recruitment of circulating leukocytes to sites of inflammation involves a series of 
sequential events such as active rolling, firm adhesion and migration [29,80]. The 
translocation of leukocytes (including monocytes, granulocytes and lymphocytes) from the 
circulation through the endothelium into the inflamed tissue areas is mediated by adhesion 
molecules activated by pro-inflammatory cytokines [81,82]. Interestingly, heparins are 
shown to interfere with leukocyte-endothelial cell adhesion and subsequently minimize the 
migration of leukocytes (Fig. 1.3) [46,53,83].  
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 Active rolling of leukocytes on the inflamed endothelial cell wall involves different 
lectins, such as L-selectin, P-selectin and E-selectin [29]. L-selectin is constitutively 
expressed on leukocytes while E-selectin and P-selectin are up-regulated on endothelial cells 
during inflammation [29]. Selectins interact with cell surface counter ligands of lectins, such 
as sialyl-Lewisx, which are tetrasaccharide compounds [83] and HS chains of syndecans 
[29]. During the rolling process, syndecan expression on the endothelial surface is up-
regulated [29]. The HS chains of syndecans, the predominant ligands for L-selectin, mediate 
the initial contact of circulating leukocytes with the vascular endothelial cells (Fig. 1.3) [29]. 
Subsequently, chemokines are required to trigger the activation of integrins that cause 
leukocyte arrest by firm adhesion through the binding of integrins to their ligands on the 
endothelium [81]. Chemokines, synthesized by activated endothelial cells, immune cells and 
inflamed tissues during inflammation [84], are bound to HS proteoglycans on endothelial 
cell surfaces before they can interact with their receptors on the surface of leukocytes 
[29,56]. As the chemokines bind to their receptors, integrins are activated to bind to their 
ligands; this assures firm adhesion and thus transmigration of leukocytes across the 
endothelium to the site of inflammation [29,85].  
 UFH and LMWH oligosaccharides have been shown to bind selectins [86]. This 
binding prevents selectins from binding to their ligands and therefore prevents the rolling of 
leukocytes on endothelial cells [66,87]. Heparins also competitively inhibit chemokines 
binding to their receptors, resulting in loss of chemotactic activity (Fig. 1.3) [83,88]. 
Additionally, heparins can effectively attenuate leukocyte-endothelial interactions by 
inhibiting ligand binding to integrins, as well as the expression of adhesion molecules such 
as ICAM-I and VCAM-1 (Fig. 1.3) [87,89,90]. As a result, heparins interfere with leukocyte 
rolling, chemokine-triggered, integrin-mediated firm adhesion of leukocytes to endothelial 
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cell surfaces, and subsequently reduce the influx of leukocytes to sites of inflammation 
[88,90]. 
 The effects of heparins on leukocyte migration could be explained by their inhibitory 
effects on cytokine production. Heparins are reported to suppress the NF-қB signalling 
pathway that is responsible for up-regulating the secretion of pro-inflammatory cytokines 
and chemokines [91,92]. This inhibition resulted in significantly reduced levels of LPS-
induced inflammatory mediators such as IL-1α, IL-6, IL-8 and TNF-α by leukocytes [91,92]. 
As such, heparins influence multiple pathways to modulate the infiltration of pro-
inflammatory immune cells by inhibiting the release of cytokines and chemokines, as well 
as modulating the function of adhesion molecules. Overall, it can be assumed that all of those 
activities are, likely to contribute in a synergistic manner to the anti-inflammatory effects of 
heparins in UC.  
1.2.2 Pre-clinical studies of heparins in UC 
The effects of heparins in UC have been investigated in murine models of colitis (Table 1.1). 
These studies differed in: i) experimental designs (e.g. either prevention or treatment 
protocol); ii) types and doses of heparins used; iii) duration of treatment (5-19 days) and iv) 
routes of administration (oral, rectal, subcutaneous or intraperitoneal). In the majority of 
studies, UFH and LMWHs have shown promising therapeutic effect [66,93-99]. Overall, a 
significant reduction in the severity of colitis with improved macroscopic and histological 
scores was observed in the treatment groups compared with the untreated colitis group. A 
remarkably reduced mucosal ulcerations, lesser distortion of crypt or gland structure in the 
epithelial lining of colon and also decreased myeloperoxidase activity were observed when 
mice with colitis were treated with heparins [73,96,100]. The ameliorating effects were 
related to the ability of heparins to facilitate mucosal healing, decrease the levels pro-
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inflammatory cytokines such as IL-1β, IL-6 and TNF-α as well as inhibit infiltration of 
leukocytes during the inflammatory process [90,91,93,94].   
 Pellequer and colleagues investigated the effect of enoxaparin in mice with colitis 
[95]. Mice were treated with enoxaparin either subcutaneously (3 mg/kg/day), orally (6 or 
20 mg/kg/day) or rectally (6 mg/kg/day) for 6 days. They showed that enoxaparin when 
given orally or rectally, the effect was to be superior to subcutaneous enoxaparin. Unlike 
subcutaneous route, both rectal and oral route of enoxaparin significantly attenuated all 
aspects of colitis activities and colonic inflammation. Similarly, using other models of 
animal colitis, it has been demonstrated that oral and rectal routes of heparins can effectively 
ameliorate colitis [93,94,101]. The possible reason of this observation could be due to high 
dose of heparins through these routes. Apart from this, these routes of administration enable 
the delivery of heparins to the site of inflammation for local effect, avoiding systemic 
exposure thus decreased risk of bleeding. To our knowledge, currently there is no study of 
the protective effect of oral enoxaparin prior to or simultaneous with the initiation of DSS. 
On the other hand, Luo et al. (2011) demonstrated the effectiveness of 100 mg/kg/day 
enoxaparin given for 10 days via oral gavage on third day after the onset of acetic acid-
induced colitis [94]. 
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Table 1.1 Use of heparins in murine experimental colitis. 
Experimental 
design 
UFH/ LMWH 
(type/dose) 
Results  Author 
and year 
DSS-induced colitis 
in male BALB/c 
mice 
s.c 3.2 mg/kg/day of dalteparin for 5 
days 
Reduced severity of 
colitis 
Wan et al. 
2002 [96] 
TNBS- and 
oxazolone-induced 
colitis in male 
BALB/c mice 
s.c 3; rectal 6; p.o gavage 6 and 20 
mg/kg/day of enoxaparin for 6 days 
Reduced severity of 
colitis in oral and 
rectal groups 
Pellequer 
et al. 
2007 [95] 
DSS-induced colitis 
in male syndecan-1-/-
and C57BL/6 mice 
i.p 5 mg/kg/day of enoxaparin for 8 
days 
Reduced severity of 
colitis in syndecan-1-/- 
mice  
Floer et 
al. 2010 
[65] 
Acetic acid-induced 
colitis in male and 
female Kunming 
species mice 
rectal 50 mg/kg/day of a LMWH 
(124.7 IU/ mg) for 10 days 
Reduced severity of 
colitis 
Luo et al. 
2010 [93] 
Acetic acid-induced 
colitis in in male and 
female Kunming 
species mice 
p.o gavage 100 mg/kg/day of UFH 
(not specified IU/mg), enoxaparin 
(not specified IU/mg), dalteparin 
(124.7 IU/ mg) for 10 days 
Reduced severity of 
colitis  
Luo et al. 
2011 [94] 
DSS-induced colitis 
in male BALB/c 
mice 
s.c 250 µg/kg/day (5 µg/mouse/day) 
of enoxaparin for 7 days 
Reduced severity of 
colitis 
Wang et 
al. 2011 
[66] 
DSS-induced colitis 
in male C57BL/6 
mice 
s.c 280 µg/kg/day (5 µg/mouse/day) 
of enoxaparin for 19 days 
Reduced severity of 
colitis 
Wang et 
al. 
2013[97] 
DNBS- and 
iodoacetamide-
induced colitis in 
male Wistar rats 
s.c 40, 80 or 200 µg/kg/day of 
enoxaparin, or 100, 200 or 400 
IU/kg/day of UFH (not specified IU/ 
mg)  for 7 days 
Reduced severity of 
colitis in 80 µg/kg/day 
of enoxaparin and 200 
IU/kg/day UFH groups 
Dotan et 
al. 2002 
[73] 
Iodoacetamide-
induced colitis in 
male Wistar rats 
s.c 50 - 500 units/kg/day of UFH (not 
specified IU/ mg) for 7 days 
Reduced severity of 
colitis 
Levine et 
al. 2002 
[100] 
TNBS-induced 
colitis in female 
Sprauge-Dawley rats 
 
s.c 0.96 and 1.92 mg/kg/day (150 and 
300 IU/kg/day) of dalteparin for 6 
days then half the doses the next 7 
days 
 
Reduced severity of 
colitis 
Xia et al. 
2004 
[102] 
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DNBS-induced 
colitis in male Wistar 
rats 
Intracolonic parnaparin 0.02-4.5 
mg/kg/day (0.005 - 0.9 mg/rat/day), 
LMWH A, B, C 1.2-3.0 mg/kg/day 
(0.3 - 0.6 mg/rat/day), and UFH 2.4 - 
3.0 mg/kg/day (0.6 mg/rat/day for) 3 
days 
Reduced severity of 
colitis 
Celasco et 
al. 2008 
[101] 
TNBS-induced 
colitis in male Wistar 
rats 
s.c 4 or 8 mg/kg/day of UFH over 7 
days 
Reduced severity of 
colitis 
Belmiro 
et al. 
2009 [98] 
Acetic acid-induced 
colitis in male Wistar 
rats 
s.c 4.44 mg /kg/day (500 IU/kg/day) 
nadroparin (112.5 IU/mg) for 7 and 
10 days 
Reduced severity of 
colitis 
Yalniz et 
al. 2012 
[99] 
 
Dextran sulphate sodium, DSS; dinitrobenzenesulfonic acid, DNBS; trinitrobenzene sulfonic acid, 
TNBS; subcutaneous, s.c; intraperitoneal, i.p; oral, p.o. 
* dalteparin (156.25 anti-Xa IU/ mg; Fragmin) and enoxaparin (100 IU anti-Xa IU/ mg; 
Clexane/Levonox) were used in studies unless otherwise specified 
1.2.3 Clinical use of heparins in UC 
A paradoxical response to UFH in patients with active UC observed more than 30 years ago 
[103,104] led to investigations of its potential role in the management of this chronic 
inflammatory condition (Table 1.2). In a 1995 report, Gaffney et al. showed improvement 
in 9 of 10 patients treated with intravenous UFH with remission maintained by subcutaneous 
administration of UFH [43]. Similarly, Brazier et al. reported complete remission in 4 of 6 
patients with UC who were treated with UFH [105]. In another study, 13 patients with UC 
or CD were treated with UFH for a total of 8 weeks [106]. Seven patients with UC, but none 
of the CD patients, achieved complete remission. One patient with UC required blood 
transfusion due to the occurrence of heparin-induced major haemorrhage. Evans and co-
workers treated 16 cases of refractory colitis with intravenous and subcutaneous  (25000 - 
40000  IU/ day) UFH [107]. They reported that 12 out of 16 patients improved and 4 patients 
required surgical intervention. However, 2 patients suffered from bleeding or bruising 
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complications. Because of the potential of bleeding, Ikehata et al. used low dose (5000 IU/ 
day) of UFH for treating patients with active UC refractory to steroid therapy [108]. They 
reported that low dose UFH was safe and useful when used with standard therapy.  
 So far three randomised clinical studies investigated the efficacy of UFH in patients 
with UC [109-111]. In one study, a total of 20 patients (17 severe UC and 3 severe Crohn's 
colitis) were treated with 5-aminosalicylic acid and either with intravenous UFH for 5 days, 
followed by subcutaneous UFH for 5 weeks or intravenous hydrocortisone for 5 days 
followed by oral prednisolone for 5 weeks [110]. UFH was found to be as effective as 
corticosteroids in treating severe colitis. Importantly, UFH was well-tolerated with no 
reported bleeding complications. In contrast, Panes et al. compared the efficacy of 
intravenous UFH as monotherapy versus methylprednisolone in hospitalised patients with 
moderate to severe UC [109]. They found that UFH was not effective as a monotherapy 
where none of the patients in the UFH group (n = 12), compared with 69% of patients in the 
methylprednisolone group (n = 13), achieved significant improvement. In addition, 3 
patients in the UFH group dropped out because of increased rectal bleeding. Another study 
by Korzenik et al. evaluated the efficacy of subcutaneous UFH in addition to standard 
therapy for the treatment of moderate to severe colitis [111]. The results indicated that 3 
patients experienced a transient increase in rectal bleeding, but were able to continue UFH 
treatment.  
 LMWHs have a better safety profile, including reduced risk of bleeding than UFH 
[48]. Therefore, subsequent studies investigated the safety, tolerability and efficacy of 
LMWHs in combination with standard therapy. In one study, 12 patients with mild-to-
moderate active UC who had either responded poorly to conventional therapy or had 
experienced relapse were treated with subcutaneous dalteparin for 12 weeks [112]. This 
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LMWH was found to be well tolerated and no serious adverse effects were reported. Also, 
11 of 12 patients improved symptomatically and 50% of patients achieved complete 
remission. Subsequently, efficacy of other types of LMWHs was also investigated in UC. 
For example, Vrij and colleagues reported that 80% of patients with severe active UC 
responded to subcutaneous nadroparin when administered twice daily for 8 weeks [113]. 
Alternatively, another study suggested that weekly dosing of subcutaneous enoxaparin was 
also effective in treating moderately active UC in patients [114].   
 However, some reports have shown disappointing results. For example, a 
prospective, double-blind, randomised placebo controlled trial investigating the efficacy of 
subcutaneous enoxaparin reported no clinical benefit over placebo in mild to moderately 
active UC [115]. With similar disappointing results, in 2007 de Bievre et al. presented a 
placebo controlled trial in which 29 patients with a mild to moderate relapse of UC during 
standard treatment were randomised to receive either subcutaneous LMWH (reviparin) or 
placebo for a period of 8 weeks [116]. The study reported no clinical advantage of the 
LMWH compared with placebo. Also, data from a larger group of patients (n = 100) revealed 
that subcutaneous administration of another LMWH (tinzaparin) did not significantly 
improve clinical outcome in patients with mild to moderately active UC [117]. 
 In the above mentioned studies, UFH or LMWHs were administered either 
intravenously or subcutaneously since heparins are commercially available as parenteral 
dosage forms. However, some studies also investigated the efficacy of orally administered 
LMWHs in UC. In one study, patients with UC (resistant to standard therapy) were treated 
with oral LMWH twice daily with sulfasalazine for more than 4 weeks. The authors reported 
that clinical remission was achieved in 95% of patients (n = 20) with no rectal bleeding 
[118]. Pastorelli et al. used an extended colon-released oral formulation of a LMWH 
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(parnaparin) in patients with mild to moderately active distal UC and refractory to 
mesalazine. A total of 70% of patients (n = 10) achieved complete clinical remission [119]. 
The positive results of this formulation of LMWH were further confirmed in a multi-centred, 
double-blind, randomised, placebo-controlled trial [120]. 
 Shen and colleagues in their meta-analysis of eight randomised controlled trials 
compared the efficacy and safety of adjuvant parenteral heparins with standard therapy in 
patients with UC. Their meta-analysis suggested that heparins have no additive benefit over 
standard therapy although their use was found to be safe in patients with UC [121]. 
Nonetheless, a Cochrane review by Chande and colleagues concluded that heparins may be 
effective in UC only if administered as oral colon-release formulation [122]. 
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Table 1.2 Use of heparins in treating patients with UC. 
Study design Patients (n) UFH/ LMWH 
(route/type/dosage) 
Concurrent treatment with 
heparins for UC 
 
Effects/ Remission rate Author and year 
      
Pilot study Refractory UC 
(10) 
i.v UFH 30000 - 36000 IU 
daily or s.c 10000 IU bd until 
advised to stop 
 
Corticosteroids (tapering and 
stopped), sulfasalazine  
Improved clinical 
outcome (9/10) 
 
Gaffney et al. 
1995 [43] 
Open label trial Moderate and 
severe UC (6) 
i.v UFH 3000 IU every 4 
hours 1 week then s.c 
calcium heparinate 0.1 ml/ 
10 kg bd 3 weeks or 4 weeks 
 
- Improved clinical 
outcome (4/6) 
Brazier et al. 
1995+ [105] 
Case study  Active UC (16) i.v or s.c UFH 25000 - 40000 
IU daily IU 4 weeks 
Corticosteroids or 5-
aminosalicylic acids or 
azathioprine 
 
Improved clinical 
outcome (12/14) 
Evans et al. 1997 
[107] 
Uncontrolled trial Mild to moderate 
UC (12) 
s.c dalteparin 5000 anti-Xa 
IU bd 12 weeks 
Corticosteroids or 5-
aminosalicylic acids or 
sulfasalazine 
 
Improved clinical 
outcome (6/12) 
Torkvist et al. 
1999 [112] 
Uncontrolled trial UC (13) and 
Crohn’s colitis 
(4) 
i.v heparin, dose aiming a 
partial thromboplastin time 
of 60 s for 2 weeks then 
12,500 IU bd 6 weeks  
 
Sulfasalzine  Improved clinical 
outcome (7/13 in UC) 
Folwaczny et al. 
1999 [106] 
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Uncontrolled trial Moderate and 
severe UC (20) 
p.o LMWH 366 IU/ kg bd 4 
weeks 
Corticosteroid (tapering and 
stopped) and sulfasalazine 
Improved clinical 
outcome (19/20) 
Cui and Jiang 
1999 [118] 
Open label trial  Moderate active 
UC (10) 
s.c enoxaparin 500 anti-Xa 
IU/ week for 12 weeks (100 
anti-Xa IU/mg) 
5-aminosalicylic acids or 
azathioprine 
Improved clinical 
outcome (10/10) 
Dotan et al. 2001 
[114] 
Open label trial Severe active UC 
(25) 
s.c nadroparin 5700 anti-Xa 
IU bd 8 weeks 
Corticosteroids, 
cyclosporins, azathioprine 
Improved clinical 
outcome (20/25) 
Vrij et al. 2001 
[113] 
Open label trial  Active UC (11) i.v UFH 5000 IU daily 6 
weeks 
Corticosteroids (tapering and 
stopped), salicylates and 
sulfasalazine 
Improved clinical 
outcome (9/11) 
Ikehata et al. 
2003+ [108] 
Open label trial Mild to moderate 
UC (10) 
p.o colon-released parnaparin 
70,140, 210mg daily 8 weeks 
(75 - 110 anti-Xa IU/mg) 
5-aminosalicylic acids Improved clinical 
outcome (8/10) 
Pastorelli et al. 
2008[119]   
Mullti-centre RCT Moderate and 
severe UC (70) 
s.c UFH 10000 IU bd or tds 6 
weeks 
Corticosteroids, or 5-
aminosalicylic acids or 
azathioprine 
Unknown (result not 
published) 
Korzenik et al 
1999+ [111] 
Single-centre RCT Severe UC (17) 
and Crohn’s 
colitis (3) 
i.v UFH 25000 - 45000 IU 
daily 5 days then s.c 10000 
IU bd 2 weeks then 5000 IU 
bd 3 weeks 
5-aminosalicylic acids  Improved clinical 
outcome (6/8 UFH 
treatment group; 8/12 
steroid treatment group) 
Ang et al. 2000 
[110] 
Multi-centre RCT Moderate to 
severe UC (25) 
i.v UFH 31456 ± 290 IU 
daily 10 days 
 
- 
No significant beneficial 
effect 
Panes et al. 2000 
[109] 
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Multi-centre RCT Mild to moderate 
UC (41) 
s.c dalteparin 5000 anti-Xa 
IU bd 8 weeks 
Corticosteroids and 5-
aminosalicylic acids or 
sulfasalazine 
No significant beneficial 
effect 
Torkvist et al. 
2001+ [123] 
Multi-centre RCT 
Double-blind 
Placebo-controlled 
Mild to moderate 
UC (100) 
s.c tinzaparin 175 anti-Xa 
IU/ kg daily 2 weeks 
followed by 4500 anti-Xa IU/ 
day 4 weeks 
Salicylates  No significant beneficial 
effect 
Bloom et al. 2004 
[117] 
Multi-centre RCT 
Double-blind 
Placebo-controlled 
Active UC  
(117) 
s.c deligoparin 75 or 125 mg 
daily 6 weeks 
 
Corticosteroids, 5-
aminosalicylic acids and/or 
azathioprine/6-
mercaptopurine 
No significant beneficial 
effect 
Korzenik et al. 
2003+ [124] 
Single-centre RCT Active UC (34) s.c enoxaparin 100 anti-Xa 
IU/ kg daily 12 weeks 
Corticosteroids and 
aminosalicylates 
No significant beneficial 
effect 
Zezos et al. 2006 
[115] 
Multi-centre RCT 
Double-blind 
Placebo-controlled 
Mild or moderate 
UC (29) 
s.c reviparin 3436 anti-Xa IU 
bd 8 weeks 
Aminoalicylates  No significant beneficial 
effect 
de Bievre et al. 
2007 [116] 
Multi-centre RCT 
Double-blind 
Placebo-controlled 
Mild to moderate 
left-sided active 
UC (121) 
p.o colon-released parnaparin 
210 mg (18000-19000 anti-
Xa IU) daily 8 weeks 
 
Aminosalicylates Improved clinical 
outcome (51/61 in 
parnaparin treatment 
group; 38/60 in control 
group) 
Celesco et al. 
2010 [120] 
 
Twice daily, bd; three times a day, tds; intravenous, i.v; subcutaneous, s.c; oral, p.o; randomised controlled trial, RCT; ulcerative colitis, UC. 
+published as abstract only 
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1.2.4 Proposed reasons for reported inconsistent clinical outcomes of heparins in UC 
The contradictory results observed with heparins are not restricted to UC only; such findings 
have also been reported in many other types of inflammatory conditions. For example, one 
randomised clinical study reported an inhibitory effect of inhaled UFH on methacholine-
induced bronchoconstrictive response [125]. In contrast, no such inhibitory effect of UFH 
on bronchoconstriction had been observed in another randomised trial [126]. Also, a LMWH 
(enoxaparin) had been shown to be an effective and simple alternative therapy for the 
management of lichen planus [127]. However, there are also reports indicating that heparins 
are not effective when used for the management of the same clinical condition [128,129].  
 There could be a number of reasons behind the observed discrepancies with regards 
to the reported clinical outcomes when heparins were used for the management of UC. These 
reasons may include the use of: i) different treatment durations (ranging from 10 days to 12 
weeks); ii) heparins as monotherapy or combined with standard therapy; iii) different dosage 
regimens of heparins (e.g. 1 mg/ml of enoxaparin daily for 12 weeks or 5 mg/ml of 
enoxaparin at weekly intervals for 12 weeks); iv) patient populations with different disease 
extent and severity (mild, moderate, severe or active or refractory UC) and v) inconsistent 
study end points (remission of disease symptoms and/or endoscopic and histologic 
improvement). Apart from the above mentioned well-known reasons, dissimilar outcomes 
could be because of: i) different routes of administration (subcutaneous, intravenous or oral) 
and ii) the structural differences between various types of LMWHs. 
 Heparins are composed of anticoagulant and non-anticoagulant oligosaccharides. 
The parenteral route of administration is likely to increase the risk of bleeding when an 
anticoagulant effect was not required. Therefore, low parenteral doses were administered in 
an attempt to avoid the bleeding complications in patients with UC [108,114]. Also, when 
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used for the treatment in UC, the availability of heparins at the site of inflammation after 
parenteral administration is unknown. Alternatively, if heparins are administered orally then 
they can be delivered to the site of inflammation. This could potentially minimize the risk of 
bleeding as well as allow the use of high doses. Data from a number of pre-clinical and 
clinical studies have suggested an increased effectiveness of LMWHs when given orally at 
high doses [95,119,130]. For example, a specific oral extended-release formulation which 
avoids degradation and systemic absorption of a LMWH was used to deliver a dose of 210 
mg parnaparin (approximately 18000 - 19000 anti-Xa IU activity) to the colonic mucosa of 
patients with active distal UC [120]. Administration of such a dose would not be possible 
through parenteral route where the anticoagulant effects predominate. Unlike parenteral 
heparins, the oral route allows the administration of high dose of LMWHs. This may explain 
the improved clinical outcome in patients with UC who received oral LMWHs compared 
with patients who were treated with intravenous UFH or subcutaneous LMWHs. 
 A total of eight LMWHs are approved for clinical use worldwide, as shown in Table 
1.3. All LMWHs are prepared through either chemical or enzymatic depolymerisation and 
have average MWs between 3800 and 6500 Da [49,131]. They display many similar 
physical, chemical and biological properties [49,51]. However, many studies have shown 
structural and compositional differences between various types of LMWHs [49,132]. Apart 
from this, the type of UFH chosen to be chemically or enzymatically digested and the degree 
of purification of the starting material both contribute to the final characteristics of the 
particular LMWH. One type of LMWH (e.g. tinzaparin) is structurally different than another 
type of LMWH (e.g. dalteparin) and therefore the clinical efficacy of two LMWHs is not 
comparable. For example, subcutaneous administration of dalteparin twice daily for 12 
weeks was found to be effective and safe in patients with active, corticosteroid-refractory 
UC [112]. On the other hand, tinzaparin showed no benefit over standard therapy when used 
 30 
 
for the treatment of active UC [117]. The presence of structurally different oligosaccharides 
in dalteparin and tinzaparin could be responsible for the observed disparity. For example, 
dalteparin is prepared by nitrous acid induced deaminative cleavage of UFH resulting in 
formation of an anhydromannitol ring at the reducing end [133]. Tinzaparin is prepared by 
enzymatic β-eliminative cleavage by heparanase I of UFH, resulting in the presence of an 
unsaturated uronate residue at the non-reducing end of virtually every chain [133]. Apart 
from this, tinzaparin is much more polydisperse in nature than dalteparin and is composed 
of oligosaccharides ranging from dp2 (two saccharide units) to dp18 (18 saccharide units). 
On the other hand, dalteparin does not have oligosaccharides smaller than dp8 and is mainly 
composed of oligosaccharides larger than dp10 [133]. Therefore it may be possible that the 
clinical effect of tinzaparin observed in patients with UC could be because of the presence 
of: i) smaller oligosaccharides (< dp 6) and/ or ii) the unique unsaturated uronate residue at 
the non-reducing end. Several in vitro studies have also shown that the presence of different 
proportion of large and small oligosaccharide chains within various LMWHs can produce 
different responses to the cells and molecules involved in the process of inflammation 
[134,135]. 
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Table 1.3 Different LMWHs with their methods of depolymerisation, average molecular weight and anticoagulant activity [49,51,136,137]. 
Product Mode of depolymerisation Average 
molecular 
weight 
(MW) 
European 
pharmacopeia 
(EP) range for 
MW 
 
Anti-Xa IU/ 
mg 
Anti-factor 
Xa/ anti-
thrombin 
EP range for anti-
factor Xa/ anti-
thrombin 
Tinzaparin  β-eliminative cleavage by heparinase I 6500 5500 - 7500 70 - 120 1.5 1.5 - 2.5 
Enoxaparin β-eliminative cleavage of benzyl ester of 
UFH by sodium hydroxide (NaOH) 
4500 3800 - 5000 90 - 125 3.9 3.3 - 5.3 
Dalteparin  Deaminative cleavage with nitrous acid 6000 5600 - 6400 110 - 210 2.5 1.9 - 3.2 
Parnaparin  Oxidative depolymerisation with copper 
(II) ion (Cu2+) and hydrogen peroxide 
(H2O2)  
5000 4000 - 6000 75 - 110 2.3 1.5 - 3.0 
Nadroparin  Deaminative cleavage with nitrous acid 4300 3600 - 5000 95 - 130 3.3 2.5 - 4.0 
Certoparin  Deaminative cleavage with isoamyl nitrite 5400 n.a 95 - 130 2.4 n.a 
Reviparin Deaminative cleavage with nitrous acid 4400 n.a 106 - 130 4.2 n.a 
Bemiparin β-eliminative cleavage of quaternary 
ammonium salt of UFH by 
cetyltrimethylammonium ion (CTA+) and 
hydroxide (OH-) 
3800 n.a 80 - 120 9.7 n.a 
      Not available, n.a 
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 The clinical efficacy of enoxaparin, one of the most widely used LMWHs for the 
treatment and prophylaxis venous thromboembolism, in the management of UC has been 
investigated. Dotan et al. found that enoxaparin when administered once a week combined 
with aminosalicylate (mesalamine) was an effective adjuvant treatment for UC [114]. They 
also concluded that a combination of enoxaparin and mesalamine therapy may delay or 
preclude the need for steroid treatment. However, Zezos and co-workers observed that daily 
administration of enoxaparin combined with aminosalicylate had no additional benefit over 
standard therapy (aminosalicylate and weekly tapered corticosteroids) [115]. The precise 
reason for the varying response to enoxaparin is currently unknown. However, one possible 
explanation could be the batch-to-batch variability of enoxaparin preparations. For example, 
in one study the clinical effect of enoxaparin in chronic inflammation was observed only 
when it was used from certain batches [138]. A LMWH is composed of a mixture of 
anticoagulant and non-anticoagulant oligosaccharides [76,134]. It is now known that the 
presence of non-anticoagulant oligosaccharides is responsible for the reported anti-
inflammatory activity of a LMWH [134]. Commercially available LMWHs are standardised 
according to their anticoagulant oligosaccharides (responsible for the anticoagulant effect) 
but not based on their non-anticoagulant oligosaccharides [132,139]. Therefore, each batch 
of enoxaparin is expected to have the same anticoagulant activity but not the same non-
anticoagulant effect (e.g. anti-inflammatory activity). In fact, Patel et al. have reported 
significant structural and compositional differences between two different batches of 
enoxaparin formulated by the same manufacturer [140]. Therefore, the clinical effect of 
enoxaparin in UC may be dependent on the amount and nature of anti-inflammatory 
oligosaccharide(s) present in any given batch of enoxaparin, which may account for the 
varied responses seen. 
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1.2.5 Complexity of heparins  
Apart from the reported inconsistent clinical outcomes, the potential of heparins in UC are 
largely hindered by the fear of bleeding from the anticoagulant activity. The investigation of 
anti-inflammatory effects of heparins is challenging because these activities are expressed 
with high heparin concentrations where the anticoagulant effects predominate. To avoid the 
bleeding complications, clinical studies have used low doses of UFH or LMWH to assess 
their roles in the management of UC. Because of the considerable therapeutic potential of 
high doses of LMWHs in the management of UC, efforts have been made to identify and 
isolate the non-anticoagulant oligosaccharides of LMWHs. The currently used approach to 
identify the non-anticoagulant fractions is further depolymerisation of LMWHs by chemical 
or enzymatic methods. Nonetheless, the depolymerisation process inflicts compositional 
changes in oligosaccharides of heparins [133] and it has been shown that this process was 
responsible for alteration of the structures of oligosaccharides important for certain 
biological activities of intact heparins [141,142]. The depolymerisation is carried out at 
elevated temperatures. Patel and colleagues found that some oligosaccharides in LMWH are 
heat sensitive and can undergo chemical modification, especially desulphation [143]. An 
oligosaccharide’s sulphation pattern is a key characteristic feature for its anti-inflammatory 
properties [134]. Apart from this, depolymerisation follows the freeze-drying process [144]. 
The freeze-drying results in physical changes of some oligosaccharides within the LMWH 
molecule. 
 To separate, isolate and identify the non-anticoagulant oligosaccharides of LMWH 
without prior chemical or enzymatic digestion is another effective approach. The main 
obstacle in the isolation of LMWH oligosaccharides is the deficiency of a high resolution 
technique. LMWHs have proven to be extremely difficult to analyse because of their high 
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negative charge and structural complexity [145]. These characteristics make the separation 
of LMWHs without further depolymerisation prior to the analysis, a difficult analytical 
challenge. A reversed-phase ion-pair high performance liquid chromatography method has 
been developed and validated for the separation and isolation of various oligosaccharides of 
LMWHs without prior enzymatic or chemical depolymerisation [146]. However, this 
technique requires a positively charged non-volatile ion-pairing reagent to separate 
negatively charged oligosaccharides of LMWH. The presence of non-volatile ion-pairing 
reagent is reported to interfere with the investigation of anti-inflammatory properties of the 
isolated oligosaccharides [147].  
 More recently an ion-exchange chromatography (IC) technique for the separation of 
a LMWH has been developed [76]. This technique successfully separated enoxaparin into 
more than 20 different oligosaccharides. Using the same technique, another study has also 
identified groups of oligosaccharides in LMWHs with high, low and no anticoagulant 
activities [134]. Each non-anticoagulant oligosaccharide should then be examined for its 
clinical efficacy against UC. Such an investigation may lead to new formulations of a 
purified LMWH oligosaccharide (or combination of purified oligosaccharides) that exhibit 
effective anti-inflammatory properties, without significant anticoagulant activity. The 
development of such a formulation could therefore serve as a novel therapeutic approach for 
the treatment of UC, as well as other inflammatory diseases. 
 In addition, when a commercially available LMWH is tested for its efficacy against 
UC it is important to have the presence of the same non-anticoagulant oligosaccharides in 
different batches. An effective way seems to be to obtain the standard chromatographic 
profiles of non-anticoagulant oligosaccharides of the particular batch of a LMWH (e.g. 
enoxaparin) with a proven value in UC. To minimize batch-to-batch variations of non-
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anticoagulant oligosaccharides and hence inconsistent clinical outcomes, enoxaparin batch-
to-batch uniformity could be confirmed by comparing the chromatographic profiles of 
enoxaparin’s non-anticoagulant fragments against its non-anticoagulant oligosaccharide(s) 
with proved anti-inflammatory effect. 
1.3 Fucoidans 
Like heparins, fucoidans are heterogenous and highly sulphated polysaccharides. Unlike 
heparins, fucoidans are naturally present in the cell wall matrix of brown algae [148]. 
Fucoidans are synthesised in the Golgi apparatus of cells as a kind of mucilage. It is believed 
that the main function of fucoidans is to prevent the plant from drying out when exposed to 
air. Although fucoidans are also found in the cell wall of invertebrates such as sea cucumber 
and sea urchin, there is only very limited information about their function in these organisms 
[148]. Fucoidans have been extracted from different brown algae such as Fucus vesiculosus, 
Fucus evanescens, Cladosiphon okamuranus, Undaria pinnatifida, Ecklonia cava and 
Laminaria japonica. Commonly, seaweeds are collected, cleaned, and dried before 
fucoidans are extracted using water or organic solvents with or without chemical or 
enzymatic hydrolysis [149]. Thus, the products derived from brown algae are mostly 
fucoidan containing extracts rather than fully purified fucoidans.  
In contrast to heparins, fucoidans are composed primarily of repeating units of 
disaccharide units with α–1,3-linked and α–1,4-linked fucose (Fig. 1.4) [148]. Apart from 
fucose, minor amounts of uronic acids, glucosamines and monosaccharides such as 
galactose, xylose, glucose and mannose are also present [150,151]. Unlike heparins with 
probable sulphation at N-, 2-O and 6-O of disaccharide units, sulphation of fucoidans is 
found at 2-O, 4-O or both positions and in rare cases at the 3-O position [152]. Neither N-
acetylated nor N-sulphated groups are present in fucoidans compared with heparins. The 
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polysaccharide chains of fucoidans are not only linear but also highly branched. The MW of 
fucoidans differ from one species to the other, ranging from 13 kDa to 1300 kDa [153]. Also, 
MW within the same species can be different. For example, crude fucoidan from Fucus 
vesiculosus purchased from Sigma has MW 20 - 200 kDa, with an average weight of 140 
kDa. Others reported that fucoidan prepared from Fucus vesiculosus has a MW between 43 
k Da and 680 kDa, with average of 160 kDa [154]. The differences might be due to the 
extraction method used, season of collection or be based on geographical differences. 
Because of the compositional diversity of crude fucoidans and their large size, attempts have 
been made to prepare low molecular weight fucoidans (LMWFs) to facilitate the 
identification of the structural basis of their biological activities. Similar to LMWHs, 
LMWFs can be obtained by chemical, physical or enzymatic depolymerisation of intact 
fucoidans [155].  
 
Figure 1.4 Structure of fucoidans.  
Typical backbone chain of fucoidans in brown algae consisting of repeating disaccharide unit of α-
1,3-fucose or α-1,4-fucose. R depicts the sites for potential substitution of fucose unit, sulphate or 
acetyl groups [151]. 
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 With recent attention regarding the usefulness of marine algae, fucoidan-rich extracts 
from brown seaweeds such as Fucus vesiculosus have become commercially available as 
dietary products and health supplements. It is believed that fucoidans enhance immune 
functions by modulating physiological responses [156]. Like heparins, fucoidans possess 
abundant biological activities ranging from anti-inflammatory, anti-oxidant, anticoagulant, 
anti-bacterial, anti-viral to anti-cancer properties [151,156]. Recently, a randomised, 
placebo-controlled, double-blind trial found increased immune responses to seasonal 
influenza vaccination in elderly volunteers who were supplemented with fucoidan extract 
from Undaria pinnatifida [157]. Their findings demonstrate the immune-stimulatory effect 
of fucoidan, echoing a possible role of fucoidan in immune-potentiation. Therefore, 
fucoidans appear to possess potential as health promoting or functional foods and as 
ingredients in cosmoceutical products. Recently, scientific interest has shifted towards 
understanding their value as pharmaceutical drugs [156,158]. At present, researchers have 
evaluated the potential of fucoidans in various therapeutic applications including 
inflammation, infection and cancer.  
1.3.1 Fucoidans in inflammation  
Fucoidans have been reported to reduce inflammation in different animal models of 
inflammatory conditions. Intravenous injection of 4 mg/kg/day of fucoidan extracts from 
nine different species of brown algae such as Fucus evanescens, Fucus serratus, Fucus 
vesiculosus, Laminaria saccharina and Cladosiphon okamuranus were compared in an acute 
model of peritonitis in rats. Each fucoidan extract reduced the number of neutrophils 
recruited into the cavity to different extent (66.4% - 94.1% inhibition) [151]. On the other 
hand, intravenously injected fucoidan from Fucus vesiculosus at 25 mg/kg prior and 
immediately after pancreatitis induction reduced the severity of inflammation in mice by 
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decreasing neutrophil infiltration and systemic inflammation [159]. Similarly, orally 
administered 300 mg/kg/day of fucoidans extracted from Undaria pinnatifida inhibited 
inflammation by suppressing the production of inflammatory cytokines in an arthritis model 
in mice [160]. Moreover, in a zebrafish model of tail-cutting acute injury and LPS-induced 
inflammation, fucoidan extract from Ecklonia cava and Fucus vesiculosus at 100 µg/ml 
respectively inhibited inflammation significantly [161]. Overall, the anti-inflammatory 
properties of fucoidan extracts appear to be similar to those of heparins. 
 Likewise, the mechanisms by which fucoidans attenuate inflammatory responses are 
thought to be similar to the action of heparins. In parallel with heparins, fucoidans extracted 
from different sources such as Fucus vesiculosus and Laminaria japonica down-regulate the 
NF-қB signalling pathway and hence reduce the levels of a number of pro-inflammatory 
cytokines such as IL-6 and TNF-α and matrix metalloproteinases (MMPs) [162-164]. 
Fucoidans interfere with P- and L-selectins, thus prevent leukocyte rolling on the 
endothelium before their adhesion [165] and extravasation from circulation into the inflamed 
site [159,166]. The anti-inflammatory effect of fucoidans is also attributed to the suppression 
of iNOS expression by immune cells, which inhibits their NO production [165]. Nonetheless, 
the cellular and molecular mechanisms of fucoidans and in particular their target molecules 
that are responsible for the different biological activities remain poorly understood.  
1.3.2 Fucoidans in UC 
In contrast to heparins, the use of fucoidans in UC has not yet been investigated in patients 
with UC. Given that oral fucoidans were found to be safe in pre-clinical and other clinical 
studies as well as the success of fucoidans in immunomodulation and improvement of 
osteoarthritis [156], it is likely that fucoidans could be used to treat chronic inflammatory 
conditions such as UC. 
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Several studies have investigated the effects of fucoidans in animal models of UC. 
Fucoidan extracts from a number of brown algae were shown to prevent or treat colitis (Table 
1.4). Not surprisingly, their specific activity was dependent on the source of the extracts. 
Administering chow containing 0·05% w/w fucoidan obtained from Cladosiphon 
okamuranus was reported to be more effective than fucoidan derived from Fucus vesiculosus 
in relieving the pathology of chronic colitis in mice [167]. It is generally thought that 
fucoidan ameliorates intestinal inflammation by down-regulating the production of pro-
inflamatory cytokines such as IL-6 by colonic epithelial cells. In addition, it was also 
demonstrated that intravenous Fucus vesiculosus extract at 25 mg/kg/day reduced mucosal 
inflammation in acute colitis by abolishing TNF-α-induced rolling and migration of 
leukocytes [166].  
 Oral fucoidan extract from Laminaria japonica (300 mg/kg/day) was reported to 
reduce the overall inflammatory scores in an acute colitis mouse model, which was 
associated with decreased levels of pro-inflammatory cytokines such as IL-1β, IL-6 and 
TNF-α, however this effect was not seen at a lower dose (100 mg/kg/day) in this model 
[168]. In contrast, oral administration of a fucoidan extract of an undisclosed source at 20 
mg/kg/day was found to be effective in ameliorating colitis in the same mouse model. 
Interestingly, a greater protective effect against colitis in mice was also observed when 
fucoidan extract was given in combination with lutein, a xanthophyll and one of known 
naturally occurring carotenoids present in fucoidan extracts, which suggests that extracts 
from algae might be composed of substances having synergistic anti-inflammatory effect 
[169].   
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Table 1.4 Fucoidans in murine experimental colitis. 
Experimental 
design 
Fucoidan 
(type/dose) 
Results Author 
and year 
DSS-induced 
acute colitis in 
male Balb/c mice 
i.v 25 mg/kg/day Fucus vesiculosus 
fucoidan (Sigma) prior 5 days and 
during 5 days colitis induction 
Reduced severity of 
colitis 
Zhang et 
al. 2001 
[166] 
DSS-induced 
chronic colitis in 
female Balb/c 
mice 
p.o via chow containing of 0·05% w/w 
Cladosiphon okamuranus fucoidan 
(Tropical Technology Centre) or Fucus 
vesiculosus fucoidan (Sigma) for 56 days 
Reduced severity of 
colitis with 
Cladosiphon 
okamuranus 
fucoidan  
Matsumoto 
et al. 2004 
[167] 
DSS-induced 
acute colitis in 
male Balb/c mice 
p.o 20 mg/kg/day fucoidan (species 
unspecified, Haewon Biotech) alone or 
in combination with Lutein (Yixin 
Pharmaceutical) for 4 days after colitis 
induction (day 8 to day 11)   
Reduced severity of 
colitis 
Lee and 
Yoon 2011 
[169] 
DSS-induced cute 
colitis in male 
Balb/c mice 
p.o 100 or 300 mg/kg Laminaria 
japonica fucoidan (Kyung Hee Hanyak 
Company) alone or in combination with 
probiotic mixture containing 3 bacterial 
genera (Bifidobacterium, Lactobacillus 
and Streptococcus) twice daily for 7 
days during colitis induction 
Reduced severity of 
colitis in 300 mg/kg 
alone or in 
combination groups 
Ko et al. 
2014 [168] 
 
Dextran sulphate sodium, DSS; intravenous, i.v; oral, p.o. 
 
1.3.3 Prospects and challenges in the development of fucoidan-based therapy in UC  
Unlike heparin, fucoidans are mainly available as oral formulation at present. Based on the 
experiences with heparins, it is assumed that the absorption and bioavailability of fucoidan 
is poor due to their high anionic polarity and large molecular size. However, low 
bioavailability is not an issue in UC where local effect is preferable over systemic exposure 
to a drug. Nonetheless, free fucoidan has been detected in human plasma after consumption 
of whole Undaria pinnatifida extract (3 g/ day) by healthy volunteers [170]. It was proposed 
that gut bacteria degrade fucoidan chains into smaller fragments, which are then absorbed 
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into the blood stream. However, the antibody used for detection of fucoidans could have 
cross-interacted with endogenous heparins. Without compositional analysis, the 
pharmacokinetic profile of each fucoidan, its degradation products and metabolites after oral 
administration are not known. Importantly, based on their similarity to heparins, oral 
administration of fucoidan is not associated with the risk of bleeding. A pilot study in healthy 
humans reported that fucoidan, when given orally, did not demonstrate anticoagulant activity 
[171]. Nevertheless, it was shown that when tested in vitro, fucoidan extracts from some 
species exhibit heparin-like anticoagulant activity by a mechanism that is not completely 
understood.  
 Since fucoidans share some structural similarities and anionic characteristics with 
heparins, it was postulated that the position of sulphate groups, degree of sulphation and 
MW of fucoidans are essential for their interaction with proteins, thereby, eliciting complex 
biological responses [148]. Indeed, the biological properties of fucoidans are dependent on 
the chemical compositions of different fucoidans [172]. In a comparison study of fucoidan 
extracts from nine different origins, a distinctive specificity and selectivity of each extract 
with regards to anti-inflammatory, anti-angiogenesis, anti-coagulant and anti-adhesion was 
reported [151]. The extracts from Laminaria saccharina and Fucus serratus effectively 
exhibited inhibitory activities in all assays. However, while the extract of Fucus vesiculosus 
strongly inhibited neutrophil infiltration in rats, they displayed no other activities in vitro. 
While fucoidan extracted from Cladosiphon okamuranus demonstrated a potent anti-
inflammatory activity, it was less effective as an anti-adherent and had no anti-angiogenesis 
and no anti-coagulation effects. It was speculated that the loss or lack of activities was related 
to reduced sulphate content and the presence of glucuronyl substituents along the 
polysaccharide chains of Cladosiphon okamuranus [151]. When the anti-inflammatory 
activity of fucoidan extracts from three seaweeds were compared for their effects on NO 
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production in LPS-induced RAW264.7 macrophages, an extract from Sargassum 
cristaefolium showed strong inhibitory effects, while the others had low or no activity. The 
optimum sulphate content was estimated to be 9.42%, while higher sulphate content or 
oversulphated fucoidan extracts had less NO inhibitory activity [173]. In term of size, 
fucoidans with a MW between 380 kDa and 1200 kDa showed higher NO inhibitory activity 
than the LMWHs between 1.9 and 106 kDa. Others also demonstrated that higher MW 
fucoidan (> 150 kDa) exhibited stronger cytotoxicity against cancer cells compared with a 
LMWH (27 - 81 kDa) derived from Undaria pinnatifida [174]. In contrast, in a study 
comparing the activity of different fucoidan fractions from Undaria pinnatifida, lower MW 
fractions (5 - 30 KDa) were considerably more active in inhibiting cell growth compared 
with fractions with higher MW (> 30 KDa) [175]. Interestingly, different MW fucoidans 
extracted from Undaria pinnatifida showed distinctive activities in an arthritis model in mice 
[160]. High MW fucoidan (100 ± 4 kDa) increased inflammation by enhancing the 
production of IFN-γ in spleen cells, whereas the LMWF (1 ± 0.2 kDa) had the opposite 
effect.  
 The variation of responses might be attributed to the differences in chemical features 
and compositions present in different crude fucoidan preparations. Fucoidans are present in 
more than a thousand different species of brown seaweeds [155]. Apart from the sources, 
location, season they are harvested, the extraction and purification process add another 
dimension to the complexity of their polymeric structure, composition as well as their purity. 
Since fucoidans are extracted differently in the literature, each isolated crude fucoidan 
preparation described by different researchers is unique in their chemical composition and 
structure. In addition, seaweeds are known for having other bioactive substances like lutein 
and polyphenols apart from fucoidan, thus numerous additional components could be 
included in fucoidan extracts, which could be confounding factors for the observed effects 
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of fucoidans. Thus it is important to note that the sourcing process is the key factor that 
influences the compositions (sequence, sulphation pattern and MW) of fucoidan extracts, 
and ultimately their biological activities.  
 It has become clear that the structural elucidation of fucoidans will be essential for a 
thorough understanding of their biological properties. The availability of analytical 
techniques such as mass spectrometry, infrared spectroscopy and nuclear magnetic 
resonance spectroscopy has facilitated the structural analysis of fucoidans [158]. These 
powerful tools provide structural information including the composition of their backbone 
monosaccharides, glycosidic linkage types, positions of sulphation and branching. However, 
studies reveal that the chemical compositions and structures of fucoidans are very complex, 
vary from species to species and highly dependent on the sources and preparation processes 
[158,176]. Like in the case of heparins, to facilitate structural and compositional analysis, 
both chemical and enzymatic methods are used to partially hydrolyse fucoidans into smaller 
fragments and to remove sulphate groups [176]. However, this is not a straightforward 
process as depolymerisation may introduce changes to the sulphation pattern, to 
oligosaccharides sizes and their residues. Therefore, similar to the situation with heparins, 
due to the complexity of this polymeric mixture, the precise structural characterization of 
fucoidans will be challenging. In fact, given the branched nature of fucoidans, the structural 
activity relationships will be significantly more difficult compared with heparins.   
1.4 Rationale of study  
UC involves dynamic process of inflammation and requires continuous optimisation of 
treatment throughout the course of disease. Therapeutic agents with different mechanisms 
of action would be important to maintain long-term remission. Heparins and fucoidans 
possess anti-inflammatory activities and are therefore potential therapeutic candidates for 
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UC. However, at present, the uncertainty around the effectiveness of heparins and fucoidans 
in UC make them unsuitable for the management of UC. This is further complicated by their 
heterogeneity. It is estimated that only 30% of oligosaccharides present in heparins actually 
possess anti-coagulation activity, and the remaining non-anticoagulant oligosaccharides may 
have other physiological functions such as anti-inflammatory activity. Commercially 
available UFH and LMWHs are standardised according to their anticoagulant activity but 
not tested for the non-anticoagulant properties. Each batch of UFH or a LMWH is expected 
to have a similar composition with regards to their anticoagulant oligosaccharides. However, 
this is not the case when the composition of non-anticoagulant oligosaccharides is 
considered. Furthermore, heparins may lead to bleeding when used in clinical conditions 
such as UC where the anticoagulation is not required. Therefore, in order to minimise the 
risk of bleeding and improve the specificity of heparins in UC, it is important to identify the 
oligosaccharides of heparins that possess anti-inflammatory activity without the 
anticoagulant side effects. Similarly, fucoidans, extracted from seaweed, are crude mixtures 
of oligosaccharides. Their composition is highly dependent on the species, site and season 
of collection as well as extraction and purification methods. Likewise, because of their 
heterogeneity, fucoidans remain underexploited as an alternative therapeutic. However, 
commercially available fucoidan extracts are claimed to improve gut health and could be 
potentially useful for patients suffering from intestinal inflammation. Thus, it is important 
to investigate and confirm their potential in UC. These necessitate pre-clinical studies of 
heparins and fucoidans as a first step towards introducing these compounds as novel 
therapeutic approaches for chronic inflammatory disorders.   
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1.5 Aim and objectives 
 
An ideal therapeutic agent for UC should be: i) effectively relieve acute inflammation, 
induce and maintain clinical remission; ii) improve mucosal healing while prevent the long-
term complication of colorectal cancer;  iii) safe or free from unwanted adverse events; iv) 
available as an oral formulation which improves patient compliances and avoids the 
inconvenience of parenteral injections; v) stable and allow targeted delivery to the site of 
inflammation and vi) economical and easily accessible.  
Therefore, the overall aim of this project was to investigate the efficacy of sulphated 
polysaccharides (enoxaparin and fucoidans) in a model of experimental colitis with the 
ultimate goal of identifying specific oligosaccharides of enoxaparin that are responsible for 
any anti-colitis activity observed.  
To achieve this, we:  
a) examined and compared the effects of UFH, LMWHs (enoxaparin and dalteparin) and 
structurally unmodified oligosaccharides of enoxaparin on human colonic epithelial 
cells in vitro. 
b) compared the effectiveness of enoxaparin given either intraperitoneally or orally via 
the diet in colitis.  
c) evaluated the effect of fucoidan extracts given intraperitoneally or orally in colitis.  
d) tested the effect of different oligosaccharides of enoxaparin in colitis. 
 
 
  
 
 
 
 
Chapter 2 
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Chapter 2 Identification of Pro- and Anti-proliferative Oligosaccharides of Heparins 
2 Abstract 
Heparins, unfractionated heparin (UFH) and low molecular weight heparins (LMWHs) are 
heterogeneous mixtures of anticoagulant and non-anticoagulant oligosaccharides. In 
addition to their well-known anticoagulant effect, heparins have shown to mediate a wide 
range of non-anticoagulant effects, including the modulation of cellular growth. However, 
contradictory results have been reported with regards to their effects on cellular proliferation, 
with some studies suggesting anti-proliferative, while others indicating pro-proliferative 
effects. This study investigated the proliferation of human colonic epithelial cancer cells in 
the presence of UFH and LMWHs (enoxaparin and dalteparin). In our experimental setting, 
all heparins caused a dose-dependent reduction in cellular growth, which correlated well 
with the induction of cell cycle arrest in G1 phase and which was not associated with 
significant changes in cell viability. The effects on cellular proliferation of 14 different 
oligosaccharides of enoxaparin obtained through ion-exchange chromatography were also 
assessed. Surprisingly, only two oligosaccharides showed distinctive anti-proliferative 
effects while the majority of oligosaccharides actually stimulated proliferation. Interestingly, 
the smallest oligosaccharide devoid of any anticoagulant activity showed the strongest anti-
proliferative effect. Notably, heparins are currently standardised only according to their 
anticoagulant activity but not based on other non-anticoagulant properties. Our results 
indicate that slight differences in the composition of heparins’ non-anticoagulant 
oligosaccharides, due to different origins of material and preparation methods, have the 
potential to cause diverse effects and highlight the need for additional characterisation of 
non-anticoagulant activities.  
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2.1 Introduction  
Unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs) have been the 
subject of considerable research interest with regard to their structural and biological 
properties [46]. UFH has been clinically used as an anticoagulant for more than 65 years. It 
belongs to the family of GAGs and it is a heterogeneous mixture of structurally unidentified 
anionic oligosaccharides [45]. UFH with an average mass of 15 to 20 kDa is extracted from 
animal tissues including bovine lung and porcine intestinal mucosa [49]. Despite the 
widespread use of UFH, it is associated with a number of problems including drug-induced 
adverse effects, low bioavailability and unpredictable dose response [48]. These problems 
have led to the development of LMWHs, which are obtained by controlled enzymatic or 
chemical depolymerisation of UFH [49]. LMWHs have an average MW ranging from 3600 
to 6500 Da [44]. In the current clinical settings, LMWHs have replaced UFH to a large extent 
because of their favourable pharmacokinetic properties and fewer adverse effects [48]. All 
LMWHs are distinct from each other depending on the tissue source of the parent UFH, and 
the methods and conditions employed for their preparation [49].  
It has now been well recognised that in addition to their well-known anticoagulant 
activity, heparins (UFH and LMWHs) possess a wide range of biological properties, 
including their ability to modulate the cellular growth [46,177]. Heparins have mostly shown 
inhibitory effects on the proliferative capacity of cells originating from different tissues and 
organisms [178,179]. For example, multiple studies have demonstrated that heparins 
inhibited the proliferation of smooth muscle cells derived from bovine, porcine, rat and 
human tissues [142,178,180-182], human normal osteoblast cells [183,184], human bone 
marrow derived mesenchymal stromal cells [185] and human mesenchymal stem cells 
derived from bone [186]. The mitogenic activity of rodent, bovine and human endothelial 
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cells was significantly inhibited in the presence of heparins [178,179,187]. Although the 
dose response varied depending on the specific cell types used, most studies generally agreed 
that the inhibition of cell proliferation by heparins is concentration-dependent [178,181]. 
Interestingly, this anti-proliferative property of heparins has also been observed in cancer 
cells, which has sparked interest in a potential therapeutic use of heparins for treating human 
malignancies [177]. Multiple studies reported that UFH and LMWHs, such as dalteparin, 
enoxaparin and nadroparin, decrease the proliferation of human lung adenocarcinoma cells 
[188-190], murine mammary adenocarcinoma cells [191], human malignant mesothelioma 
cells [192], human osteosarcoma cells [184] and primary human glioma-derived cells [193].  
Despite a number of studies reporting that heparins exert anti-proliferative effects, 
surprisingly, some studies have indicated that heparins can also possess the opposite effect. 
For example, it was reported that UFH can stimulate human intestinal cancer cell growth 
[194,195] and can increase the proliferation of primary rat intestinal cultures in a dose-
dependent manner [196]. In addition, some studies have reported no change in cell 
proliferation in the presence of heparins [197-199]. Therefore, the current literature on the 
regulation of cell growth by heparins remains contradictory at present.  
Heparins are heterogeneous mixtures of sulphated oligosaccharides. Along with the 
oligosaccharides possessing anticoagulant properties, a large number of non-anticoagulant 
oligosaccharides also present in the mixture [200]. Anticoagulant oligosaccharides contain 
a unique pentasaccharide sequence responsible for the anticoagulant effects of heparins [44]. 
In recent years, attention has shifted to the non-anticoagulant activities of heparins [46]. 
Importantly, many studies have shown that the non-anticoagulant effects of heparins, such 
as anti-inflammatory activities, are independent of their anticoagulant activity and largely 
dependent on the presence of non-anticoagulant oligosaccharides [46,142]. A number of 
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studies have investigated the effects of heparins on angiogenesis [201]. Interestingly, it has 
also been observed that UFH has a contrasting effect; some of the chemically synthesised 
oligosaccharides of heparins have an anti-angiogenic effect, while some have a pro-
angiogenic effect and importantly these effects are dependent on the size and sulphation 
patterns of oligosaccharides [201-203].  
 The ability of heparins to modulate cellular growth has largely been studied with intact 
heparins (mixture of oligosaccharides) [190,194,198,199] instead of their individual 
unmodified oligosaccharides. We hypothesised that intact heparins are responsible for either 
anti- or pro-proliferative effects depending on the types of non-anticoagulant 
oligosaccharides present in the heterogeneous mixture of heparins. Hence, the present 
investigation examined and compared the cellular growth modulation effects of intact UFH, 
intact LMWHs (namely enoxaparin and dalteparin) and structurally unmodified 
oligosaccharides of enoxaparin on several human intestinal epithelial cell lines.  
2.2 Materials and methods 
Human colon carcinoma epithelial cell lines (HCT-116, HT-29 and DLD-1) were obtained 
from European Collection of Cell Cultures (ECACC) and cultured under standard conditions 
(37˚C, 5% CO2, 95% humidity) in modified McCoy’s 5A medium or Roswell Park Memorial 
Institute (RPMI) 1640 medium. All culture media were supplemented with 2 mM L-
glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin and 10% v/v heat inactivated foetal 
calf serum (FCS, Gibco, Life Technologies Victoria, Australia). When cells had reached 
confluence, they were washed twice with phosphate buffered saline (PBS) and followed by 
1mM ethylenediaminetetraacetic acid (EDTA) solution before being harvested using trypsin 
(0.5 g/L)/ EDTA (0.2 g/L). Cells were routinely passaged twice a week and seeded at 
concentrations of 2 or 3 ×104 cells /cm2. All chemicals and supplies were obtained from 
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Sigma-Aldrich (Castle Hill, NSW, Australia) unless otherwise specified. All cell culture 
plastics were obtained from Corning (Tewksbury, MA, USA) unless otherwise specified. 
2.2.1 Foetal calf serum mitogenic assay 
To assess the mitogenic effect of FCS on the intestinal epithelial cell line (HCT-116), 1500 
or 2500 HCT-116 cells/ 100 μl/ well were seeded in 96 well-plates (flat bottom) in McCoy’s 
5A media containing 5% v/v FCS overnight. The media was removed after 24 hours and 
replaced with media containing FCS at 0.1%, 0.5%, 1%, 2% or 10%. Five parallel wells 
were used for each concentration of FCS in a single experiment. At 24, 48 and 72 hours after 
the media change, cell proliferation was indirectly assessed by measuring metabolically 
active cells using a commercially available water-soluble tetrazolium dye, WST-1 reagent 
(Roche, Mannheim, Germany).  
2.2.2 Basic fibroblast growth factor mitogenic assay 
To test the mitogenic capacity of basic fibroblast growth factor (bFGF), 2500 HCT-116 cells/ 
100 μl/ well were seeded in 96 well-plates in McCoy’s 5A media containing 5% FCS 
overnight. The culture media was removed after 24 hours and replaced with fresh media 
containing 5% v/v FCS and 0, 0.1, 1 or 10 nM bFGF respectively. At 24, 48, 72 and 96 
hours, cell proliferation was measured using WST-1 reagent. Alternatively, 1500 or 2500 
HCT-116 cells/ 100 μl/ well were seeded and incubated overnight before a media change. 
Cells were incubated for the following 24 hours in the media with reduced FCS (0.1%, 0.5% 
or 1.0% v/v) before the addition of 10 µl of bFGF to achieve final concentration of 0.1 nM 
bFGF. PBS and FCS (10% v/v) were included as negative and positive controls respectively. 
Cell proliferation was measured using WST-1 reagent at -24, 0, 24 and 48 hours. All 
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treatment conditions were analysed in five parallel wells and means of absorbance plotted 
from one of the two similar experiments.  
 
2.2.3 Quantification of cell proliferation using WST-1 reagent 
Cell proliferation was indirectly assessed by quantifying metabolically active cells using 
WST-1. For this purpose, 50 μl of growth media were discarded from each well before 5 μl 
of WST-1/ well was added and incubated for 4 hours. The absorbance of the formazan dye 
in solution was measured at 450 nm (Thermo Scientific Multiskan GO UV/Vis microplate 
spectrophotometer, SkanIt Software). The reference wavelength is set at 690 nm. 
Background values from cell-free media only wells incubated with dye were obtained. Cell 
proliferation was presented as average of absorbance (A, A450nm – A690nm) or expressed as 
fold change of control and standard deviation.  
2.2.4 UFH and LMWHs 
Heparin (DBL heparin sodium, Hospira, 5000 IU/ 0.2 ml, referred to unfractionated heparin 
(UFH) in the text), enoxaparin (Clexane, Sanofi Aventis, 20 mg/ 0.2 ml) and dalteparin 
(Fragmin, Pfizer, 2500 IU/ 0.2 ml) were diluted with phosphate buffer saline (PBS) when 
necessary to achieve final concentrations of 0 (for control), 0.01, 0.1, 1, 10, 100, 200, 400, 
1000 μg/ml (with 160 IU = 1 mg heparin, 100 IU = 1 mg enoxaparin and 156.25 IU = 1 mg 
dalteparin).  
2.2.5 Isolation of enoxaparin oligosaccharides 
2.2.5.1 HPLC instrumentation  
To isolate individual enoxaparin oligosaccharides, a high performance liquid 
chromatography (HPLC) system consisting of a Dionex UltiMate 3000 pump, Dionex 
 52 
 
UltiMate 3000 auto sampler, Dionex UltiMate 3000 RS Column compartment and Dionex 
UltiMate 3000 Variable Wavelength detector (Thermo Scientific, NSW, Australia) was 
used. Data acquisition and instrument control were carried out using Chromeleon® software. 
2.2.5.2 Ion-exchange chromatography  
The separation of enoxaparin was carried out using a previously described ion-exchange 
chromatography (IC) method [76]. IC was performed using a Carbo PacTM PA-100 (250 × 
9 mm × 8.5 µm) anion ion-exchange column (Thermo Scientific, NSW, Australia). The 
mobile phases consisted of 2 M NaCl (A) and Milli-Q water (B). The mobile phase was 
filtered using a Millipore vacuum equipped with a 0.45 µm filter. The filtered mobile phase 
was degassed using an ultrasonic bath (Sonorex RK-100, Bendelin Electronic, Germany) for 
10 minutes prior to its use. The separation of enoxaparin was achieved using a linear gradient 
elution of mobile phase A from 32% to 74% over 70 minutes. Then the column was re-
equilibrated with 32% of mobile phase A for 15 minutes. The flow rate was maintained at 2 
ml/ minute. UV detection was carried out at 232 nm. A total of 250 µl enoxaparin (50 mg/ml) 
was loaded into the column for each injection of sample.  
2.2.5.3 Collection and desalting of IC separated enoxaparin oligosaccharides  
The collection and desalting of IC separated enoxaparin oligosaccharides was carried out as 
described previously [76]. A total of sixteen runs (n = 16) of enoxaparin separation were 
carried out to collect sufficient amount of oligosaccharides for assay. Briefly, for each 
enoxaparin run, fourteen (14) oligosaccharides of enoxaparin (1.5 - 33 ml each) were isolated 
and collected over the same elution period between 10.0 and 65.0 minutes in 15 ml tubes. 
The IC collected samples contain NaCl, water and the enoxaparin oligosaccharides. The 
samples were concentrated using a miVac DNA centrifugal concentrator (Genevac Ltd, 
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Suffolk, UK) at 50 °C until the formation of salt crystals. The salt was subsequently removed 
using methanol precipitation. For this purpose, to each sample containing salt crystal, 
approximately 12 ml of 80% v/v anhydrous methanol was added and vortexed to dissolve 
crystallized salt in the solvent. The solution was then centrifuged (10 minutes, 3000 rpm, 
GLC-2, Sorvall, DJB Labcare, Newport Pagnell, UK) before the supernatant containing 
NaCl was carefully removed, leaving the precipitated oligosaccharides behind. The desalting 
step was repeated until all crystallized salt was fully removed to attain precipitated 
oligosaccharides. To ensure oligosaccharides were fully precipitated, the samples were kept 
at 4 °C overnight. The supernatant was carefully discarded the following day and traces of 
methanol were removed using the miVac DNA concentrator (Genevac Ltd, Suffolk, UK). 
The remaining precipitant of each centrifuge tube was dissolved in 500 µl of Milli-Q water. 
Approximately 4 ml of the same oligosaccharides of enoxaparin were then combined into a 
single tube and the volume was reduced to 1 ml each by concentration. The samples were 
then stored at 4 ˚C until use. The concentration of each enoxaparin oligosaccharide was 
calculated using the peak areas of desalted oligosaccharides. These oligosaccharides were 
tested for their effects on colony formation at 100 µg/ml. The effects of oligosaccharides 2 
and 7 on cell cycle were also tested.  
2.2.6 Cell growth assay  
A total of 2500 HCT-116 cells were seeded in 12 well-plates using McCoy’s 5A culture 
media containing either 0.5% or 10% FCS respectively. Final concentrations of heparin, 
enoxaparin, dalteparin (as indicated: 0.01 - 400 µg/ml) were added into wells in triplicate. 
Cell growth was followed over a maximum period of two weeks with media replacement bi-
weekly before the cells were stained with trypan blue or alternatively protein quantification. 
For cell staining in 12 well-plates, cells were fixed with ice cold methanol at - 20 °C for 10 
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minutes before being incubated with 0.4% w/v trypan blue for 5 minutes. Cells were washed 
twice with tap water and air-dried overnight. Images of 12-well plate from one of the three 
similar experiments was taken with a Canon trans-illuminescent flatbed scanner.  
2.2.7 Protein quantification 
Protein levels were measured using the Bio-Rad detergent-compatible protein assay (BioRad 
Laboratories, Gladesville, NSW, Australia) according to the manufacturers protocol. Briefly, 
bovine serum albumin (BSA) standards were prepared in lysis buffer as serial dilutions 
between 0.08 and 5 mg/ml. Cells were washed with PBS twice before being lysed in 100 
µl/well of lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 0.5% Tween 20 and 0.2% Triton 
X-100) for 15 minutes at 4 °C. The lysate of each well was centrifuged in Eppendorf tubes 
(10 minutes, 14000 rpm, 4 ˚C, Eppendorf® Micro Centrifuge, 5417R, Eppendorf, NY, 
USA). For measuring protein content, 10 µl of supernatant or protein standards were pipetted 
in triplicate into a 96 well-plates before 25 μl of reagent AS (alkaline copper tartrate and 
surfactant) and 200 μl of reagent B (diluted Folin) were added into each well. After 15 
minutes, absorbance was read at 750 nm (Thermo Scientific Multiskan GO UV/Vis 
microplate spectrophotometer, SkanIt Software). Protein concentrations were calculated 
using the standard curve derived from the BSA standards. One representative protein content 
of each condition compared with control from three independent experiments was 
demonstrated. 
2.2.8 Colony formation assay 
Cells (HCT-116: 200, 500, 800, 1000 or 2000 cells/ dish; DLD-1: 800 cells/ dish, HT-29: 
800 cells/ dish) in 10 ml of RPMI 1640 or McCoy’s 5A media containing FCS (0.5%, 2%, 
5% or 10%) were seeded into 10 cm tissue culture dishes (Nunc, Thermo Fisher Scientific, 
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Victoria, Australia) to allow overnight adherence without drug interference. Cells were 
treated in four replicate dishes per condition for 2 individual experiments with 10 - 50 μl of 
heparin, enoxaparin and dalteparin to achieve required final concentrations (0.01 - 400 
µg/ml) or 61 - 266 μl of enoxaparin oligosaccharides for 100  µg/ml in a single experiment. 
The cells were incubated for two weeks without media change before being washed twice 
with PBS and fixed with 2% w/v paraformaldehyde in PBS for 15 minutes at room 
temperature. Subsequently, colonies were stained with 1 ml of 0.4% w/v trypan blue or 0.1% 
w/v crystal violet (Oxoid, West Heidleberg, VIC, Australia) for 5 minutes before washed 
twice with tap water and air-dried. Colonies consisting of more than 50 cells were manually 
scored using a standard light microscope (Inverted Microsope, Model INV-100, Aktivlab, 
SA, Australia). Colony formation was expressed as the number of colonies or as the 
percentage of colonies compared to control values.  
2.2.9 Cell viability assays 
2.2.9.1 Colorimetric assay 
A total 2500 HCT-116 cells/ 100 μl/ well were seeded in 96 well-plates in McCoy’s 5A 
media containing 5% v/v FCS overnight before the FCS concentration was reduced to 0.5% 
v/v by media change. After 24 hours, 10 μl of heparin, enoxaparin and dalteparin were added 
into each well to achieve concentrations of 0.01 - 1000 µg/ml. PBS and 10 % v/v FCS were 
included as negative and positive controls respectively. For all experiments at least five 
parallel wells were used for a single condition. After 24 hours incubation with and without 
treatment, cell proliferation was measured using WST-1 reagent as above. Cell proliferation 
in the treatment groups was presented as fold-change of absorbance relative to the negative 
control, the average of four to five independent experiments. 
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2.2.9.2 Assessment of cell viability using trypan blue exclusion assay 
Briefly, 5000 cells (HCT-116, DLD-1 and HT-29)/ well were seeded into 24-well-plates 
overnight in McCoy’s 5A or RPMI 1640 media containing 2% v/v FCS before incubation 
with heparin, enoxaparin or dalteparin at 400 µg/ml in four replicate wells. Cells were 
harvested by trypsinization on day 5 after the start of treatment, collected by centrifugation 
(5 minutes, 300 g, centrifuge CM-6MT, Elmi Ltd, Riga, Latvia) before being resuspended 
in 100 μl of culture media and 100 μl of 0.4% w/v trypan blue solution. Healthy (no staining) 
and damaged cells (nucleus stained blue) were scored using a Neubauer Chamber. Briefly, 
resuspended cells were allowed to diffuse beneath the coverslip. By using light inverted 
microscope, the number of cells in the 25 central squares of the grid was counted. Total cell 
counts per area were recorded for each condition. Cell viability was expressed as the 
percentage of damaged to viable cells, presented as mean from quadruplets of one of the 
three similar experiments.  
2.2.9.3 Detection of apoptotic cells 
Apoptosis was measured using a commercially available kit (Annexin V-FITC Apoptosis 
Detection Kit; BD Pharmigen). Briefly, 2 × 104 HCT-116 cells were seeded into T-25 flasks 
overnight in McCoy’s 5A media containing 2% v/v FCS before being incubated with final 
concentrations of heparin or enoxaparin at 400 µg/ml. After four days of treatment, cells 
were harvested by trypsin, washed with PBS twice. Cells were resuspended in 100 μl of 
binding buffer in a 5 ml round bottom FACS tube (BD Falcon, BD Biosciences, NSW, 
Australia). To each tube, 5 µl of fluorescein isothiocyanate (FITC) conjugated annexin-V 
and 5 µl of propidium iodide (PI; 50 μg/ml) were added and incubated in the dark at room 
temperature for 15 minutes. After incubation, 400 μl of binding buffer were added before 
cells were analysed by flow cytometer (FACSCanto, Becton Dickinson, CA, USA) to 
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differentiate apoptotic cells (annexin V-FITC positive and PI negative, lower right quadrant) 
from necrotic cells (annexin V-FITC and PI positive, upper right quadrant). Five thousand 
events were collected from each sample (FACS Diva software, Becton Dickinson) and 
analysed (FlowJo software, version 10; Treestar, Ashland, USA).  Samples were analysed 
in triplicates in a single experiment. 
2.2.10 Cell cycle analysis 
Cell cycle analysis was carried out using PI staining and flow cytometry. HCT-116 cells (4 
× 105) were seeded in 6 well-plates and allowed to adhere for 7 hours followed by treatment 
with heparin, enoxaparin, dalteparin or enoxaparin oligosaccharides in triplicate per 
condition at the concentration as indicated: 100 µg/ml or 400 µg/ml. Three independent 
experiments were performed for heparins whereas a single experiment was performed for 
enoxaparin oligosaccharides. After 18 hours of drug exposure, cells were harvested by 
trypsinization and washed with PBS before being resuspended in 750 µl of PBS. Three 
millilitres of ice cold 95% ethanol was added steadily to the cells while vortexing and the 
cells were fixed overnight at 4 °C. Subsequently, the cells were washed with PBS twice 
before being resuspended in 500 µl of PBS and counted to adjust the cell density to 1 × 106 
cells/ ml.  The cell solution from each sample was transferred into a 5 ml round bottom 
FACS tube and treated with 5 µl of Ribonuclease A (10 mg/ml) (Sigma-Aldrich, Castle Hill, 
NSW, Australia) before the cellular DNA was labelled with 50 µl of PI (1 mg/ml) and 
incubated in dark in water bath at 37 °C for 15 minutes. Fluorescence was measured using a 
flow cytometer (FACSCanto, Becton Dickinson, CA, USA). Ten thousand events per sample 
were collected in a list mode with the accompanying software (FACS Diva software, Becton 
Dickinson). Effects on the cell cycle were determined by changes in percentage of cell 
distribution at each phase of the cell cycle, and assessed by histograms (FlowJo software, 
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version10; Treestar, Ashland, USA). The proportion of cells in sub-G1, G1, S and G2 phase 
was quantified and presented as percentage in each phase from total cells.  
2.2.11 Statistical analysis  
All data are presented as mean ± standard deviation (SD) or as percent change compared to 
control. Using GraphPad Prism (version 6, GraphPad Software Inc, CA, USA), statistical 
significance was evaluated using Student’s t-test and one way analysis of variance 
(ANOVA), where appropriate, followed by Dunnett’s multiple comparisons tests to evaluate 
the difference between treatment groups and control. A p value of < 0.05 was considered 
statistically significant. 
2.3 Results  
2.3.1 Serum-dependent cell growth  
In order to investigate the proliferative capacity of human colonic epithelial cells in response 
to a growth factor or heparins, we first assessed the basal growth rate of human colonic 
epithelial cells in the presence of different concentrations of FCS (0.1% to 10% v/v). The 
proliferation of HCT-116 cells was reflected by increased absorbance, which reflects 
increasing numbers of metabolically active cells (Fig. 2.1). FCS had a dose-dependent 
growth stimulating effect on cell proliferation based on the abundance of different growth 
factors and nutrients. From 24 to 72 hours, the absorbance signal increased from 
approximately 0.2 to 1.5 as a function of serum concentration (Fig. 2.1A & Fig. 2.1B). The 
signal was the lowest when FCS was restricted at 0.5% or 0.1% compared to higher 
concentrations of FCS. At 24 and 48 hours, the signals obtained from 2500 cells/ well (Fig. 
2.1B) were consistently higher than 1500 cells/ well (Fig. 2.1A) irrespective to any FCS 
concentrations. Similarly, a faster cell growth was seen over the period of 24 to 48 hours for 
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2500 cells/ well; the growth rate became slower from 48 to 72 hours for the conditions with 
FCS at 1, 2, 5 or 10% v/v (Fig. 2.1B). On the other hand, the growth rate of 1500 cells/ well 
increased linearly from 24 to 72 hours for all FCS concentrations above 1% (Fig. 2.1A).  
 
Figure 2.1 FCS-dependent epithelial cell growth.  
HCT-116 cell proliferation at 10%, 5%, 2% and 0.5, 0.1, 0% of FCS with seeding density at (A) 1500 
cells/ well and (B) 2500 cells/ well. Data represents the mean of five individual samples per treatment 
of one typical experiment. Error bars depict standard deviations. 
2.3.2 Effect of basic fibroblast growth factor on HCT-116 cells  
Previously, human colonic epithelial cells, HCT-116, were reported to respond to basic 
fibroblast growth factor (bFGF) stimulation in culture media containing 5% of FCS [57]. 
We aimed to replicate the results to investigate the effect of bFGF on cell proliferation before 
studying the cellular proliferation response in the presence of heparins. However, when 
replicating the previous described conditions, we did not detect any significant mitogenic 
effect of bFGF. Compared to untreated control, the absorbance signal of treated wells did 
not significantly differ at any time points from untreated wells and reached a plateau after 
approximately 72 hours (Fig. 2.2A). Furthermore, there was also no indication of the 
reported dose-dependency of bFGF in 5% FCS containing media detectable.  
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 Since high concentrations of growth factors contained in FCS (5%) could likely have 
prevented the mitogenic effect of additional bFGF supplementation, we reduced the 
concentration of FCS in the culture medium and cells were conditioned for 24 hours before 
cells were exposed to 0.1 nM bFGF, which was reportedly an optimal concentration to 
stimulate cell growth [57,204]. At a cell density of 2500 cells/ well in media containing 1% 
of FCS, no significant differences were seen at 24 and 48 hours in the presence of 0.1 nM 
bFGF compared to untreated control (Fig. 2.2B). Even at a lower cell density (1500 cells/ 
well) and reduced FCS concentrations (0.5% v/v, Fig. 2.2C and 0.1% v/v, Fig. 2.2D), 
absorbance increased steadily but the differences between the bFGF-treated and untreated 
were not significant at any point. In media containing 0.1% FCS, where cells responded well 
to FCS (10%), bFGF resulted in only a 10.2% increase in absorbance after 24 hours 
compared to untreated control (Fig. 2.2D). Due to these disappointing results, we stopped 
investigating the effects of bFGF on cell growth and thus abandoned the study on possible 
interactions between bFGF and heparins.  
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Figure 2.2 Epithelial cell growth with bFGF.  
(A) HCT-116 cell proliferation in the presence of 0.1, 1 and 10 nM of basic fibroblast growth factor 
(bFGF) in culture media containing 5% of FCS.  HCT-116 cell proliferation in the absence and 
presence of 0.1 nM of bFGF in culture media containing (B) 1%, (C) 0.5%, (D) 0.1% of FCS. FCS 
was added to media to a final concentration of 10% v/v FCS as positive control. Data represents the 
mean of five individual samples per treatment of one typical experiment. Error bars depict standard 
deviations.  
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2.3.3 Serum dependency of the effect of heparins on cell growth  
Since heparins were previously reported to inhibit cell proliferation [184], we attempted to 
compare UFH efficacy against enoxaparin under normal growth conditions (10% v/v FCS) 
with the same cell line. Contrary to previous report [194,205,206], no reduction of cell 
growth by UFH or enoxaparin in HCT-116 cells was detected using colony formation as 
readout. There was also no indication of a dose dependency under these conditions (Fig. 
2.3A) that was reported earlier [205]. To investigate if the abundance of growth factors in 
the serum could mask any effects of UFH in our cell culture, the colony formation assay was 
repeated in the absence or presence of UFH at different FCS concentrations (Fig. 2.3B). 
Under these conditions, UFH clearly showed a significant reduction (p = 0.0053) of colony 
numbers at 5% FCS (58.2% of control) and lead to a strong trend (74.2% of control) at 2% 
FCS. While at 10% FCS concentration no difference in colony numbers was detected, at 
0.5% the lack of colonies prevented any analysis (Fig. 2.3B).  
 This serum concentration dependency was also observed when we investigated cell 
growth in a mass culture at 0.5% FCS concentration (Fig. 2.3C). Under these conditions, 
HCT-116 cells were clearly able to proliferate in the absence of heparins. However, in the 
presence of all heparins, a significant reduction in cell density could be observed. In 
agreement with the results above, no treatment-induced difference in cell density was evident 
at 10% FCS (Fig. 2.3C). Consequently, for all further experiments, FCS concentrations of 
0.5% to 2% were used. The observed reduction in cell density was quantified by measuring 
protein content per well and again UFH concentrations between 100 and 400 ug/ml 
significantly (p < 0.001) reduced protein content per well dose-dependently by up to 60.8% 
of control at the highest UFH concentration (Fig. 2.3D).  
 63 
 
  
Figure 2.3 Effect of heparins on epithelial cell 
growth.  
(A) Colony formation of HCT-116 cells in the 
presence of 10% of FCS with exposure to three 
different concentration of heparin or enoxaparin. 
Data represents the mean of four individual 
samples per concentration of one typical 
experiment. Error bars depict standard deviations. 
(B) Colony formation of HCT-116 cells at 10%, 
5%, 2% and 0.5% of FCS with exposure to 100 
μg/ml of heparin. Data represents the mean of four 
individual samples per concentration of a typical 
experiment. Error bars depict standard deviations. 
** p < 0.01 versus control. (C) HCT-116 cells 
were grown in the absence (control) or presence 
of 100 μg/ml of heparin, enoxaparin and 
dalteparin respectively, before fixed and stained 
with trypan blue. (D) HCT-116 cells were grown 
in media containing 0.5% v/v FCS and heparin 
(0.01 - 400 μg/ml) for 14 days before protein 
content / well was measured. Data represents the 
mean of triplicates from a representative 
experiment. Error bars depict standard deviations. 
** p < 0.01 versus control. 
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2.3.4 Dose-dependent reduction of colony formation by heparins 
To compare a possible dose-dependent reduction of proliferation by UFH against LMWHs, 
concentrations ranging from 0.01 to 400 μg/mL were tested in the colony formation assay 
(Fig. 2.4A-C). UFH and the two LMWHs, enoxaparin and dalteparin, dose-dependently 
reduced colony formation by up to 34.9%, 44.5% and 33.0%, respectively. Interestingly, 
significant reductions in colony numbers were detected at 10 μg/ml for enoxaparin (Fig. 
2.4B), while significance was achieved for UFH (Fig. 2.4A) and dalteparin (Fig. 2.4C) only 
at concentrations at and above 100 μg/ml. This effect was clearly not cell line specific since 
UFH and LMWHs induced comparable reductions in colony numbers in 3 different intestinal 
cancer cell lines (HCT-116, DLD-1, HT-29) used (Fig. 2.4D).  
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Figure 2.4 Inhibition cellular colony formation 
by heparins.  
Colony formation of HCT-116 cells in the 
presence of (A) heparin, (B) enoxaparin, (C) 
dalteparin and 2% v/v FCS. (D) Epithelial cells 
(HCT-116, DLD-1, HT-29) were exposed to 400 
μg/ml in media containing 2% v/v FCS. Data 
represents the average of four individual samples 
per concentration of a typical experiment. Error 
bars depict standard deviations. * p < 0.05, ** p < 
0.01 versus control.  
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2.3.5 Inhibition of cell cycle progression by heparins 
In order to explain the observed reduction of colony numbers by heparins, their effect on 
cell cycle progression was analysed (Fig. 2.5). Consistent with the results described above, 
after 18 hours of treatment both UFH and LMWHs significantly increased the proportion of 
cells in G1 phase and at the same time decreased cell numbers in S and G2 phase (Fig. 2.5A 
and 2.5B).  
 
Figure 2.5 Inhibition of cell cycle progression by heparins.  
Flow cytometric cell cycle analysis of HCT-116 cells after 18 hours exposure to heparin, enoxaparin, 
dalteparin at 400 μg/ml in media containing 2% of FCS. (A) Representative histograms of cell counts 
versus propidium iodide (PI) for control versus treatment groups. (B) Graphical representation of the 
percentage of cells in G1, S, G2 phases determined by gating. Data represents the mean of three 
individual samples per treatment of a typical experiment. Error bars depict standard deviations. * p 
< 0.05, ** p < 0.01 versus control. 
 67 
 
2.3.6 Effect of heparins on cellular viability 
Although the observed effects on cell cycle progression alone could explain the reduced 
colony numbers described above, heparins have also been reported to induce cell death 
[207]. To investigate if cell death was also present in this experimental system, cellular 
viability was measured by the commonly used redox-dye WST-1 (Fig. 2.6A). In HCT-116 
cells, after 24 h of treatment with UFH and LMWHs, no signs of cell death could be detected 
even at concentrations up to 1 mg/ml (Fig. 2.6A). A second assay based on trypan blue 
exclusion was employed to detect possible delayed toxicities. Consistent with the prior 
results, this approach also failed to demonstrate any significant toxicity of heparins after 5 
days of treatment in 3 different cell lines (Fig. 2.6B). Finally, Annexin V-FITC combined 
with PI staining was performed to detect the possible presence of apoptotic and/or necrotic 
cells (Fig. 2.6C). After treatment of HCT-116 cells with UFH or enoxaparin, no increased 
numbers of apoptotic (quadrants Q2 and Q3) or necrotic cells (quadrants Q1 and Q2) could 
be detected (Fig. 2.6C).  
 68 
 
 
Figure 2.6 Effect of heparins on cellular viability.  
(A) HCT-116 cells were treated with heparin, enoxaparin, dalteparin (0.01-1000 μg/ml) for 24 hours 
before the cell viability was measured using WST-1. The fold change of absorbance signal in 
negative control was designated as 1. This data represents the average of five replicates from four 
independent experiments. Error bars depict standard deviations. (B) Epithelial cells (HCT-116, DLD-
1, HT-29) were incubated with heparin, enoxaparin, dalteparin at 400 μg/ml in media containing 2% 
of FCS in for over 5 days. The cell viability was determined by trypan blue dye exclusion assay 
where viable cells without staining blue while non-viable cells appearing blue were counted. Error 
bars depict standard deviations. (C) HCT-116 cells were untreated or treated with heparin and 
enoxaparin at 400 μg/ml in media containing 2% of FCS. After 96 hours, Annexin V-FITC/ PI 
staining was analysed by flow cytometry. Data represents samples of control, heparin and enoxaparin 
of a typical experiment. 
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2.3.7 Differential effects of enoxaparin oligosaccharides on proliferation and cell 
cycle 
Heparins are a complex mixture of oligosaccharides of different lengths or sizes, various 
degrees and distribution of sulphate groups and sulphation patterns with and without 
anticoagulant activity [208]. We therefore investigated if different oligosaccharides might 
harbour different activities with regards to the proliferative capacity of cells as observed in 
the previous results. For this purpose, enoxaparin was separated into 14 different 
oligosaccharides using IC based on size and charge (Fig. 2.7A). Enoxaparin is a polydisperse 
mixture of highly sulphated oligosaccharides with molecular weights or sizes from dp2 (two 
saccharides ∼600 Da) to dp24 (twenty four disaccharides ∼ 8000 Da). As the 
oligosaccharides increase in size, so does the degree of sulphation. Based on this chemical 
nature of oligosaccharides, larger oligosaccharides are retained longer or eluted later in the 
columns during the IC salt gradient separation as the sulphate groups interact with the 
oppositely charged stationary phase. The collected intact oligosaccharides from IC are 
highly polar and soluble in water. The retention time of enoxaparin oligosaccharides were 
as shown in Figures 2.7 (A).  
IC allowed a maximum of 12.5 mg of enoxaparin/ 250 μl to be loaded onto a semi-
preparative CarboPac PA100 column with each injection. Compared to analytical column, 
this semi-preparative column facilitated the collection of sufficient quantities of 
oligosaccharides for the investigation of their non-anticoagulant activities after 16 runs. For 
example, the concentrations of IC-derived oligosaccharide 2 (dp2, two saccharides) and 
oligosaccharide 7 (dp6, six saccharides) after desalting were found to be approximately 5.69 
mg/ml and 6.95 mg/ml respectively, with end volume of 1 ml each. These concentrations 
were sufficient to investigate the proliferative activities of each oligosaccharide at 100 
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µg/ml. The concentration of each desalted oligosaccharides was calculated using the 
differences in the peak areas of oligosaccharides and oligosaccharides of enoxaparin at 
known concentrations eluted at the same time. The average recoveries of enoxaparin 
oligosaccharides were found to be 80% [76]. 
When these oligosaccharides were individually assessed for their effect on colony 
formation, distinct profiles were observed (Fig. 2.7B). While some oligosaccharides (2 and 
11), potently and significantly reduced colony formation, others (6, 7, 8, 10, and 12) 
surprisingly increased colony numbers. It has to be noted that under these conditions, the 
intact enoxaparin, which contains all oligosaccharides, inhibited colony formation dose-
dependently (grey bars) as described above (Fig. 2.7B). Based on the differential effects on 
proliferation and also their respectively no and low inherited anticoagulant activity [76], 
oligosaccharides 2 and 7 were selected for comparison,. This differential effect of 2 selected 
exemplary oligosaccharides could also be demonstrated when looking at cell growth in a 
mass culture (Fig. 2.7C). While oligosaccharide 2 clearly reduced cell density more potently 
compared to intact enoxaparin at the same concentration, oligosaccharide 7 resulted in a 
strong increase in cell density. Finally, these two oligosaccharides were also tested for their 
effects on cell cycle progression (Fig. 2.7D). Consistent with the results from the colony 
formation assay, oligosaccharide 2 strongly increased the number of cells in G1 phase while 
leading to a significant reduction in S and G2 phase cells (Fig. 2.7D). It is important to note 
that at the same concentration, this effect was more pronounced for oligosaccharide 2 
compared to intact enoxaparin (Fig. 2.7D). In line with the previous data, oligosaccharide 7 
significantly reduced the number of cells in G1, while effects on S and G2 phase did not reach 
statistical significance. There was no difference of sub-G1 peaks of treated cells compared to 
control (data not shown).   
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Figure 2.7 Differential effects of enoxaparin 
oligosaccharides on proliferation and cell cycle.  
(A) Ion-exchange chromatographic separation of 
enoxaparin oligosaccharides. Numbers and lines 
indicate enoxaparin oligosaccharide tested. (B) 
Effect of enoxaparin (E1: 10 μg/ml; E2: 100 μg/ml, 
E3: 200 μg/ml) and its oligosaccharides (1-14: 100 
μg/ml) on HCT-116 epithelial cell colony forming 
capacity in media containing 2% of FCS. The total 
colony formations were enumerated at the end of 
experiment and presented as percentage change 
versus negative control. This data represents the 
average of four individual samples per 
concentration of a typical experiment. Error bars 
depict standard deviations. * p < 0.05, ** p < 0.01 
versus negative control. (C) HCT-116 cells were 
incubated in the absence (control) or presence of 100 
μg/ml of enoxaparin (enox.) or its oligosaccharides 
(2 and 7) respectively before fixed and stained with 
trypan blue. (D) Flow cytometric cell cycle analysis 
of HCT-116 cells after 18 hours exposure to 100 
μg/ml of enoxaparin and its oligosaccharides (2 and 
7) in media containing 2% of FCS. Graph depicts 
quantification of the percentage of cells in G1, S, and 
G2 phases. Data represents the average of three 
individual samples per treatment of a typical 
experiment. Error bars depict standard deviations. * 
p < 0.05, ** p < 0.01 versus control. 
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2.4 Discussion 
Human epithelial cell proliferation is stimulated by various growth factors such as epidermal 
growth factor (EGF) and basic fibroblast growth factor (bFGF) [209]. However, the in vitro 
response of cells to growth factors including bFGF is cell specific [204,210]. A number of 
colonic epithelial cell lines established from human colon carcinoma, are currently used for 
in vitro investigations [194,204]. One of them used in this study is an aggressively growing 
but poorly differentiated as well as microsatellite unstable cell line called HCT-116 
[204,211]. In line with studies showing that cell proliferation was dependent on FCS 
concentrations [212,213], the proliferation of HCT-116 increased concentration-
dependently. On the other hand, we did not observe that HCT-116 cells significantly 
responded to bFGF stimulation, despite reports that described increased proliferation of 
HCT-116 cells in response to 0.1 nM bFGF by 14% and 19% [57,204]. The differences in 
experiment setting such as initial cell number and the incubation of cells with different serum 
concentrations (0 or 5%) could explain the discordant observations. Nonetheless, HCT-116 
cell line has been described as a bFGF-independent and EGF-independent colon cancer cell 
line [194,214].  
 Considerable interest has focussed on a potential role of heparins in accelerating 
bFGF-stimulated proliferation to assist wound healing [57,64]. In the context of the study, 
the binding of bFGF to its high affinity receptors was reported to be facilitated by HS or 
heparin [215]. It is thought that heparins can act in parallel with bFGF to stimulate colon 
epithelial cell proliferation [57,204]. Heparins were also shown to affect the signalling of 
bFGF in a concentration-dependent fashion. While UFH at low concentrations (0.1 - 30 nM) 
enhanced bFGF receptor binding and thus stimulated cell growth, inhibition of bFGF binding 
to its receptor by UFH was demonstrated at higher concentrations (10 µM) [216]. In our 
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study, the possible growth effects of heparins and bFGF were investigated in media with 
reduced fetal calf serum concentration but not in other commercially available improved 
serum-reduced media such as Opti-minimal essential medium (MEM). So far, it is unclear 
if the response of HCT-116 epithelial cells to heparins or bFGF would be different in other 
media formulations such as OPTI-MEM. On the other hand, a previous study demonstrated 
only a maximum growth increase of 14% in response to 0.1 nM bFGF in serum-free medium 
[204], thus we did not pursue the growth effect of bFGF on HCT-116 epithelial cells in 
serum-free media and further. In view of the uncertainty in the literature and no apparent 
effect of bFGF on HCT-116 cell proliferation in our study, we therefore focused on the sole 
influence of heparins on colonic epithelial cell proliferation.  
 Together with previous reports [46,177,217], the data presented here demonstrate 
that in addition to their anticoagulation activity, heparins can effectively modulate additional 
biological functions. This study concentrated on the growth inhibitory activity of UFH and 
LMWHs. We and others demonstrated that under cell culture conditions of reduced serum 
concentrations, UFH and LMWHs can dose-dependently inhibit proliferation of different 
cell lines in vitro [188,218]. It has to be noted that in contrast to our experiments that are 
characterized by reduced serum levels, some investigators reported a reduced cell 
proliferation by UFH in the presence of 10% or even 20% v/v FCS [178,182,219]. However, 
in these studies in order to increase the sensitivity of cells to the anti-proliferative effect of 
UFH, cells were arrested by serum-starvation for up to 96 hours before the exposure to 
heparins, which effectively tests the ability of UFH to delay the re-entry of synchronized 
cells into the cell cycle. This approach is quite different to our experimental setting, which 
measures the inhibition of cell proliferation in unsynchronized cells.  
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Although the majority of studies described a significant inhibition of cellular 
proliferation by heparins, some reports also indicated that increased cell death might be 
associated with the observed effects in some cell lines [185,188,190]. In the experimental 
setting described here, increased cell death could have well accounted for the reduced colony 
formation in the presence of heparins. However, using three different assays no significant 
levels of either necrosis or apoptosis could be detected in the cell lines tested with both UFH 
and LMWHs. This is in line with other studies [205,206], in which heparins do not affect 
cell viability or the apoptotic levels. At the same time, it cannot be completely excluded that 
some cells might respond to exposure to heparins with cell death in different experimental 
settings such as extended exposure to high heparin concentrations. Moreover, compared to 
cancer cell lines used in this study, primary cells such as endothelial cells [207] and 
mesenchymal stromal cells [185] have been reported to be more susceptible to heparin-
induced cell death. 
 The current literature strongly suggests that the cell cycle effects of heparins we and 
others observed are not cell type specific, since inhibition of proliferation was demonstrated 
in cells from a multitude of tissues and organisms [141,182,184,190,220]. In this context, it 
is important to note that some studies indicate that different cell types might have slightly 
different dose-effect-responses to UFH [178]. Overall, a wide range of UFH and LMWHs 
concentrations have been investigated and, dependent on the types of heparins and cell 
culture conditions used, effective concentrations varied only slightly. The inhibitory effect 
of heparins on cell proliferation was reported to be concentration-dependent [220,221]. 
However, in our experimental setting, there was a lack of true dose-dependent effect of 
heparins on cell proliferation which could be due to the specific range of heparin 
concentrations tested, a potential lack of sensitivity of the assay used or the use of different 
cell lines. Nevertheless, most studies agree that cellular proliferation is significantly 
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inhibited by UFH at a dose between 10 μg/ml and 100 μg/ml [178,179,181,182,218]. For 
enoxaparin, 25-50 µg/ml were reported to significantly inhibit proliferation of epithelial cells 
[188,205], while the minimum inhibitory concentration of dalteparin was found at 10 IU/ml 
(approximately 64 µg/ml) [190]. Our results describe reduced proliferation between 10 
μg/ml and 400 μg/ml, with a significant reduction at 10 μg/ml of enoxaparin and 100 μg/ml 
for dalteparin or UFH, respectively, and therefore largely mirror the effective dose ranges 
described in previous studies. Thus, the effectiveness of these compounds might be less 
dependent on the cell type but rather more dependent on the experimental setting and more 
importantly on the origin of the compound.  
 Despite the well-established, standardized and quality-controlled methods of heparin 
production, heparins (UFH and LMWHs) remain complex mixtures of heterogeneous 
oligosaccharides and we have shown here that these oligosaccharides contain different and 
interestingly even opposing biological activities. This observation for the first time 
rationalizes the variation in the responses reported by different laboratories when using 
heparins. Heparins are available from different sources and manufacturers [222], and contain 
different anti-proliferative properties [223]. Although all commercially available heparins 
are characterized by their specific anticoagulant activity based on anti-factor Xa and 
thrombin activity, this does not guarantee a uniform composition of other activities, since 
they are currently not tested for. Thus, differences in composition other than the overall 
anticoagulant activity in preparations from different manufacturers and sources are likely to 
contribute to the differences seen when testing the non-anticoagulant activities. In support 
of this hypothesis, it was suggested previously that the compositional differences in non-
anticoagulant oligosaccharides between batches of enoxaparin could be responsible for the 
inconsistent patient response to treatment of an inflammatory skin condition [129,138]. 
Furthermore our results can for the first time explain the conflicting literature with regards 
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to the pro- and anti-proliferative effects that have been described for heparins [194,195,224]. 
Based on our observation that enoxaparin consists of pro- and anti-proliferative 
oligosaccharides, it can be hypothesized that only small variations in the quantity and 
presence of specific oligosaccharides can alter the overall proliferative response to 
enoxaparin and also likely other heparins. This question is currently under investigation by 
other student in our laboratory. 
 Repeating disaccharides of an alternating sequence of uronic acid and glucosamine 
serve as the basic building blocks of heparin chains. However, sulphation groups can be 
unevenly distributed along the chains and serve as a means to introduce significant biological 
complexity [45]. Depending on the sources of raw material and the conditions of the 
purification process, unique structural features of the final products can be found from the 
extract [49,208]. This may include the presence of more, less or inactive moieties, or 
uncharacterized heparin molecules from the natural occurrence of GAGs in the extracted 
tissues [225]. For example, in 2007 and 2008 hundreds of hypersensitive reactions were 
reported worldwide after administration of heparin preparations contaminated with an 
impurity known as oversulphated chondroitin sulphate [136]. It is believed that this 
contaminant was introduced to certain batches of heparin during the extraction and 
manufacturing process [226]. This highlights the compositional complexity and structural 
variability that is currently present in the commercially available heparin mixtures, which is 
likely to represent a significant potential for varying clinical responses. 
 In order to identify oligosaccharides that are responsible for altered cellular 
proliferation in this study, enoxaparin was fractionated using IC, which generates molecules 
of varying size and sulphation status with and without anticoagulant activity [76]. This study 
demonstrates that not all oligosaccharides result in significant changes to the mitogenic 
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activity of cells. The selection of enoxaparin oligosaccharides for comparison depends not 
only on the differential effects on proliferation but also their inherited anticoagulant activity 
[76]. The antithrombin binding of enoxaparin is due to the presence of pentasaccharide 
sequence on the enoxaparin chains. Oligosaccharide 2 was selected because it contained the 
highest anti-proliferative activity (-76.6 ± 13.1%) and was the smallest molecule 
(disaccharide) from the mixtures of oligosaccharides. The disaccharide is distinctively 
shorter than the required smallest sequence of pentasaccharide for antithrombin binding [44], 
and thus is very unlikely to have any anticoagulant activity. On the other hand, 
oligosaccharide 7 represents hexasaccharides with only low anticoagulant activity [76] that 
can significantly increase the mitogenic activity of cells (61.6 ± 9.3%). This suggests that 
specific structures of heparin oligosaccharides are responsible for their effects on 
proliferation.  
On another point, although oligosaccharide 11 resulted in 42.6 ± 11.9% inhibition of 
colony formation, oligosaccharide 11 represents decasaccharides (dp10) and has relatively 
higher anti-factor Xa activity compared to oligosaccharides 2 and 7 [134]. Similarly, 
oligosaccharide 12 (dodecasaccharide) which had the highest pro-proliferative activity was 
not selected for further tests since it displayed the strongest anticoagulant activity [134]. This 
is not surprising since it was previously reported that dodecasaccharides display significantly 
increased anti-coagulant activity as they contain two antithrombin binding pentasaccharides 
[227]. In contrast to our data, dodecasaccharide or even larger fragments have been reported 
to possess anti-proliferative activity in vitro, while hexasaccharides were previously 
identified as the minimum chain length for any anti-proliferative activity [141,221], while 
in contrast to our data disaccharides were only associated with very low anti-proliferative 
effects [141]. At the same time, Garg and colleagues concluded that size per se does not 
determine the anti-proliferative activity of heparin oligosaccharides [217]. This discrepancy 
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is again likely caused the different methods of oligosaccharide preparation from UFH, which 
are predominantly based on different chemical or enzymatic reactions. It is noteworthy that 
chemical or enzymatic digestion significantly increase the structural heterogeneity of 
heparins, causing variations in chain length and the substitution of important chemical 
groups present on glucosamine and urinate residues [49,208]. Therefore, even subtle changes 
in preparation could conceivably lead to different compositions and pharmacological 
profiles of heparins and thus different experimental results. Overall, the data by us and others 
illustrate that comparative studies from different labs using heparins from different sources 
and preparative methods are unlikely to lead to consistent results unless the detailed structure 
of individual oligosaccharides can be identified. 
 Even though a large body of evidence shows that heparins can influence cell growth, 
the details on how heparins regulate or modulate cell proliferation are still lacking. While 
further studies are needed to uncover the detailed mechanism by which heparins affect 
cellular proliferation, this study provides the framework for the standardized isolation of 
enoxaparin oligosaccharides with pro- and anti-proliferative activities. Furthermore, this 
standardized isolation of oligosaccharides is a crucial pre-requisite for exploring other 
potential therapeutic uses of heparin oligosaccharides. 
2.5 Conclusion  
Using a powerful chromatographic technique, this study has for very first time demonstrated 
that different oligosaccharides obtained from intact heparin have different and even opposing 
effects. Out of all oligosaccharides tested, oligosaccharide 2 (disaccharide) showed the 
largest anti-proliferative effect while oligosaccharide 7 (hexasaccharide) profoundly 
stimulated proliferation. Since oligosaccharide 2 is too small to have any anticoagulant 
activity and oligosaccharide 7 has only minimal anticoagulant activity, the effects of 
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heparins on cellular proliferation appear largely independent of their anticoagulant activity. 
All commercially available heparins have comparable anticoagulant activities; however, 
their non-anticoagulant oligosaccharide content greatly differs among the different heparin 
preparations. The composition of non-anticoagulant oligosaccharides generally depends on 
the source of isolation and the type of preparation employed. Therefore, depending on the 
structural characteristics of non-anticoagulant oligosaccharides, heparins can have either 
pro- or anti-proliferative effects. This study provides the platform for future studies 
determining the non-anticoagulant characteristics of oligosaccharides responsible for the 
different cellular effects as well as investigating their biological properties in vivo.  
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Chapter 3 Orally Administered Enoxaparin Ameliorates Acute Colitis by Reducing 
Macrophage-associated Inflammatory Responses 
3 Abstract  
Inflammatory bowel diseases, such as ulcerative colitis, cause significant morbidity and 
decreased quality of life. The currently available treatments are not effective in all patients, 
can be expensive and have potential to cause severe side effects. This prompts the need for 
new treatment modalities. Enoxaparin, a widely used antithrombotic agent, is reported to 
possess anti-inflammatory properties and therefore we evaluated its therapeutic potential in 
a mouse model of colitis. Acute colitis was induced in male C57BL/6 mice by administration 
of dextran sulphate sodium (DSS). Mice were treated once daily with enoxaparin via oral or 
intraperitoneal administration and monitored for colitis activities. On termination (day 8), 
colons were collected for macroscopic evaluation and cytokine measurement, and processed 
for histology and immunohistochemistry. Oral but not intraperitoneal administration of 
enoxaparin significantly ameliorated DSS-induced colitis. Oral enoxaparin-treated mice 
retained their body weight and displayed less diarrhoea and faecal blood loss compared to 
the untreated colitis group. Colon weight in enoxaparin-treated mice was significantly lower, 
indicating reduced inflammation and oedema. Histological examination of untreated colitis 
mice showed a massive loss of crypt architecture and goblet cells, infiltration of immune 
cells and the presence of oedema, while all aspects of this pathology were alleviated by oral 
enoxaparin. Reduced number of macrophages in the colon of oral enoxaparin-treated mice 
was accompanied by decreased levels of pro-inflammatory cytokines. Oral enoxaparin 
significantly reduces the inflammatory pathology associated with DSS-induced colitis in 
mice and could therefore represent a novel therapeutic option for the management of 
ulcerative colitis.  
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3.1 Introduction    
Ulcerative colitis (UC) is a chronic inflammatory condition with millions of sufferers 
worldwide [228]. In UC, chronic inflammation of the inner lining of the colon leads to 
abdominal pain, diarrhoea, bloody stool and weight loss, and results in decreased quality of 
life. Currently, pharmacological and surgical interventions are the two main management 
approaches for UC [2]. Drugs such as corticosteroids, aminosalicylates, and 
immunosuppresants, which aim to decrease inflammation, show limited effectiveness for 
long term remission and are associated with significant side effects [36]. Monoclonal 
antibodies, such as infliximab, that inhibit tumour necrosis factor (TNF-α) have shown 
considerable success [229]. However, they are expensive, about 30 - 40% of patients do not 
respond to TNF-α inhibitors and in up to 40% of patients the initial therapeutic response is 
lost after 1 - 2 years [39]. Surgery is reserved for about 20 - 30% of patients who are 
unresponsive to medication and develop life-threatening complications such as perforation, 
refractory rectal bleeding, toxic megacolon and fulminant colitis [2]. Even after surgery, 
patients are predisposed to the risk of complications such as small bowel obstruction, 
anastomotic strictures, pouchitis and pouch failure [36].  
 Therefore, the search for safer and more effective agents for the management of UC 
continues. Among these agents, heparins (unfractionated heparin, UFH and low-molecular-
weight heparins, LMWHs) have attracted much interest for their paradoxical responses. In 
clinical practice, heparins are widely used for the treatment and prophylaxis of venous 
thromboembolism [48]. However, many studies have demonstrated therapeutic usefulness 
of heparins apart from their anticoagulant activity, of which their anti-inflammatory 
properties have attracted much interest among researchers around the world [46].  
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 Heparins are GAGs and are composed of a heterogeneous mixture of highly 
sulphated anticoagulant and non-anticoagulant molecules known as oligosaccharides [49]. 
LMWHs have replaced UFH clinically to a large extent because of their improved 
pharmacokinetic properties and fewer side effects. Thromboembolic complications have 
been reported in patients with UC and it was found serendipitously that UFH is linked to 
remission of UC when patients were treated with UFH for deep vein thrombosis or 
pulmonary embolism [43]. Since then, several pre-clinical as well as open-labelled clinical 
studies have demonstrated the usefulness of heparins in UC [73,109,114,119].  
 However, some pre-clinical and clinical studies have shown little or no significant 
clinical advantage of LMWHs compared to placebo when used for the management of UC 
[115-117,230,231]. The observed differences in clinical outcome could be due to the fact 
that these studies were not only heterogeneous in regards to their methodological approaches 
and definitions for clinical outcomes, but also used different heparins. For example, two 
LMWHs, dalteparin and nadroparin, have reported to be effective in patients with steroid 
resistant UC [112,113]. On the other hand, tinzaparin (another LMWH) has shown no 
additive benefit over standard therapy in patients with UC [117]. LMWHs are prepared by 
different chemical or enzymatic processes and are dissimilar to each other in both their 
physical and chemical properties [49]. Many studies have shown real and significant 
differences between various LMWHs based on their oligosaccharide analysis [133,232]. 
Dotan et al. found that enoxaparin may be an effective therapy for active UC and may delay 
or preclude the need for corticosteroid treatment [114]. On the other hand, Zezos and co-
workers reported no additional therapeutic benefit of enoxaparin compared with classical 
therapy. In vivo investigations of enoxaparin in other inflammatory conditions (e.g. lichen 
planus) have also reported contradictory results [129,138]. Commercially available 
enoxaparin or any other LMWH is normally standardized according to its anticoagulant 
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activity (anticoagulant oligosaccharides) but not the other molecules (non-anticoagulant 
oligosaccharides), which results in batch-to-batch variation [132,140]. It has been reported 
that the differences in non-anticoagulant oligosaccharides between different batches of 
enoxaparin may be responsible for the inconsistent clinical findings [138]. We have also 
previously reported the structural variations in two different batches of enoxaparin 
formulated by the same manufacturer [140].  
 It is known that the absorption of LMWHs from the gut is poor after oral 
administration because of their hydrophilicity, high negative charge and large size [233]. 
Therefore, in previous clinical studies LMWHs were administered parenterally. However, 
such macromolecules are composed of anticoagulant and non-anticoagulant 
oligosaccharides and hence the risk of bleeding is increased when used for medical 
conditions other than where an anticoagulant effect is required. For example, in one study, 
administration of a LMWH resulted in the massive haemorrhage in a patient with UC [234]. 
Therefore, studies investigating the role of LMWHs in inflammatory conditions have used 
low parenteral doses in an attempt to avoid bleeding complications. However, it has been 
reported that their anti-inflammatory activities are expressed with high LMWH 
concentrations where the anticoagulant effects also predominate [120]. If heparins are 
administered orally, because of their lack of systemic absorption, they can be delivered to 
the site of inflammation in UC. This route would potentially minimize the risk of bleeding 
as well as allow the use of high doses. Given the mixed findings with the use of enoxaparin 
in UC, we investigated and compared the efficacy of orally and parenterally administered 
enoxaparin utilizing the most widely used animal model of chemically-induced colitis, with 
the aim of determining the probable underlying mechanisms of enoxaparin in attenuating 
colitis.  
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3.2 Materials and methods 
3.2.1 Animal colitis model 
All animal experiments were approved by the Animal Ethics Committee of the University 
of Tasmania (Ethics approval number: A13576) and conducted in accordance with the 
Australian Code of Practice for Care and Use of Animals for Scientific Purposes (8th Edition 
2013). Male C57BL/6 mice, (aged 8 - 10 weeks; 21 - 30 g, average ≈ 25 g), were obtained 
from the University of Tasmania animal breeding facility and housed in a temperature-
controlled environment with a 12-hour day/ night light cycle. Individual body weights were 
assessed daily over an initial acclimation period of 7 days. All mice were non-fasting and 
had access to food and autoclaved tap water for drinking ad libitum during experiment. 
Colitis was induced by feeding mice with 3% w/v dextran sulphate sodium (DSS, MW = 
40000-50000, USB, Affymetrix Inc, Ohio, USA) dissolved in drinking water from day 1 to 
day 8.  Control mice received water without DSS from day 1 to day 8.  
3.2.2 Formulation of enoxaparin  
Enoxaparin solution for intraperitoneal administration was prepared by diluting enoxaparin 
(100 mg/ml; Clexane, Sanofi Aventis, NSW, Australia) with water for injection to obtain a 
final concentration of 0.25 mg/ml. Food mash containing enoxaparin for oral administration 
was prepared by dissolving 9.6 g sucrose (4% w/w of food mash) in 100 ml autoclaved tap 
water followed by addition of 0.4 ml of enoxaparin (100 mg/ml) solution. Powdered food 
(130 g) (Barastoc Rat & Mouse Pellet, Ridley AgriProducts, Melbourne, Australia) was then 
added slowly with constant stirring to this solution to prepare a homogenous food mash 
mixture. Then 3 g of this mixture containing 0.5 mg of enoxaparin was transferred to food 
trays. Each food tray was stored at -20 °C until used.  
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3.2.3 Treatment with enoxaparin  
Mice were assigned randomly into six groups: i) untreated healthy control mice (C, n = 6) 
ii) healthy mice treated with oral enoxaparin (C+OE, n = 3) iii) healthy mice treated with 
intraperitoneal enoxaparin (C+IPE, n=3) iv) mice which received DSS (through drinking 
water) and vehicle (water for injection or food mash) (DSS, n = 14) v) mice which received 
DSS in drinking water and treated with oral enoxaparin (DSS+OE, n = 12) and vi) mice 
which received DSS in drinking water and were treated with intraperitoneal enoxaparin 
(DSS+IPE, n = 6). Enoxaparin (20 mg/kg/day for oral or 0.5 mg/kg/day for intraperitoneal 
injection) was given from day 1 to day 7.   
3.2.4 Evaluation of intestinal inflammation  
Mice were monitored daily for change in body weight. Determination of body weight daily 
is crucial to monitor the development of colitis and its severity. Stool consistency and the 
presence of blood in the stool were scored daily (Table 3.1) [235]. The anal area was 
examined for the presence of blood and faeces was collected and tested for the presence of 
blood using Hemoccult II slides (Beckman Coulter Inc., California, USA).  
Table 3.1 Scoring system for stool consistency and blood in stool [235] 
Score    Stool consistency     Blood in faeces  
0 Normal formed pellet    None/ negative  
1 Soft but still formed (pasty when pressed) Hemoccult + 
2 Loose stool      Visual blood in stool 
3 Watery stool/ diarrhoea     Gross bleeding/ bloody anus 
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3.2.5 Termination of experiment and tissues sampling 
Mice were killed by carbon dioxide inhalation followed by cervical dislocation on day 8. 
The entire colon was carefully removed and examined macroscopically. The colon length 
was measured before opening it longitudinally for observation of colonic content. After 
mechanical cleaning, colon weight was determined and the colon tissue was then divided 
longitudinally for histology and measurement of cytokine levels.  
3.2.6 Histologic evaluation of colitis 
Colon tissue was fixed with 10% v/v buffered formalin and processed for paraffin 
embedding. Paraffin embedded tissue was cut into sections (4 μm thickness) before using 
for hematoxylin and eosin (H&E) staining and immunohistochemistry. All H&E sections 
were graded blindly for the severity of tissue damage at distal and proximal regions as 
described previously [236-238].  
3.2.7 Immunohistochemistry  
For immunohistochemical staining, antigen retrieval was performed by incubating the 
sections for 10 minutes at 97 °C in 1 mM EDTA buffer, pH 8 or 10 mM citrate buffer, pH 
6. Activity of endogenous peroxidase was blocked by incubating sections with 3% v/v 
hydrogen peroxide for 20 minutes. Sections were then washed with 0.05 M Tris-buffered 
saline containing 0.5% v/v Tween 20 (TBST), pH 7.6. Subsequently, sections were 
incubated with serum-free protein block (Dako, Victoria, Australia) for 10 minutes. Colon 
sections were then incubated with primary antibodies: anti-F4/80 (ab111101, Abcam, 
Cambridge, UK, 1:100); anti-claudin-4 (ab15104, Abcam, 1:200); anti-occludin (ab64482, 
Abcam, 1:50) or its isotype control antibody (monoclonal rabbit immunoglobulin G, 
ab172730, Abcam, assay dependent concentration) overnight at 4 ˚C or at room temperature 
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for 1 hour. Sections were then washed 3 × 5 minutes and allowed to react with secondary 
antibody: anti-rabbit immunoglobulin G conjugated to horseradish peroxidase (ab7090, 
Abcam, 1:300) at room temperature for 1 hour. Histological signal was developed using 
3,3’-diaminobenzidine in a chromogen solution (ab64238, Abcam, 1:50) before 
counterstaining the sections with hematoxylin. Sections were dehydrated and mounted using 
mounting medium (Dako, Victoria, Australia) and then examined microscopically (Leica 
DM2500, Image Pro Plus 7.0 software) for positively stained cells. The number of F4/80-
positive macrophages was counted at high-power field (400 × magnification) and averaged 
from ten fields. 
 For double immunofluorescence staining, sections were dewaxed and rehydrated 
before antigen retrieval using 10 mM citrate buffer, pH 6 for 15 minutes at 97 °C. Sections 
were incubated with serum-free protein block (Dako, Victoria, Australia) and permeabilized 
with 0.4% v/v Triton-X at room temperature for 30 minutes. Sections were incubated with 
primary antibodies: anti-F4/80 (ab16911, Abcam, 1:25); anti-IL1β (ab9722, Abcam, 1:300), 
anti-iNOS (ab136918, Abcam, 1:100), anti-mannose receptor (CD206) (ab64693, Abcam, 
1:2000) overnight at 4 °C or at room temperature for 1 hour. The omission of primary 
antibodies and replacement with isotype controls (rabbit immunoglobulin G and normal rat 
serum at assay-dependent concentration) served as independent negative controls. Sections 
were washed with TBST 3 × 10 minutes and incubated with species-specific secondary 
antibodies: anti-rat IgG H&L AlexaFluor 594 (ab150160, Abcam, 1:1000) and anti-rabbit 
IgG H&L AlexaFluor 488 (A11070, Thermo Fisher Scientific, Melbourne, Australia, 
1:1000) at room temperature for 2 hours. Sections were rinsed 3 × 10 minutes, followed by 
a quick wash with distilled water before mounting using Glycerol Mounting Medium 
(Abcam) that contained 4’,6-diamidino-2-phenylindole (DAPI) and 1,4-diazobicyclo-2,2,2-
octane (DABCO). Labelled tissues were visualized using a Leica DM LB2 microscope. 
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Fluorescence images (400 × magnification) were captured using NIS-Elements 4.13 (Nikon) 
software. The number of fluorescence-positive cells was counted from five representative 
high-power fields (400 × magnification) per tissue section and expressed as percent of 
double positive cells/ total number of macrophages. 
3.2.8 Tissue explant culture and measurement of cytokine levels 
Each collected tissue was cut, weighed and washed with cold PBS before transferring to a 
12 well plate containing 1 ml/ well of RPMI 1640 culture medium (In Vitro Technologies 
Pty Ltd, Melbourne, Australia) supplemented with 10% v/v foetal calf serum (Gibco, Life 
Technologies, Melbourne, Australia), penicillin (100 mU/L) and streptomycin (100 mg/L) 
(Sigma-Aldrich Pty Ltd, Sydney, Australia). After 24 hours of incubation, supernatant was 
collected from each well and stored at -80 °C until further analysis. The cytokine levels were 
determined by immunoassay using a Bio-Plex Pro Mouse cytokine 23-plex kit (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA) following manufacturer instructions. Briefly, 
standards were prepared by reconstituting the cytokine standard with culture media. Solution 
containing coupled magnetic beads was added into each well of a 96 well plate. Standard 
and samples were then added in duplicate and incubated for 30 minutes. After that, detection 
antibodies were added and incubated before final incubation with streptavidin-
phycoerythrin. Cytokine levels were measured and analysed using a Bio-Plex 200 instrument 
(Bio-Rad Laboratories) and Bioplex Manager software, version 6 (Bio-Rad Laboratories) 
respectively. The cytokine levels were normalized by dividing the cytokine results (pg/ml) 
by the measured biopsy weight (mg) to obtain pg/ml of cytokines/ 10 mg of tissue.  
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3.2.9 Statistical analysis 
Results are presented as mean ± standard deviation (SD), or points of minimum, median, 
mean, maximum and interquartile range. Using GraphPad Prism (version 6, GraphPad 
Software Inc, CA, USA), statistical significance was evaluated using one or two way 
analysis of variance (ANOVA) followed by multiple comparison test: Dunnett’s test to 
evaluate the difference between each treatment group and the colitis control group or 
Tukey’s test to determine the differences between different groups. Pearson’s correlation 
coefficient (r2) was determined for the relationship between two variables when necessary. 
A p value of < 0.05 was considered statistically significant. 
 
3.3 Results  
3.3.1 Orally administered enoxaparin ameliorates colitis-induced weight loss  
In line with previous reports [239], we observed a reduction of approximately 15% body 
weight over an 8 day DSS treatment period (Fig. 3.1A). Oral enoxaparin attenuated body 
weight loss where the difference in the body weight loss between DSS-treated (DSS) and 
oral enoxaparin treated (DSS+OE) mice was significant on day 6 (2.9%, p = 0.0007), day 7 
(4.9%, p < 0.0001) and day 8 (8.1%, p < 0.0001) (Fig. 3.1A). On the other hand, difference 
in the body weight loss between DSS and intraperitoneal enoxaparin (DSS+IPE) was not 
significant from day 1 to day 8 (Fig. 3.1A). 
3.3.2 Enoxaparin ameliorates colitis-associated diarrhoea and blood in stool  
Over the treatment period, we observed an increased occurrence of loose stool and diarrhoea 
in mice receiving DSS (Fig. 3.1B). Consistent with an amelioration of weight loss, orally 
administered enoxaparin significantly reduced the occurrence of loose stool or diarrhoea on 
day 6 and day 7 (Fig. 3.1B). On the other hand, intraperitoneal enoxaparin also reduced the 
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mean stool consistency score on day 7 (Fig. 3.1B). Both oral and intraperitoneal enoxaparin 
significantly prevented the presence of blood in stool on day 5 only; this effect was not seen 
on day 6 and 7 (Fig. 3.1C). There was no statistical difference between oral and 
intraperitoneal enoxaparin treatment for both mean stool consistency and stool blood scores.  
 
Figure 3.1 Effect of enoxaparin during acute colitis.  
(A) Daily body weight changes during colitis induction in C57BL/6 mice with and without 
enoxaparin compared to healthy control. Stool samples collected from mice were scored for (B) 
consistency and the presence of (C) occult blood on a daily basis during experiment. Results are 
expressed as mean ± SD of n = 3 - 14 mice. * p < 0.05 and ** p < 0.01. Control, C; control with oral 
enoxaparin, C+OE; control with intaperitoneal injection of enoxaparin, C+IPE; untreated colitis, 
DSS; colitis with oral enoxaparin, DSS+OE; colitis with intraperitoneal injection of enoxaparin, 
DSS+IPE. 
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3.3.3 Orally administered enoxaparin alleviates macroscopic changes of the colon  
Having observed beneficial clinical changes by orally administered enoxaparin, we then 
investigated the effects of enoxaparin in ameliorating macroscopic changes of colon (Fig. 
3.2.1 and Fig. 3.2.2A). Acute colitis was associated with a significant shortening of the 
colon. The length of colon was reduced by 20.8% compared to healthy control (Fig. 3.2.2B). 
Oral enoxaparin significantly prevented shortening of colon by 10.2% (p = 0.025) compared 
to DSS. Intraperitoneal enoxaparin had no effect on the length of colon (Fig. 3.2.2B). Oral 
enoxaparin also reduced the severity of gross changes in the luminal contents of the distal 
colon compared to untreated colitis (Fig. 3.2.2C).  
 Colon weight change, a well-known independent marker of intestinal oedema and 
inflammation, was presented as colon weight over body weight. Oral enoxaparin suppressed 
the increase in relative colon weight by 14.2% (p = 0.011) compared to untreated colitis. On 
the other hand, intraperitoneal enoxaparin reduced the relative colon weight by only 4.2%, 
which was not significant (p = 0.91) (Fig. 3.2.2D). 
 
 
Fig. 3.2.1 Representative images of gross appearance of cecum.  
C57BL/6 mice were given 3% w/v DSS in their drinking water from day 1 to day 8. Control mice 
were given water only. They were treated with or without oral (p.o.) enoxaparin. Cecums were 
collected on day of termination. Control, C; control with oral enoxaparin, C+OE; untreated colitis, 
DSS; colitis with oral enoxaparin, DSS+OE.  
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Figure 3.2.2 Effect of enoxaparin on macroscopic appearance of colon.  
(A) Representative images of colons from mice treated with and without enoxaparin. (B) The colons 
were measured for their length. (C) The appearance of colon luminal content was evaluated before 
the measurement of colon weight. (D) The relative colon weight was presented as colon weight 
divided by body weight. Results are expressed as mean ± SD of n = 3 - 14 mice. * p < 0.05 and ** p 
< 0.01. Control, C; control with oral enoxaparin, C+OE; control with intraperitoneal injection of 
enoxaparin, C+IPE; untreated colitis, DSS; colitis with oral enoxaparin, DSS+OE; colitis with 
intraperitoneal injection of enoxaparin, DSS+IPE.   
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3.3.4 Orally administered enoxaparin decreases colon damage and infiltration of 
inflammatory cells  
Colons of healthy untreated mice showed intact surface epithelium, intact mucosa and 
submucosa, non-disrupted crypt architecture, complete goblet cells with mucus vacuoles and 
only a small number of leukocytes (Fig. 3.3). In contrast, DSS treated mice showed structural 
damage and infiltration of inflammatory cells into the colon. Careful evaluation of colon 
tissues revealed regional DSS-induced injuries mainly confined to the distal colon where 
diffused destruction of crypt architecture, goblet cell loss, submucosa oedema and increased 
infiltration of inflammatory cells was evident (Fig. 3.3). Oral enoxaparin reduced the 
disruption of crypt architecture and epithelium, reduced globlet cell loss, showed less severe 
submucosa oedema, and also reduced infiltration of inflammatory cells (Fig. 3.3). The 
cumulative histological scores for both the proximal colon (Fig. 3.4A) and distal colon (Fig. 
3.4B) were significantly lower in orally treated mice with colitis compared to untreated 
colitis (4 versus 8 and 16 versus 23 respectively). Intraperitoneal administration of 
enoxaparin did not reduce the colon damage and infiltration of inflammatory cells (Fig. 3.3). 
Also, the cumulative histological scores were not statistically different compared to DSS 
(Fig. 3.4).  
 94 
 
 
Figure 3.3 Effect of enoxaparin on histological changes of colon.  
Representative hematoxylin and eosin stained colon sections of healthy and colitis mice with and 
without enoxaparin. Scale bars = 100 µm for 400 × and 400 µm for 100 × magnification. Control, C; 
control with oral enoxaparin, C+OE; control with intraperitoneal injection of enoxaparin, C+IPE; 
untreated colitis, DSS; colitis with oral enoxaparin, DSS+OE; colitis with intraperitoneal injection 
of enoxaparin, DSS+IPE. 
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Figure 3.4 Effect of enoxaparin on histological changes of colon.  
Cumulative histology damage scores for (A) proximal colon and (B) distal colon. Results are 
expressed as mean ± SD of n = 3 - 14 mice. ** p < 0.01. Control, C; control with oral enoxaparin, 
C+OE; control with intraperitoneal injection of enoxaparin, C+IPE; untreated colitis, DSS; colitis 
with oral enoxaparin, DSS+OE; colitis with intraperitoneal injection of enoxaparin, DSS+IPE.  
3.3.5 Orally administered enoxaparin reduces the levels of pro-inflammatory 
cytokines 
As expected, colon tissues of mice administered with DSS showed significant increase in a 
wide range of inflammatory cytokines (Fig. 3.5.1 and Fig. 3.5.2). Oral enoxaparin reduced 
the levels of a number of cytokines significantly. The levels of IL-1α, IL-1β, IL-10, MIP-1α, 
MIP-1β, G-CSF and GM-CSF were reduced by 44.6% (p = 0.0002), 40.4% (p = 0.0011), 
54.5% (p < 0.0001), 63.6% (p = 0.0002), 62.3% (p = 0.0263), 51.6% (p = 0.0013) and 40.1% 
(p < 0.0001) respectively (Fig. 3.5.1 A-G). However intraperitoneal enoxaparin produced 
inconsistent response. For example, it reduced MIP-1α level by approximately 45% (Fig. 
3.5.1C). On the other hand, the levels of G-CSF, GM-CSF and IL-4 were increased 
significantly (Fig. 3.5.1 E, F, H). Unlike intraperitoneal enoxaparin, oral enoxaparin did not 
affect the levels of cytokines in healthy mice.  
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Figure 3.5.1 Effect of enoxaparin on colonic cytokine levels.  
Distal colon tissues of mice were cultured for 24 hours. Supernatants were collected and cytokine 
levels were measured using Bio-Plex assay. Cytokine levels in the supernatant were normalized to 
tissue weight to obtain pg/ml of cytokines/ 10 mg of tissue. Results are expressed as minimum, 25th 
percentile, median, mean, 75th percentile and maximum of cytokine levels of 3 - 5 mice. * p < 0.05 
and ** p < 0.01. Interleukin, IL; macrophage inflammatory protein, MIP; granulocyte colony-
stimulating factor, G-CSF; granulocyte–macrophage colony-stimulating factor, GM-CSF; Control, 
C; control with oral enoxaparin, C+OE; control with intraperitoneal injection of enoxaparin, C+IPE; 
untreated colitis, DSS; colitis with oral enoxaparin, DSS+OE; colitis with intraperitoneal injection 
of enoxaparin, DSS+IPE.  
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Figure 3.5.2 Effects of enoxaparin on colonic cytokine levels.  
Distal colon tissues of mice were cultured for 24 hours. Supernatants were collected and measured 
for cytokine levels by using Bio-Plex assay. Cytokine levels in the supernatant were normalized to 
tissue weight to obtain pg/ml of cytokines/ 10 mg of tissue. Results are expressed as minimum, 25th 
percentile, median, mean, 75th percentile and maximum of cytokine levels of 3 - 5 mice. * p < 0.05 
and ** p < 0.01. Out of range, OOR; Interleukin, IL; interferon, IFN; keratinocyte-derived 
chemokine, KC; monocyte chemotactic protein-1, MCP-1; regulated and normal T cells expressed 
and secreted, RANTES; tumor necrosis factor-α, TNF-α; Control, C; control with oral enoxaparin, 
C+OE; control with intraperitoneal injection of enoxaparin, C+IPE; untreated colitis, DSS; colitis 
with oral enoxaparin, DSS+OE; colitis with intraperitoneal injection of enoxaparin, DSS+IPE. 
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 Since increased cytokine levels in the colonic mucosa of UC patients are closely 
related to the severity of inflammation and tissue damage [240-242], we determined the 
Pearson’s correlation coefficients between cytokine levels (that statistically significantly 
decreased by oral treatment) and the percentage body weight change in individual mice on 
day 8. Consistent with clinical observations, cytokine levels significantly and positively 
correlated with the severity of body weight loss (Fig. 3.6 A-G). Mucosal concentrations of 
IL-1α (r2 = 0.77, p < 0.0001), IL- 1β (r2 = 0.70, p < 0.0001), MIP-1α (r2 = 0.69, p < 0.0001), 
MIP-1β (r2 = 0.58, p < 0.0001), G-CSF (r2 = 0.61, p < 0.0001), GM-CSF (r2 = 0.66, p < 
0.0001) and IL-10 (r2 = 0.74, p < 0.0001) were each substantially correlated with the 
percentage of body weight loss.  
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Figure 3.6 Correlation between colonic cytokine levels and body weight changes during acute 
colitis.  
Changes in cytokine levels were correlated with the changes of body weight of individual mice. The 
value of the Pearson correlation coefficient (r2) is reported and significance is indicated by p value. 
Interleukin, IL; macrophage inflammatory protein, MIP; granulocyte colony-stimulating factor, G-
CSF; granulocyte–macrophage colony-stimulating factor, GM-CSF; Control, C; control with oral 
enoxaparin, C+OE; control with intraperitoneal injection of enoxaparin, C+IPE; untreated colitis, 
DSS; colitis with oral enoxaparin, DSS+OE; colitis with intraperitoneal injection of enoxaparin, 
DSS+IPE. 
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3.3.6 Orally administered enoxaparin affects macrophage numbers and 
differentiation status during colitis 
Macrophages play an important role during acute colitis by secreting various pro-
inflammatory mediators [243]. Therefore, we investigated if the observed reduction in 
cytokines could be a result of reduced number of macrophages in the colonic mucosa. When 
we compared the number of macrophages between different types of treatment, significantly 
higher macrophage numbers (33.3 ± 7.1/ field) were observed in the mucosa and submucosa 
in DSS-treated mice compared to healthy control mice (1.1 ± 1.2/ field) (Fig. 3.7). Consistent 
with the reduced cytokine levels, oral enoxaparin also significantly decreased the number of 
macrophages (17.8 ± 5.4/ field, p < 0.0001) in the mucosa and submucosa. On the other 
hand, intraperitoneal enoxaparin was not effective in decreasing the number of macrophages 
in the colon tissue (29.2 ± 6.5/ field) (Fig. 3.7).  
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Figure 3.7 Effect of enoxaparin on macrophage infiltration into the inflamed colon.  
(A) Representative immunostaining of F4/80-positive macrophages in the distal colon from healthy 
and colitic mice treated with and without enoxaparin. (B) Quantification of macrophages (F4/80+ 
cells) in the colons. Results are expressed as mean ± SD of ten representative high-power fields per 
tissue section of 3 - 5 mice each. ** p < 0.01. Scale bar = 100 µm for 400 × magnification. Control, 
C; untreated colitis, DSS; oral enoxaparin, OE; intraperitoneal injection of enoxaparin, IPE. 
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 In addition to the absolute numbers of macrophages, we also looked at their 
differentiation status. When we detected M1 macrophages (F4/80 and iNOS positive cells, 
Fig. 3.8A) in the colon tissue, only low numbers were observed mainly in the mucosa (double 
headed arrow) of healthy control colons. In response to DSS treatment, as expected large 
numbers of M1 macrophages were detected not only within the oedematous submucosa 
(arrow heads) but also within the mucosa (double headed arrow). In response to enoxaparin 
treatment, those macrophage numbers were significantly reduced with a few M1 cells 
present only in the mucosa (double headed arrow) (Fig.3.8A).  
 In contrast, when we looked at M2 macrophages (F4/80 and CD-206 positive cells, 
Fig. 3.8B), the majority of macrophages were present in the mucosa of healthy colon (double 
headed arrow). In response to DSS, only a very low numbers of M2 macrophages were 
present in the mucosa and submucosa, while in response to enoxaparin treatment, larger 
numbers of M2 macrophages were present in the mucosa and submucosa (Fig. 3.8B).   
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Figure 3.8 Effect of enoxaparin on macrophage phenotypes.  
Co-immunostaining of macrophages and their phenotypes. Representative images of (A) M1 
macrophages (F4/80+ and iNOS+) and (B) M2 macrophages (F4/80+ and CD206+) using colon tissue 
from n = 3 - 5 mice. F4/80 positive cells were visualized using Alexa Fluor® 594-conjugated goat 
anti-rat IgG (red) and iNOS or CD206 positive cells using Alexa Fluor® 488-conjugated goat anti-
rabbit IgG (green). Nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI, blue). 
Localization of mucosa (double-headed arrow) and submucosa (arrowheads) is indicated. Scale bar 
= 50 µm for 400 × magnification. Control, C; untreated colitis, DSS; colitis with oral enoxaparin, 
DSS+OE. 
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 Quantitative analysis of these histological results showed that overall, a healthy colon 
contained twice as many M2 compared to M1 macrophages (open bars, Fig. 3.9). In contrast, 
the M1/M2 ratio increased markedly in DSS-induced colitis, with 92.0 ± 5.9 % of 
macrophages being M1 while only a minority were M2 cells (black bars, Fig. 3.9). On the 
other hand, oral enoxaparin treatment significantly increased the levels of M2 macrophages 
by 31.3 % (p = 0.03), whereas the M1 cells were reduced by 30.9% (p = 0.0007) compared 
to untreated colitis colons (grey bars, Fig. 3.9).  
 
Figure 3.9 Effect of enoxaparin on macrophage phenotypes.  
Quantification of macrophages expressing M1 and M2 phenotype markers in the colon. Results are 
expressed as percentage of double-positive macrophages from total macrophages ± SD of five 
representative high-power fields per tissue section of n = 3 - 5 mice each. * p < 0.05 and ** p < 0.01. 
 
 IL-1β acts as central mediator of pro-inflammatory immune responses. We therefore 
investigated a possible mechanistic link between reduced IL-1β-levels and reduced M1 
macrophage numbers in enoxaparin-treated mice (Fig. 3.10). Relative to healthy mice, IL-
1β immune-labelling increased under conditions of untreated colitis. At the same time, in 
the enoxaparin-treated colon, we observed a reduced expression of IL-1β confirming our 
previous results (Fig. 3.5). However, using co-localization of IL-1β staining with detection 
of a macrophage marker (F4/80), we were unable to demonstrate that IL-1β was expressed 
by macrophages in this disease model (Fig. 3.10).    
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Figure 3.10 Effect of enoxaparin on IL-1β expression on colon tissues.  
Co-immunostaining of macrophages and IL-1β. Representative images of IL-1β and F4/80 staining 
of colons from n = 3 - 5 mice. F4/80 positive cells were visualized using Alexa Fluor® 594-
conjugated goat anti-rat IgG (red) and IL-1β positive cells using Alexa Fluor® 488-conjugated goat 
anti-rabbit IgG (green). Nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI, blue). 
Localization of mucosa (double-headed arrow) and submucosa (arrowheads) is indicated. Scale bar 
= 50 µm for 400 × magnification. Control, C; untreated colitis, DSS; colitis with oral enoxaparin, 
DSS+OE. 
3.3.7 Orally administered enoxaparin retains occludin and claudin-4 by attenuating 
crypt loss  
The intact intestinal epithelium serves as a protective layer, which is maintained by the 
intercellular interactions between tight junction proteins such as occludin and claudins [13]. 
Immunohistochemistry was performed to determine the localization of tight junction 
proteins, occludin and claudin-4. As shown in Figure 3.11, occludin and claudin-4 proteins 
were homogenous as well as continuous on colonic epithelial cell membrane in healthy 
control. In contrast, in sections with untreated colitis, massive mucosal erosion and crypt 
loss prevented the reliable detection of tight junction proteins (Fig. 3.11). However, in mice 
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receiving oral enoxaparin, colonic occludin and claudin-4 staining indicated a greater 
proportion of intact colonic crypts (Fig. 3.11). On the other hand, intraperitoneal enoxaparin 
resulted in a tight junction protein staining comparable to untreated colitis mice, while 
enoxaparin treatment in healthy mice via the diet or by intraperitoneal injection did not alter 
the distribution or quantity of tight junction proteins in the colon. 
 
Figure 3.11 Effect of enoxaparin on epithelial tight junctions of colon.   
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Immunostaining of (A) occludin and (B) claudin-4 in the distal colon of healthy and colitis mice 
treated with and without enoxaparin. Scale bar = 100 µm for 400 × magnification. Control, C; 
untreated colitis, DSS; oral enoxaparin, OE; intraperitoneal injection of enoxaparin, IPE.  
3.4 Discussion  
In this study, we have described the therapeutic potential of the LMWH, enoxaparin, for the 
amelioration of acute colitis. Oral enoxaparin reduced the severity of clinical activity, 
histological damage and the immunological response associated with colitis. To our 
knowledge, this is the first report to demonstrate that enoxaparin given through the diet is 
highly effective in ameliorating experimental colitis, while inducing no mortality and 
adverse effects in healthy mice. Consistent with other study [65], our results showed that 
enoxaparin given as intraperitoneal injection did not reduce the severity of colitis. To date, 
animal studies investigating the efficacy of different doses of subcutaneously administered 
enoxaparin have reported inconsistent results. For example, subcutaneous enoxaparin at 80 
μg/kg/day over 7 days effectively ameliorated experimental colitis, while this effect was not 
observed at lower (40 μg/kg/day) or higher (200 μg/kg/day) doses in the same study [73]. 
Likewise, positive effects for subcutaneous enoxaparin at doses of 250-280 μg/kg/day have 
been reported [66,97], while enoxaparin at 3 mg/kg/day was shown to be less efficacious 
[95]. Overall, our results are comparable to previous studies showing that enoxaparin is more 
effective when administered orally and not parenterally. Oral enoxaparin was previously 
reported to reduce the severity of colitis [94,95], while on the other hand intraperitoneal 
enoxaparin at a dose of ten times higher (5 mg/kg/day) [65] than our study (0.5 mg/kg/day) 
also did not relieve colitis-associated symptoms in mice, in agreement with our results. One 
limitation of prior studies is the uncertainty around the local availability of drug in the 
intestine when delivered subcutaneously or intraperitoneally, which is further complicated 
by observations that subcutaneous administration of enoxaparin produced inconsistent 
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results at different doses as described above. At present it is unclear if the reported 
discrepancies are a result of different dosing regimens or if they are related to the use of 
different pre-clinical colitis models. Overall, our results, together with the reports described 
above, strongly suggest that after parenteral administration, LMWHs cannot reliably reach 
areas of inflammation at the intestinal mucosa or submucosa. In contrast, current evidence 
supports the idea that oral administration is effective to deliver enoxaparin locally. From a 
patient’s perspective, this is not only the preferred option, but this route of administration is 
likely to restrict the systemic availability of LMWHs, which therefore reduces the risk of 
bleeding complications. We did not test the stability of enoxaparin in the food mixture after 
storage in freezer (a freezing/thawing cycle). However, Patel et. al (2009) had demonstrated 
that slow freezing to - 196 °C with rapid thawing, or rapid freezing with slow thawing, 
resulted in only negligible loss of anti-factor Xa activity of enoxaparin [144].    
 Previously, the disease activity index was commonly used to summarise three 
clinical scores of colitis [95,97]. In this study however, we evaluated individual clinical 
parameters on a daily basis to identify differences of colitis severity and to better understand 
treatment-specific responses. Using this approach, oral enoxaparin showed a significant 
protection against weight loss, diarrhoea and intestinal bleeding as well as attenuation of 
histological features of colitis. 
 A multitude of cytokines is implicated in the pathogenesis of UC [15]. These 
mediators form a complex network that regulates mucosal inflammation and affect the 
integrity of epithelium [15]. Since pro-inflammatory cytokines from patient samples 
correlate with disease activity [240,244], treatments that modulate these mediators are likely 
to be of therapeutic use. In our study, we quantified a larger number of cytokines compared 
to previous studies to get a broader understanding of the immunological cytokine response 
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during intestinal inflammation and especially in response to enoxaparin treatment. The 
presence of elevated pro-inflammatory cytokines during intestinal inflammation was in 
general agreement with previous studies [243,245,246]. Although these studies reported on 
a significantly lower number of cytokines, overall they mirrored our results of a broad pro-
inflammatory environment [245,246]. Also, in our study, oral enoxaparin reduced the levels 
of a number of mucosal cytokines including IL-1α, IL-1β, IL-10, MIP-1α, MIP-1β, G-CSF, 
GM-CSF during colitis. The importance of individual cytokine levels is reflected by their 
good correlations with the colitis-induced body weight loss of each animal.  
 Macrophages found in the colon of active UC patients are key mediators of human 
UC [247] and induce tissue damage by secreting inflammatory cytokines in the colonic 
mucosa during acute colitis [243]. Discrete macrophage subsets with divergent effects are 
often grouped functionally as M1 (monocyte-derived or classically activated or pro-
inflammatory) and M2 (tissue-resident or alternatively activated or anti-inflammatory) 
macrophages [247-249]. During intestinal inflammation, monocytes are recruited and 
differentiated into pro-inflammatory macrophages within the lamina propria under the 
influence of GM-CSF [247]. This growth factor is necessary for the development, 
differentiation and proliferation of monocyte-derived inflammatory macrophages and is 
known to contribute to M1 polarization [248]. As expected by the reduced levels of GM-
CSF in response to oral enoxaparin treatment, reduced numbers of M1 macrophages and 
elevated numbers of M2 macrophages were detected. These results are in agreement with 
other reports where M1 macrophages contributed critically to DSS-induced colitis, while 
M2 macrophages were protective [250,251]. Although our data suggest that that oral 
enoxaparin effectively reduced GM-CSF level, which could in part be responsible for 
suppressed M1/M2 ratio, this observation has to be confirmed in detailed future studies. 
Since macrophages are a major source of other pro-inflammatory cytokines, this connection 
 110 
 
could also explain the reduction of multiple other cytokines such as IL-1α, IL-1β, IL-10, 
MIP-1α and MIP-1β that originated from inflamed colon tissues. However, the precise 
source of cytokines in this model of colitis is not completely known at present and these 
mediators could in principle be secreted by a variety of cells during inflammation. In human 
IBD, it is thought that IL-1β is expressed by macrophages in the inflamed colon [252]. In 
contrast, in our mouse model, we were unable to demonstrate IL-1β expression in intestinal 
macrophages. Together with the strong reduction of IL-1β in colon tissue in response to 
enoxaparin, this suggests that enoxaparin either does not only target macrophages or that the 
observed changes to IL-1β level are a secondary effect. In contrast to previous observations 
[73,94], the expression of TNF-α was not significantly affected by enoxaparin treatment. 
TNF-α is thought to play a significant role in inflammatory cellular signalling which is 
reflected by the successful clinical use of TNF-α inhibitors in UC patients [229]. However, 
it is likely that a number of factors including disease location, type of inflammation, 
pathogenic mechanisms and levels of multiple cytokines in combination affect the response 
to colitis treatment [15]. Therefore, agents that target a single pro-inflammatory cytokine are 
likely limited in their ability to offer an effective maintenance therapy over extended periods 
of time, while simultaneously modulating multiple pro-inflammatory mediators to reduce 
maturation and infiltration of immune cells could provide a more sustainable strategy against 
inflammation. 
 Epithelial barrier integrity is essential to a healthy gut function [8] and our 
understanding of how epithelial homeostasis is altered in response to intestinal inflammation 
is indispensable to develop therapeutic interventions that facilitate mucosal healing and 
normalize epithelial functions. In UC, the reduction of tight junctions, associated with 
increased intestinal permeability and impaired epithelial function [253-255] is at least 
partially caused by chronic inflammation [8]. In line with our results, previous studies 
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reported a disrupted and irregular expression pattern of tight junction proteins including 
occludin and claudin-4 in the colonic mucosa in mice with DSS-induced colitis [256,257]. 
However, in this study, DSS-treatment led to massive epithelial damage with loss of 
epithelial cells that prevented us to reliably quantify tight junction proteins. Nevertheless, 
both tight junction proteins could act as surrogate markers to indicate the effect of oral 
treatment as it correlates with the retention of crypt architecture. Since it is likely that oral 
enoxaparin mainly acts locally to relieve the severity of colitis [95], it is conceivable that its 
interaction with epithelial cells could directly protect them against DSS-induced damage. 
Protecting epithelial integrity would retain the epithelial barrier function and protect against 
infiltration of microbial antigens into lamina propria. The retention of crypt architecture 
could be the main reason for the localized and regular staining of tight junction proteins in 
colitis mice treated with oral enoxaparin, which is similar to the staining observed in healthy 
mice. 
 Although heparins are well-known for their non-anticoagulant effects [46], their 
exact mode of action in UC remain unclear. Different mechanisms including a reduced 
infiltration of leukocytes as well as pro-inflammatory mediators have been postulated 
[73,90,98]. Heparins are structurally similar to HS. Loss of cell surface HS proteoglycans is 
reported in patients with UC, resulting in decreased intestinal mucosal healing [57]. It has 
been also postulated that heparins can increase mucosal healing in UC or during colitis by 
substituting the loss of cell surface HS proteoglycans. Like other LMWHs and UFH, 
enoxaparin is also composed of a complex mixture of structurally unknown 
oligosaccharides. Further work to identify the specific components of enoxaparin that are 
responsible for the observed effects will be a pre-requisite to identify their mode(s) of action 
as well as to progress the most promising molecules towards clinical trials. 
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3.5 Conclusion 
Overall, enoxaparin given at an early stage of colitis significantly prevents the development 
of colitis and reduces the pathology associated with acute colitis induced by DSS. This study 
extends our current understanding of oral administration of enoxaparin during acute colitis, 
which is a crucial step towards the use of enoxaparin for the treatment of colitis. The ability 
of enoxaparin to reduce inflammation and retain epithelial integrity along with the possibility 
of oral delivery to provide a better safety profile for clinical use, serves as a rationale to 
develop enoxaparin components as a therapeutic for patients with UC. Similar 
investigational approach using other heparin-like molecules such as fucoidans would be 
interesting to see if these molecules also display similar in vivo activity when used in animal 
model of colitis. 
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Chapter 4 Fucoidan Extracts Ameliorate Acute Colitis 
4 Abstract  
Inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn’s disease, are an 
important cause of morbidity and impact significantly on quality of life. Overall, current 
treatments do not sustain a long-term clinical remission and are associated with adverse 
effects, which highlight the need for new treatment options. Fucoidans are complex 
sulphated, fucose-rich polysaccharides found in edible brown algae and are described as 
having multiple bioactivities including potent anti-inflammatory effects. Therefore, the 
therapeutic potential of two different fucoidan preparations, fucoidan-polyphenol complex 
(Maritech Synergy) and depyrogenated fucoidan (DPF) was evaluated in the dextran sulphate 
sodium mouse model of acute colitis. Mice were treated once daily over 7 days with 
fucoidans via oral (Synergy or DPF) or intraperitoneal administration (DPF). Signs and 
severity of colitis were monitored daily before colons and spleens were collected for 
macroscopic evaluation, cytokine measurements and histology. Orally administered Synergy 
and DPF but not intraperitoneal DPF treatment, significantly ameliorated symptoms of 
colitis based on retention of body weight, as well as reduced diarrhoea and faecal blood loss, 
compared to the untreated colitis group. Colon and spleen weight in mice treated with oral 
fucoidan was also significantly lower, indicating reduced inflammation and oedema. 
Histological examination of untreated colitis mice confirmed a massive loss of crypt 
architecture and goblet cells, infiltration of immune cells and oedema, while all aspects of 
this pathology were alleviated by oral fucoidan. Importantly, in this model, the macroscopic 
changes induced by oral fucoidan correlated significantly with substantially decreased 
production of 15 pro-inflammatory cytokines by the colon tissue. Overall, oral fucoidan 
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preparations significantly reduce the inflammatory pathology associated with DSS-induced 
colitis and could therefore represent a novel nutraceutical option for the management of IBD. 
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4.1 Introduction 
Inflammatory bowel disease (IBD) is a known medical burden in most developed countries 
and a significant cause of morbidity [228]. Due to the nature of chronic inflammation 
involving the gut mucosa, patients present with symptoms such as abdominal pain, 
diarrhoea, bloody stool and weight loss, which significantly decreases their quality of life 
[2,3]. Currently, pharmacological and surgical interventions are the two main management 
approaches for IBD. Currently available drugs, which aim to decrease inflammation, show 
limited effectiveness for long term remission and are associated with side effects [36]. 
Monoclonal antibodies that inhibit TNF-α such as infliximab have shown clinical usefulness 
but at a relatively high cost [258,259]. Furthermore, about 20 - 40 % of patients do not 
respond to TNF-α inhibitors, while in up to 50 % of patients, the therapeutic response is lost 
after 1 - 2 years [39,260,261]. Surgery is reserved for about 20 - 30 % of patients who are 
unresponsive to medication and develop life-threatening complications such as perforation, 
refractory rectal bleeding and toxic megacolon [2,3]. Even after surgery, patients are 
predisposed to the risk of postoperative complications such as bowel obstruction, 
anastomotic strictures, pouchitis, sexual dysfunction and pouch failure [2,3]. Therefore, 
there is an urgent need for new treatment options that are safe, able to sustain clinical 
remission and improve mucosal gut healing.  
 Animal models have become a useful tool to study the pathophysiology of IBD and 
to test the in vivo efficacy of potential therapeutic agents [262]. A number of chemically-
induced colitis models have been described that use different colitogenic substances, such 
as dextran sulphate sodium (DSS), di- or tri-nitrobenzene sulfonic acid, oxazolone or acetic 
acid [235]. DSS-induced colitis in mice is the most commonly used model; it is associated 
with severe epithelial damage and a robust inflammatory response in the colon [263,264]. 
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DSS-treated mice show signs of acute colitis including rectal bleeding, body weight loss, 
passage of fresh blood through the anus, usually in or with stools and diarrhoea [263,265]. 
Macroscopic and histological examination reveals shortening of the intestine, submucosal 
ulceration and loss of globlet cells and crypt structure, as well as infiltration of large numbers 
of inflammatory cells into the colonic mucosa [239,263,265]. These macroscopic and 
histopathological changes are associated with the excessive production of pro-inflammatory 
cytokines [266,267]. Although this animal model has limitation regarding the accurate 
representation of the clinical course of IBD patients, it nevertheless recapitulates the 
common clinical features of inflammation and histopathology seen in human disease [263]. 
Importantly, despite its shortcomings, this model has been validated through the use of 
several clinically used therapeutic agents against IBD [267].  
 Given the need for new treatment options for IBD, we have tested two fucoidan 
extracts in the DSS-induced colitis model. Fucoidans are a class of sulphated, fucose-rich 
polymers found in edible brown macroalgae and echinoderms, which are commercially 
available as dietary supplements. Fucoidans exhibit different bioactivities, which have been 
reported in many pre-clinical in vitro and in vivo models [156]. However, the efficacy and 
characteristics of these bioactivities can vary significantly and depend on the source, species, 
MW, composition and structure of the molecules, as well as on the route of administration. 
The reported bioactivities of fucoidans are diverse and include anticoagulation, blocking of 
lymphocyte adhesion and invasion, inhibition of multiple enzymes, induction of apoptosis, 
antiviral activity and, most importantly for this study, a substantial anti-inflammatory 
activity [156,166,172]. Specifically, current evidence that fucoidans can be beneficial for 
regulating gut health is derived from a variety of pre-clinical models and studies. In a mouse 
model of chronic colitis orally delivered fucoidan (from Cladosiphon) was reported to 
downregulate the levels of the pro-inflammatory cytokine IL-6, which was also confirmed 
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through in vitro studies [167]. Similarly, in a rat model of acute colitis, an orally delivered 
polysaccharide food supplement containing fucoidan reduced monocyte numbers and 
improved clinical markers of colitis [268]. Fucoidan is also known to protect against aspirin-
induced gastric ulcers in a rat model [269] and is known from pre-clinical and clinical 
investigations to inhibit gastric pathogens [270-272].  
 Fucoidan extracts are commercially available as dietary supplements and for this 
study, two preparations of fucoidan from Fucus vesiculosus were compared. One is a highly 
purified preparation of fucoidan (depyrogenated fucoidan, DPF) with a relatively low MW, 
whereas the other (Maritech Synergy) is a fucoidan that is naturally complexed with 
polyphenols. We demonstrate here for the first time that orally delivered fucoidan or a 
fucoidan polyphenol complex both significantly suppress the inflammatory response in the 
acute DSS-induced model of colitis. These findings could open the way towards new 
treatment options for patients with IBD.   
4.2 Materials and methods 
4.2.1 Animal colitis model 
All animal experiments were approved by the Committee of Animal Ethics of the University 
of Tasmania (A13576) and were conducted in accordance with the Australian Code of 
Practice for Care and Use of Animals for Scientific Purposes (8th Edition 2013). Male 
C57BL/6 mice (aged 8 - 10 weeks; 21 - 27 g, average weight ≈ 25 g) were obtained from the 
University of Tasmania animal breeding facility and housed in a temperature-controlled, 
non-sterile environment under a 12-hour day/ night light cycle. Mice derived from different 
litters and at different time points over a period of three weeks were randomised into the 
different treatment arms based on body weight and age to ascertain comparable group 
compositions. Body weights of mice were assessed daily over an initial acclimation period 
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of one week. All mice were non-fasting and had access to food and drinking water 
(autoclaved tap water) ad libitum. Colitis was induced by supplementing 3 % w/v of dextran 
sulphate sodium (DSS, MW = 40,000-50,000, USB, Affymetrix Inc, Ohio, USA) in the 
drinking water of mice from day 1 to day 8 (day of termination). Control mice received 
drinking water without DSS.  
4.2.2 Formulation of fucoidan extracts 
Depyrogenated fucoidan (DPF) and fucoidan-polyphenol complex (Maritech Synergy), 
extracts (Table 4.1) from marine brown seaweed Fucus vesiculosus (bladder wrack) were 
provided by Marinova Pty Ltd, Tasmania, Australia.  
Table 4.1 Fucoidan extract composition* 
Extract 
 
Fucoidan  
Neutral 
Carbohydrates 
(%) 
Sulphates  
(%) 
Counter-
ions       
(%) 
Poly-phenols  
(%) 
Uronic 
acids    
(%) 
Peak MW 
(kDa) 
Fucus-
polyphenol 
(Maritech 
Synergy) 
40.2 21.8 6.3 26.2 3.6 203.1 
High-purity 
fucoidan 
(DPF) 
59.5 26.6 11.9 < 0.5 1.4 61.7 
 
*Data provided by Marinova Pty Ltd 
Both extracts are polydisperse, containing fractions from 5 kDa to above 1000 kDa. Fucus-
polyphenol is the more polydisperse and features a greater proportion of high molecular weight 
molecules. The major component of the neutral carbohydrate content of both compounds is fucose. 
The fucus-polyphenol extract (Maritech Synergy) contains 25.8 % fucose overall, whilst the high-
purity fucoidan (DPF) contains 53.3 % fucose.  
 DPF injection solution (5 mg/ml) was prepared by dissolving DPF in water for 
injection and filtered using a 0.45 µm filter. Fucoidan-containing food mash was prepared 
as described previously [273]. Briefly, 0.75 g of fucoidan extract (DPF or Synergy) and 9 g 
of sucrose (4 % w/w of food mash) were separately well-suspended/ dissolved in autoclaved 
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water before they were homogenously mixed into a solution with a final weight of 105 g. 
Food powder (120 g) was then dispersed slowly into the mixture with stirring to make a food 
paste. The food mash was aliquoted as 3 g/dish and stored at -20 °C.  
4.2.3 Treatment with fucoidan extracts 
Healthy control (HC) mice received standard chow while another group which received DSS 
in their drinking water and only vehicle through the food represented the disease control 
(DSS). Three treatment groups (n = 10 mice/ group), where all mice received DSS in their 
drinking water, were randomised for treatment with fucoidan extracts for 7 days (day 1 - day 
7). The first treatment group was injected intraperitoneally with DPF injection solution 
(IPDPF, 0.25 mg/ mouse, 10 mg/kg/day). The second and third treatment groups were given 
oral DPF and Maritech Synergy respectively (ODPF and OS; 10 mg/ mouse, 400 mg/kg/day). 
For the oral treatment groups, the mice were single-caged throughout the experiment to 
ascertain the defined daily intake of fucoidan from prepared food mash. In addition, all mice 
had access to normal food pellets ad libitum. 
4.2.4 Evaluation of intestinal inflammation  
Mice were weighed and observed daily for stool consistency and the presence of blood in 
the stool and sign of gross bleeding on the anus site [235]. Stool samples were obtained from 
individual mice and were tested by using Hemocult II slides (Beckman Coulter Inc., 
California, USA).  
4.2.5 Termination of experiment and tissue sampling 
Mice were sacrificed on day 8 by carbon dioxide inhalation followed by cervical dislocation. 
Upon dissection, the spleen was removed and weighed. The full colon was then carefully 
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removed. Colon length was measured between the ceco-colic junction and the proximal 
rectum. Subsequently, the entire colon was opened longitudinally to remove the faecal 
content before the wet weight of each colon was measured. The colon was then divided 
longitudinally to be used for either fixation in 10 % v/v buffered formalin and histological 
analysis or for tissue explant culture.  
4.2.6 Histologic evaluation of colitis 
Fixed colons were processed into paraffin blocks and were cut into 4 μm sections, which 
were stained with hematoxylin and eosin. Subsequently, all sections were graded in an 
investigator-blinded manner regarding the severity of the tissue damage using light 
microscopy (Leica DM2500, Leica Microsystems Pty Ltd, NSW, Australia and Leica 
application suite version 3 software) at 100 × / 400 × magnification. The severity of colitis 
was assessed according to the criteria described previously [236-238]. 
4.2.7 Tissue explant culture and measurement of cytokine levels 
Tissue from the distal colon was cut and washed with cold PBS before each sample was 
transferred into a 12 well-plate containing 1 ml/ well of RPMI 1640 culture medium (In 
Vitro Technologies Pty Ltd, Victoria, Australia) supplemented with 10 % v/v foetal calf 
serum (FCS, Gibco, Life Technologies, Victoria, Australia), penicillin (100 mU/L) and 
streptomycin (100 mg/L) (Sigma-Aldrich Pty Ltd, NSW, Australia). After 24 hours of 
incubation, supernatants were collected and stored at -80 °C until further analysis. A Bio-
Plex Pro Mouse cytokine 23-plex kit (Bio-Rad Laboratories, Inc., California, USA) was used 
to determine the cytokine levels in the tissue culture supernatants. Following the 
manufacturer instructions, cytokine standards and undiluted culture supernatants were tested 
in duplicate on a Bio-Plex 200 instrument equipped with Bioplex Manager software, version 
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6 (Bio-Rad Laboratories, Inc., California, USA). The cytokine levels were normalized by 
dividing the cytokine results (pg/ml) by the measured tissue weight (mg) and expressed as 
pg/ml cytokine/ 10 mg of tissue. 
4.2.8 Statistical analysis 
All statistical analyses were performed using GraphPad Prism (version 6, GraphPad 
Software Inc, CA, USA). Statistical significance was evaluated using one or two way 
analysis of variance (ANOVA), followed by a multiple comparison test: Dunnett’s test or 
Tukey’s test. Pearson’s correlation coefficient (r2) was determined for the relationship 
between two variables when necessary. A p value of < 0.05 was considered statistically 
significant. 
4.3 Results  
4.3.1 Oral fucoidan extracts ameliorate colitis-induced weight loss 
Mice receiving DSS in the drinking water developed acute colitis, evidenced by a significant 
reduction of body weight, on day 8 (-12.3 ± 4.3 %; p < 0.0001) (Fig. 4.1A). Oral 
administration of both fucoidan extracts significantly reduced body weight loss compared to 
untreated colitis (Fig. 4.1A). Statistically significant differences were obtained on day 7 (p 
= 0.05) and day 8 (p < 0.0001), with a maximum weight loss of only 5.9 ± 4.4 % for mice 
treated with oral DPF (ODPF). Likewise, mice treated with oral Synergy (OS) only showed 
a weight loss of 7.8 ± 3.1 % on day 8 which was significantly different to untreated mice (p 
= 0.0005). There was no significant difference between the effectiveness of the oral fucoidan 
extracts. In contrast, intraperitoneal (i.p) DPF (IPDPF) showed no protection but resulted in 
significantly increased weight loss on day 8 (-17.5 ± 2.1 %, p = 0.001) compared to the 
untreated mice.  
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Figure 4.1 Effect of fucoidan extracts during acute colitis.  
(A) Daily changes of body weight during colitis induction in C57BL/6 mice with and without 
fucoidan extracts treatment versus healthy control. Body weight changes, expressed as percentage, 
were calculated by dividing body weight on each day with the initial body weight before the start of 
DSS treatment. Stool samples were scored for (B) consistency and (C) occult blood on a daily basis 
during experiment. Data represent percentage or mean ± SD of n = 6 - 10 animals. Significance is 
indicated by * p < 0.05 and ** p < 0.01 using two-way ANOVA followed by Tukey’s post-test. 
Healthy control, HC; untreated colitis, DSS; intraperitoneal injection of depyrogenated fucoidans, 
IPDPF; oral treatment of depyrogenated fucoidans, ODPF; oral treatment of Maritech Synergy, OS. 
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4.3.2 Oral fucoidan extracts delay the development of diarrhoea and the 
appearance of blood in stool 
After exposure to DSS, untreated mice showed clear changes in stool consistency (Fig. 4.1B) 
and the presence of blood in stool (Fig. 4.1C) compared to mice without exposure to DSS. 
As early as day 2, mice receiving DSS developed soft stool that still contained formed 
pellets. On day 3, stool of untreated mice with DSS tested positive for occult blood. The 
severity of symptoms progressively increased towards the end of the experiment, when mice 
had bloody soft stool or diarrhoea. Consistent with retention of body weight, mice which 
received oral DPF (ODPF) or Synergy (OS) showed significant protection against diarrhoea 
over the entire observation period (Fig. 4.1B). Oral fucoidan extracts also significantly 
protected against the presence of blood in stool from day 4, although this protection was lost 
at day 7 (Fig. 4.1C). Intraperitoneal DPF (IPDPF) was not effective in alleviating DSS-
induced blood in stool (Fig. 4.1C) or worsening of stool consistency (Fig. 4.1B).  
4.3.3 Oral fucoidan extracts protect against changes to colon and spleen  
After the observation period, DSS-induced changes to colon and spleen were analysed. DSS-
treated mice showed significantly shorter (6.4 ± 0.5 cm; about 77 %) compared to healthy 
control mice (8.3 ± 0.7 cm) (Fig. 4.2A). Although protection by oral fucoidan did not reach 
significance compared to untreated mice, there was a trend towards reduced colon shortening 
for ODPF and OS (6.9 ± 0.6 cm and 7.0 ± 0.5 cm; respectively; about 84 % of healthy 
controls). Wet colon weight, an indicator of intestinal oedema and inflammation, was 
presented as the ratio of colon weight over body weight (mg/g). As expected, the untreated 
colitis group showed the highest relative weight (9.4 ± 1.2 mg/g) (Fig. 4.2B). The relative 
colon weight was significantly reduced by 19.1 % for ODPF (7.7 ± 0.9 mg/g; p = 0.01) and 
16.5 % for OS (7.9 ± 1.0 mg/g; p = 0.03) compared to the untreated group (Fig. 4.2B). 
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Consistent with the previous results, IPDPF showed no effect with regards to colon length 
(6.5 ± 0.3 cm) (Fig. 4.2A) or relative colon weight (8.9 ± 1.5 mg/g) (Fig. 4.2B).  
  
 Intestinal inflammation is associated with spleen enlargement [264] and as expected, 
the relative spleen weight of the mice receiving DSS in our study was significantly increased 
(5.1 ± 2.0 mg/g; p = 0.006) compared to spleens from healthy control mice (n = 6) (Fig. 
4.2C). Oral administration of either DPF or Synergy protected against the increased relative 
spleen weight (3.4 ± 0.5 mg/g and 3.4 ± 0.9 mg/g, respectively; p = 0.009) compared to 
untreated colitis mice, whereas IPDPF did not affect relative spleen weight (4.2 ± 0.5 mg/g, 
p = 0.28) (Fig. 4.2C). 
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Figure 4.2 Effect of fucoidan extracts on colon and spleen.  
Colons were measured for their length (A) and weight. Spleens were also removed and weighed. The 
organ weights were then presented as a ratio of colon weight (B) or spleen weight (C) over body 
weight respectively. Data represent the mean ± SD of n = 6 - 10 animals. Significance is indicated 
by * p < 0.05 and ** p < 0.01 using one-way ANOVA followed by Dunnett’s post-test. Healthy 
control, HC; untreated colitis, DSS; intraperitoneal injection of depyrogenated fucoidans, IPDPF; 
oral treatment of depyrogenated fucoidans, ODPF; oral treatment of Maritech Synergy, OS. 
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4.3.4 Oral fucoidan extracts decrease colon damage and infiltration of 
inflammatory cells  
Histological examination of colon tissue revealed that all DSS-treated mice displayed 
erosion or destruction of epithelium, crypt distortion, loss of goblet cells, submucosal 
oedema, increased colonic wall thickness and inflammatory cellular infiltration in the colon, 
mostly affecting the distal colon (Fig. 4.3A). While healthy mice showed no signs of 
histological colon damage (score 0), DSS resulted in cumulative damage scores of 8.1 ± 4.4 
for the proximal colon (Fig. 4.3B) and 22.6 ± 4.3 for distal colon (Fig. 4.3C). Co-treatment 
with oral fucoidan extracts induced protection as evidenced by retention of colonic structure, 
reduced infiltration of inflammatory cells and reduced submucosa oedema (Fig. 4.3A), 
which overall resulted in a significant overall reduction of cumulative histological disease 
scores for the distal colon (14.4 ± 6.6; 36.3 %, p = 0.005 and 15.0 ± 5.6; 33.6 %, p = 0.007 
for ODPF and OS respectively) (Fig. 4.3B and 4.3C). In contrast histology scores for the 
proximal colon demonstrated no significant protection by oral fucoidan extracts. IPDPF also 
showed no marked protection against distal or proximal colon damage, as indicated by high 
histological scores for the distal colon (22.7 ± 2.3) (Fig. 4.3C). 
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Figure 4.3 Effect of fucoidan extracts on colon histology.  
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(A) Representative hematoxylin and eosin stained colon sections of healthy controls, untreated mice 
with colitis and colitic mice that received fucoidan extracts. Cumulative histology damage scores for 
(B) Proximal colon (PC) and (C) Distal colon (DC). Data represent the mean ± SD of n = 6 - 10 
animals. Significance is indicated by * p < 0.05 and ** p < 0.01 using one-way ANOVA followed 
by Dunnett’s post-test. Scale bars = 100 µm for 400 × and 400 µm for 100 × magnification. Healthy 
control, HC; untreated colitis, DSS; intraperitoneal injection of depyrogenated fucoidans, IPDPF; 
oral treatment of depyrogenated fucoidans, ODPF; oral treatment of Maritech Synergy, OS. 
4.3.5 Oral fucoidan extracts reduce the levels of pro-inflammatory cytokines 
Cytokines are important mediators of the mucosal immune response. We therefore 
quantified colon tissue-derived cytokine levels to characterize the extent of inflammation 
during the acute colitis in the DSS model and the effects of fucoidan extracts. DSS treatment 
induced a significant increase of a multitude of cytokines during the acute colitis period (Fig. 
4.4). Compared to untreated colitis, both oral fucoidan extracts significantly lowered the 
levels of IL-1α, IL-1β, IL-10, MIP-1α, MIP-1β, G-CSF and GM-CSF (Fig. 4.4 and Table 
4.2). In addition, oral Synergy also significantly reduced the levels of IL-3, IL-12 (p40), IL-
12 (p70), IL-13, TNF-α and eotaxin (Fig. 4.4 and Table 4.2).  
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Figure 4.4 Effect of fucoidan extracts on colon-derived cytokine levels.  
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Distal colon tissue samples were cultured for 24 hours. The supernatants were assessed for cytokine 
levels using a Bio-Plex assay kit. Cytokine levels in the supernatant were normalized to tissue weight 
to obtain pg/ml of cytokines/ 10 mg of tissue. Data represent minimum, 25th percentile, median, 
mean, 75 percentile and maximum of cytokine levels of n = 5 animals. Significance is indicated by 
* p < 0.05 and ** p < 0.01 using one-way ANOVA followed by Dunnett’s post-test. Concentrations 
fell out of range, OOR, exceeding upper detection limits; n.s, non-significant; interleukin, IL; 
monocyte chemotactic protein-1, MCP-1; keratinocyte-derived chemokine, KC; interleukin, IL; 
tumor necrosis factor-α, TNF-α; granulocyte colony-stimulating factor, G-CSF; granulocyte-
macrophage colony-stimulating factor, GM-CSF; macrophage inflammatory protein, MIP; regulated 
and normal T cells expressed and secreted, RANTES; interferon-γ, IFN-γ; Healthy control, HC; 
untreated colitis, DSS; intraperitoneal injection of depyrogenated fucoidans, IPDPF; oral treatment 
of depyrogenated fucoidans, ODPF; oral treatment of Maritech Synergy, OS. 
Table 4.2 Effect of fucoidan extracts on colon-derived cytokine levels. 
 
Cytokine 
Colon explant culture 
Treatment versus DSS 
Intraperitoneal DPF Oral DPF Oral Synergy 
% change p value % change p value % change p value 
IL-1α -36.4 0.017 -55.9 0.0002 -71.3 < 0.0001 
IL-1β -28.6 0.016 -51.2 < 0.0001 -55.7 < 0.0001 
IL-3 n.s n.s -50.7 0.0242 
IL-10 -31.1 0.0308 -62.2 < 0.0001 -69.2 < 0.0001 
IL-12 (p40) n.s n.s -26.5 0.0386 
IL-12 (p70) n.s n.s -29.4 0.0398 
IL-13  n.s n.s -30.8 0.0179 
MIP-1α -52.8 < 0.0001 -46.5 0.0004 -60.9 < 0.0001 
MIP-1β n.s  -60.0 0.0037 -72.7 0.0004 
G-GSF -43.7 0.0193 -80.6 < 0.0001 -85.2 < 0.0001 
GM-GSF n.s -51.0 < 0.0001 -51.9 < 0.0001 
Eotaxin n.s n.s -36.6 0.0041 
IFN-γ 85.6 0.0309 n.s n.s 
TNF-α n.s n.s -68.0 0.0003 
RANTES 115.8 < 0.0001 n.s n.s 
Supernatants from colon tissue explant culture were assessed for cytokine levels. The percent (%) 
change versus the DSS colitis group for each cytokine is shown. Not significant, n.s; interleukin, IL; 
macrophage inflammatory protein, MIP; granulocyte colony-stimulating factor, G-CSF; 
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granulocyte-macrophage colony-stimulating factor, GM-CSF; interferon-γ, IFN-γ; tumor necrosis 
factor-α, TNF-α; regulated and normal T cells expressed and secreted, RANTES. 
 Importantly, at the level of each individual mouse, the fucoidan-treatment-induced 
reduction of pro-inflammatory cytokine levels significantly correlated with the protection 
against body weight loss (Fig. 4.5). For two cytokines, IL-6 and MCP-1, DSS increased their 
levels beyond the upper detection limit of the assay, while co-treatment with both oral 
fucoidan extracts decreased their levels back into the measurable range (Fig. 4.4S and Fig. 
4.4T). In contrast to the oral fucoidan formulations, the overall cytokine response to IPDPF 
was inconsistent. While IPDPF reduced the levels of IL-1α, IL-1β, IL-10, G-CSF and MIP-
1α, the levels of IFN-γ and RANTES were significantly increased by this treatment (Fig. 4.4 
and Table 4.2). 
 132 
 
 
Figure 4.5 Correlation between colon-derived cytokine levels and treatment-induced changes 
to body weight.  
Changes in cytokine levels by fucoidan extracts were correlated with the changes to body weight for 
individual mice. The value of Pearson correlation coefficient (r2) is reported and significance is 
indicated by p value. Interleukin, IL; tumor necrosis factor-α, TNF-α; granulocyte colony-stimulating 
factor, G-CSF; granulocyte-macrophage colony-stimulating factor, GM-CSF; macrophage 
inflammatory protein, MIP; regulated and normal T cells expressed and secreted, RANTES; 
interferon-γ, IFN-γ; healthy control (open circle); untreated colitis (closed circle); intraperitoneal 
injection of depyrogenated fucoidan (closed square); oral treatment of depyrogenated fucoidan 
(closed diamond); oral treatment of Maritech Synergy (closed triangle). 
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4.4 Discussion 
We have shown here that oral fucoidan extracts can effectively protect against DSS-induced 
acute colitis. Not only did the oral formulations alleviate the macroscopic pathologies such 
as body weight loss and stool consistency, they also significantly reduced the underlying 
intestinal inflammation. Although previous reports have demonstrated anti-inflammatory 
activities of fucoidan and fucoidan-containing extracts in different experimental models in 
vitro and in vivo [156,159,161,165,268,274-276], this is the first report to demonstrate that 
dietary fucoidan extracts from Fucus vesiculosus are highly effective in ameliorating 
experimental colitis through a consistent down-regulation of a significant number of pro-
inflammatory cytokines.  
 Many different cytokines are involved in the pathogenesis IBD [277]. They form a 
complex network that regulates mucosal inflammation and affects the integrity of epithelium 
[15]. Since pro-inflammatory cytokines from patient samples correlate with disease activity 
[240,244], treatments that modulate these mediators are likely to be of therapeutic use. In 
our study, we quantified a larger number of cytokines compared to previous studies to get a 
broader understanding of the immunological cytokine response during intestinal 
inflammation and especially in response to fucoidan treatment. 
 Despite the numerous reports describing the different anti-inflammatory activities of 
fucoidans, there is no information available that would highlight a single mode of action that 
could be responsible for the effects observed in this study. It is now generally accepted that 
the inflammatory response in patients and animal models of IBD is predominantly 
macrophage driven [247,251,278]. During intestinal inflammation, monocytes are recruited 
and differentiated into macrophages within the lamina propria [247] and it is believed that 
the initial exposure of interstitial macrophages to bacterial antigens is responsible for the 
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activation of macrophages and that at least in the DSS model these activated macrophages 
subsequently stimulate the proliferation of T cells [279]. In particular the highest DSS-
induced cytokines in our study, G-CSF and MIP-1α, which were up-regulated by more than 
200-fold and 100-fold respectively, support the strong involvement of macrophages in this 
model. On the other hand, fucoidans were reported to influence pro-inflammatory signalling 
molecules and pathways in macrophages, such as p38, Erk, JNK [165], HMGB1 and NF-κB 
[163]. These signalling pathways are essential for macrophages to become a major source of 
other pro-inflammatory cytokines and consistent with this previously described in vitro 
activity of fucoidans [280], we observed a marked reduction of most measured cytokines 
that originate from inflamed colon tissues. 
 Particularly TNF-α is thought to play a significant role in inflammatory cellular 
signalling, which is reflected by the successful clinical use of TNF-α inhibitors in patients 
with IBD [258]. Consistent with this hypothesis, macrophage-derived TNF-α production 
was reportedly blocked by fucoidan treatment in an in vitro co-culture model of gut 
inflammation [276,281]. However, in contrast to previous observations our results illustrate 
that the highly purified fucoidan extract (DPF) was unable to normalize the expression of 
TNF-α, while the polyphenol containing extract (Synergy) significantly reduced elevated 
TNF-α levels, which suggests additional benefits of the polyphenol content of fucoidan 
extracts to suppress TNF-α signalling. 
 In addition to macrophages, epithelial cells are also involved in driving the 
inflammatory cascade by secreting IL-6 in both patients and animal models of colitis [167]. 
Although our measurements for IL-6 under conditions of acute colitis exceeded the range of 
the assay, our data nevertheless suggest that both oral fucoidan extracts also reduce IL-6 
levels (Fig. 4.4S), which would be consistent with previous observations [167]. 
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 One of the first studies of fucoidan use in a mouse model of acute colitis 
demonstrated reduced mucosal damage and retained crypt architecture [166]. In that study, 
in contrast to our approach of dietary treatment, fucoidan was administered intravenously. 
In line with this route of administration and results from in vivo microscopy, the authors 
convincingly argued that the beneficial effects were most likely explained by the well-known 
inhibition of selectins by fucoidans [151,156], which can prevent lymphocyte adhesion. In 
addition, fucoidans have also been reported to inhibit the next stage of lymphocyte tissue 
infiltration, the invasion, by directly inhibiting the expression [162] and activity of MMPs 
[156,282]. MMPs are implicated in tissue invasion of immune cells under pro-inflammatory 
conditions and, consistent with this inhibitory activity of fucoidans, histology results in our 
colitis model suggested significantly reduced lymphocyte invasion and oedema. 
 Given the significant size of fucoidans, which is between 5 and 1000 kDa, it appears 
plausible that the route of administration can significantly alter efficacy due to restricted 
absorption and tissue distribution of the parent molecule. Since oral fucoidans are likely to 
reach the target tissue in the case of IBD, most pre-clinical animal studies have therefore 
preferred oral formulations over intravenous injections for this indication [166,167,268]. Not 
only is this the most preferable form of administration for patients with IBD, it is also 
potentially the least stressful for rodents in pre-clinical in vivo studies. It nevertheless has to 
be stated that oral administration by gavage can also constitute a significant stress to the 
animals and if not performed accurately can be associated with damage to the GI tract. 
Consequently, previous studies used fucoidan-containing food chow to treat rodents, without 
having control over the ingested amount of fucoidan [167]. In contrast, the present study is 
the first to accurately control the amount of fucoidan in food that has been ingested per day 
by mixing a defined amount of fucoidan in a separate portion of food chow that the animals 
eat preferentially before eating their normal food. This method has been successfully used 
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before [273], is very well tolerated and also allows to study the unstressed behaviour of the 
animals due to minimal animal handling. 
 In line with previous reports, our results strongly support the use of oral fucoidan 
extracts while, in contrast, intraperitoneal fucoidan was unable to reduce disease severity in 
our disease model. In fact, in the case of body weight as a clinical marker, intraperitoneally 
administered fucoidan appeared to worsen the condition. This result was also reflected at the 
level of cytokines, where IPDPF showed a trend towards increasing the levels of some pro-
inflammatory cytokines in DSS-treated animals. These results are not unexpected, since a 
recent study indicated that intraperitoneal fucoidan can effectively lead to the activation of 
dendritic cells (DCs) in the spleen [283]. The activation of DCs in this report was associated 
with increased production of IL-6, IL-12 and TNF-α. In line with an activation of immune 
cells by intraperitoneal fucoidan, we observed increased levels of IFN-γ and RANTES and 
a trend towards increased levels of IL-3, GM-CSF, IL-12(p40), IL-5 and IL-17 by IPDPF. 
In contrast to the study by Jin et al. [283], especially oral Synergy reduced the production of 
IL-12 and TNF-α, and likely also of IL-6, by cells of the intestinal tissue. These discrepant 
bioactivities highlight that the multiple activities of fucoidans are highly dependent on the 
specific formulation and route of administration used, which determines distribution to 
specific tissues in the organism. In line with several reports, our results do not provide any 
evidence for toxicity by oral fucoidan extracts [156,284,285].  
 Based on our in vivo findings, it forms an interesting picture that fucoidan extracts 
as well as enoxaparin could be potential therapeutic modalities for UC. We did not compare 
the efficacy of fucoidans to enoxaparin. Alternatively, it would be desirable to identify the 
active component(s) that (is) are responsible for the observed in vivo anti-inflammatory 
effects. Compared to enoxaparin, fucoidans are relatively more complex with a wider range 
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of MW (5 - 1000 kDa) and have different branching chains. In contrast, enoxaparin, a 
mixture of linear oligosaccharides, has a MW between 3800 to 5000 Da [51]. Different 
analytical techniques have been utilised to separate, isolate and elucidate the structural 
properties of these sulphated polysaccharides [131,172]. Commonly, the mixture is degraded 
enzymatically or chemically, before their structural analysis. Yet, the molecular structures 
including the chain length and sulphation pattern could be altered during depolymerisation 
process, complicating their structural characterisation. Currently there is a lack of 
standardised methods for fucoidan extraction as well as purification. Also, no efficient 
analytical techniques that are capable of separating the mixture of fucoidans to different 
components without changing the chemical and physical properties are available. In contrast, 
enoxaparin, a pharmaceutical grade anticoagulant agent, is produced from UFH using a well-
established, standardised and quality-controlled method [49]. Unlike fucoidans, enoxaparin, 
without changing the chemical and physical properties, has been successfully separated into 
different oligosaccharides by IC technique according to their size and charge [76]. Hence, it 
would be interesting to identify the active component(s) which (is) are responsible for the 
observed anti-inflammatory activity of enoxaparin.  
4.5 Conclusion 
Overall, our results indicate that oral fucoidan extracts can significantly reduce the pathology 
associated with acute colitis induced by DSS. Given that multiple factors including disease 
location, type of inflammation, pathogenic mechanisms and the combination of multiple 
cytokines affect the response to colitis treatment [15], it is conceivable that drugs that target 
a single pro-inflammatory cytokine are likely to be limited in their ability to offer an effective 
maintenance therapy for IBD over extended periods of time. In contrast, fucoidans that 
simultaneously modulate multiple pro-inflammatory mechanisms and mediators could 
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provide a more sustainable strategy against intestinal inflammation. This study extends our 
current understanding of oral administration of fucoidan extracts during acute colitis, which 
is a crucial step towards its use for the treatment of colitis. The ability of fucoidan extracts 
to reduce inflammation and to retain epithelial integrity along with the possibility of oral 
delivery serves as justification to develop and evaluate fucoidan extracts as therapeutic 
alternatives for patients with IBD. 
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Chapter 6 General Conclusion 
6  
6.1  Summary  
Despite an increased understanding of the process involved in pathogenesis of UC, the exact 
cause of UC remains elusive. This debilitating disorder has no cure and the symptoms of 
colitis have a considerable impact on the quality of life. Currently approved therapeutic 
agents have limited efficacy and are associated with unwanted side effects. It highlights the 
need to develop new and safe therapeutic modalities for the management of UC. The 
naturally occurring highly sulphated polysaccharides, heparins and heparin-like molecules 
such as fucoidans, have received considerable interest as potential therapeutic options in UC.  
Heparins (UFH and LMWHs) are clinically well-known anticoagulants. Their 
polysaccharide chains are heterogeneous both in their chemical compositions and chain 
lengths. Apart from their anticoagulant activity, there is evidence that heparins target 
multiple cellular events during inflammation. This has made heparins potentially important 
anti-inflammatory candidates. However, the current literature remains inconsistent with 
regards to the effects of heparins on cellular activities as well as the efficacy of heparins in 
UC. In addition, clinical applications of heparins in biological conditions other than where 
anticoagulation is required are largely hindered by their anticoagulant effects. This effect of 
heparins potentially increases the risk of bleeding. It is known that the pentasaccharide 
sequence in heparin chains is responsible for their anticoagulant activity. However, two third 
of heparin chains do not possess this sequence and may be responsible for other biological 
effects including anti-inflammatory effects. Thus we aimed to investigate the effects of 
heparins on cells and then identify oligosaccharides responsible for the effect of a LMWH, 
namely enoxaparin in colitis. Like heparins, fucoidans are also highly sulphated 
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polysaccharides and therefore have a wide range of biological activities including anti-
inflammatory effects. Thus we also evaluated the potential of fucoidan extracts in colitis.  
Using a number of cell-based assays, we first examined the effect of UFH, two 
LMWHs (namely dalteparin and enoxaparin) on colonic epithelial cell growth. Our results 
illustrated that UFH, enoxaparin and dalteparin inhibited cell proliferation. The inhibitory 
effect was well-correlated with the induction of cell cycle arrest in G1 phase and was not 
associated with significant changes in cell viability. Since enoxaparin was the most potent 
of them with regards to reduction of cell growth, we then tested the effect of individual 
oligosaccharides of enoxaparin. Enoxaparin was separated into different oligosaccharides 
using a validated IC method. The isolated oligosaccharides of intact enoxaparin have 
different degree of polymerisation ranging from 2 saccharides (dp2; ~ 600 Da) to 24 
saccharides (dp24; ~ 8000 Da). Each individual 14 IC-derived oligosaccharides of 
enoxaparin had either no, anti- or pro-proliferative effects on cell growth, depending on its 
compositions. Disaccharide devoid of anticoagulant activity had the strongest anti-
proliferative effect, whereas hexasaccharides actually promoted the cell growth.  
Based on our in vitro results, we tested the effectiveness of enoxaparin using a pre-
clinical model of colitis. Results obtained from an animal model of colitis indicated that 
orally administered but not intraperitoneal injected enoxaparin prevented the development 
of severe acute colitis. Oral treatment ameliorated colitis disease activity as well as alleviated 
the macroscopic and pathologic features of colons. It is conceivable that the observed effects 
of oral enoxaparin in mitigating acute colitis were associated, at least in part, with a reduction 
of macrophage-induced responses and the suppression of inflammatory cytokines.  
Like enoxaparin, fucoidan extracts from Fucus vesiculosus when administered orally 
relieved acute colitis by reducing a number of inflammatory mediators. This effect was not 
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seen when fucoidans extracts were injected intraperitoneally. Similar to enoxaparin, given 
the nature of high complexity, it is unclear which active components in the mixtures of 
fucoidan polysaccharides contribute to the observed activity. Both enoxaparin and fucoidans 
are polydisperse mixture of oligosaccharides or polysaccharides of variable molecular 
weights. Which oligosaccharide(s) from the mixture is (are) responsible for their effect in 
colitis is unknown at present. Hence, it is difficult to elucidate the associated mechanism of 
enoxaparin and fucoidan extracts in reducing colitis. We therefore tested different 
oligosaccharides of enoxaparin in order to identify the oligosaccharide(s) responsible for the 
effect of intact enoxaparin. The results indicated that oligosaccharides (dp2 - dp6) shorter 
than dp8 were responsible for the activity of enoxaparin. Among the oligosaccharides tested, 
tetrasaccharide and hexasaccharide were found the most active in preventing colitis-
associated body weight loss and colonic changes. 
Our in vitro and in vivo results indicated that enoxaparin oligosaccharides could 
affect cellular response as well as colitis, depending on the composition of oligosaccharides. 
Currently, all commercially available heparins are standardised according to their anti-factor 
Xa activity and are not tested for their non-anticoagulant activities. Our data for the first time 
can explain the inconsistent biological effects of heparins when different preparations were 
investigated for the biological effects other than anticoagulant activity. Depending on the 
structural compositions, different heparin preparations could result in different biological 
responses. Although the structures of oligosaccharides required for the activity have not been 
identified, the results demonstrated that the non-anticoagulant activities of enoxaparin 
including the anti-colitis effect are unrelated to the antithrombin binding pentasaccharide. In 
fact, disaccharide and tetrasaccharide are insufficient in length to bind antithrombin for the 
expression of anticoagulant effect, thus eliminating the risk of bleeding.  
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In summary, highly sulphated polysaccharides including enoxaparin and fucoidan 
extracts have anti-inflammatory potential in colitis. Specifically, enoxaparin relieved 
inflammation by reducing macrophage-associated inflammatory responses. Oral 
administration is likely to deliver these anionic macromolecules directly to the sites of 
inflammation, to exert local effects. This route of administration is especially convenient 
when used for managing UC. Furthermore, isolating and testing different oligosaccharides 
of enoxaparin allowed us to identify specific oligosaccharides that are responsible for the 
observed biological effects. Our approach highlighted the importance of evaluation of the 
biological effects attributed by different oligosaccharides present in enoxaparin or other 
mixtures of sulphated polysaccharides, as a first step toward novel oligosaccharide-based 
therapies.  
6.2 Limitations  
This study evaluated sulphated polysaccharides including heparins and fucoidans via cell-
based assays and in a model of colitis. As a direct consequence of the methodology used, a 
number of limitations need to be considered. The nature of in vitro assays is the absence of 
internal biochemical processes and the inability to represent complex interaction or 
responses in organism. It is unclear how heparins and the oligosaccharides of enoxaparin 
affect cell growth, resulting in either inhibition or stimulation of cell proliferation.  
In this study, we used a mouse model of DSS-induced acute colitis. DSS-induced 
colitis is a robust and low cost screening method to identify potential therapeutic candidates. 
However, the efficacy of enoxaparin, its oligosaccharides and fucoidans extracts 
administered during colitis induction did not address the potential of these agents in treating 
colitis. We opted for 8-days prophylactic protocol instead of treatment after colitis induction 
due to the ethical concern in our setting (> 15% of body weight loss required euthanasia) as 
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well as to limit the discomfort and the pain caused to the animals. To increase the holding 
capacity of animal facility, there were inevitable changes in animal housing system, which 
resulted in alteration of colitis disease activity induced by DSS.  
In the animal study, we only tested the effect of a single LMWH (enoxaparin), its 
oligosaccharides and two fucoidan extracts, both derived from Fucus vesiculosus at the 
selected doses. The optimal dose of each agent was not determined. The effects of UFH, 
other LMWHs as well as fucoidans obtained from other algal species were not investigated. 
Since no two preparations of UFH, LMWHs or fucoidan extracts from different species are 
similar in their oligosaccharide composition, the results of this study cannot be generalised 
to other types of heparins or fucoidan extracts. Although the IC technique enabled the 
separation of enoxaparin into sufficient amount of intact oligosaccharides for in vitro and in 
vivo study, the scalability of this method is limited by the use of semi-preparative CarboPac 
PA100 column. 
6.3 Future directions 
Finding new therapeutics to manage chronic inflammatory diseases is not only important 
but also challenging. It will be interesting to investigate other heparins or heparin-like 
molecules to see whether these highly sulphated polysaccharides share similar properties or 
they behave differently depending on their unique compositions. In addition, the 
development of sulphated polysaccharide-based therapies requires robust testing and a 
thorough understanding of their structure-activity relationships. A combination of 
orthogonal analytical approaches is required to permit structural analysis of the 
oligosaccharide for the identification of their composition, sequence, active motive and 
molecular target with a view to relate this information to their observed activity. Animal 
models of chronic colitis which simulate human UC could be further used to confirm the 
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effect of fucoidan extracts, enoxaparin and its oligosaccharides as well as to investigate the 
potential mechanism (s) by which they exert the anti-inflammatory activity. Future studies 
should also aim to identify the optimal doses as well as the safety of enoxaparin 
oligosaccharides when used in patients with UC.  
There is a need to advance the separation technology to scale up enoxaparin 
oligosaccharides for the formulation of desired dosage forms. Also, using well-designed 
animal models, the pharmacokinetic profiles and optimal dose ranges of oligosaccharides 
for anti-UC effect should be determined. Since the absorption of oral heparin 
oligosaccharides through intestinal mucosa is poor due to their lack of lipophilicity and large 
size, the orally administered oligosaccharide can be selectively delivered to the colonic site 
of inflammation in UC. Oral targeted- released formulation improves patient compliance due 
to ease of administration and minimal side effects.  
To develop this innovative treatment more efficiently, another important aspect is to 
ensure the product meets the regulatory standards in terms of stability, safety, quality control 
and assurance. Reliable assays should be developed to compare and standardise the 
properties and thus the anti-UC activities of oligosaccharides. For example, molecular 
weight properties of oligosaccharides, which are known to impact their biological activity, 
should meet the range of molecular weight restrictions to minimize variation within 
commercially derived heparin oligosaccharides. All the results that will be obtained through 
the approach suggested here can form the basis for the development of heparin-derived 
oligosaccharides for the treatment of UC. Unlike investigations using a novel drug moiety, 
the vast clinical experience with heparins would significantly facilitate a rapid bench-to-
bedside transition. 
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8.2 Appendix B 
 
Histology score sheet for DSS-induced acute colitis       
 PC DC 
Distribution of inflammation   
0=none   
1= focal   
2=multifocal   
3=diffuse   
Crypt Architecture   
0=normal   
1=irregular   
2=moderate crypt loss (10-50%)   
3=severe crypt loss (50-90%)   
4=small/medium sized ulcers (<10 crypt widths)   
5=large ulcers (>10 crypt widths)   
Loss of crypts    
0=no damage   
1=30% shortening of crypts    
2=65% shortening of crypts   
3=total loss of crypts   
4=loss of entire epithelial layer   
Extent of crypt loss in the region    
0=no crypt loss   
1=<25%   
2=25-50%   
3=50-75%   
4≥75%   
Tissue Damage   
0=no damage   
1=discrete lesions   
2=mucosal erosions   
3=extensive mucosal erosion with submucosal damage    
Goblet Cell Loss   
0= normal <10% loss   
1=10-25%   
2=25-50%   
3≥50%   
Submucosa scored for oedema   
0 = no change   
1 = mild   
2 = moderate   
3 = profound   
Inflammatory Cell Infiltration   
0=occasional infiltration   
1=increasing leukocytes in lamina propria   
2=confluence of leukocytes extending to submucosa   
3=transmural extension of inflammatory infiltrates   
Crypt abscesses    
0=none   
1=1-5   
2=6-10   
3≥10   
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